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Summary
Proteins and their interactions are fundamental to cellular life. Disruption of protein-protein, protein-RNA,
or protein-DNA interactions can lead to disease, by affecting the function of protein complexes or by
affecting gene regulation. A better understanding of these interactions on the molecular level gives rise to
new methods to predict protein interaction, and is critical for the rational design of new therapeutic agents
that disrupt disease-causing interactions. This thesis consists of three parts that focus on various aspects
of protein interactions and their prediction in the context of disease.
In the first part of this thesis, we classify interfaces of protein-protein interactions. We do so by sys-
tematically computing all binding sites between protein domains in protein complex structures solved by
X-ray crystallography. The result is SCOPPI, the Structural Classification of Protein–Protein Interfaces.
Clustering and classification of geometrically similar interfaces reveals interesting examples comprising
viral mimicry of human interface binding sites, gene fusion events, conservation of interface residues, and
diversity of interface localisations. We then develop a novel method to predict protein interactions which
is based on these structural interface templates from SCOPPI. The method is applied in three use cases
covering osteoclast differentiation, which is relevant for osteoporosis, the microtubule-associated network
in meiosis, and proteins found deregulated in pancreatic cancer. As a result, we are able to reconstruct
many interactions known to the expert molecular biologist, and predict novel high confidence interactions
backed up by structural or experimental evidence. These predictions can facilitate the generation of hy-
potheses, and provide knowledge on binding sites of promising disease-relevant candidates for targeted
drug development.
In the second part, we present a novel algorithm to search for protein binding sites in RNA sequences.
The algorithm combines RNA structure prediction with sequence motif scanning and evolutionary conser-
vation to identify binding sites on candidate messenger RNAs. It is used to search for binding sites of the
PTBP1 protein, an important regulator of glucose secretion in the pancreatic beta cell. First, applied to a
benchmark set of mRNAs known to be regulated by PTBP1, the algorithm successfully finds significant
binding sites in all benchmark mRNAs. Second, collaborators carried out a screen to identify changes
in the proteome of beta cells upon glucose stimulation while inhibiting gene expression. Analysing this
set of post-transcriptionally controlled candidate mRNAs for PTBP1 binding, the algorithm produced a
ranked list of 11 high confident potential PTBP1 binding sites. Experimental validation of predicted targets
is ongoing. Overall, identifying targets of PTBP1 and hence regulators of insulin secretion may contribute
to the treatment of diabetes by providing novel protein drug targets or by aiding in the design of novel
RNA-binding therapeutics.
The third part of this thesis deals with gene regulation in disease. One of the great challenges in
medicine is to correlate genotypic data, such as gene expression measurements, and other covariates,
such as age or gender, to a variety of phenotypic data from the patient. Here, we address the problem
of survival prediction based on microarray data in cancer patients. To this end, a computational approach
was devised to find genes in human cancer tissue samples whose expression is predictive for the survival
outcome of the patient. The central idea of the approach is the incorporation of background knowledge
information in form of a network, and the use of an algorithm similar to Google’s PageRank. Applied to
pancreas cancer, it identifies a set of eight genes that allows to predict whether a patient has a poor or
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good prognosis. The approach shows an accuracy comparable to studies that were performed in breast
cancer or lymphatic malignancies. Yet, no such study was done for pancreatic cancer. Regulatory net-
works contain information of transcription factors that bind to DNA in order to regulate genes. We find
that including background knowledge in form of such regulatory networks gives highest improvement on
prediction accuracy compared to including protein interaction or co-expression networks. Currently, our
collaborators test the eight identified genes for their predictive power for survival in an independent group
of 150 patients. Under a therapeutic perspective, reliable survival prediction greatly improves the correct
choice of therapy. Whereas the live expectancy of some patients might benefit from extensive therapy
such as surgery and chemotherapy, for other patients this may only be a burden. Instead, for this group, a
less aggressive or different treatment could result in better quality of the remaining lifetime.
Conclusively, this thesis contributes novel analytical tools that provide insight into disease-relevant
interactions of proteins. Furthermore, this thesis work contributes a novel algorithm to deal with noisy
microarray measurements, which allows to considerably improve prediction of survival of cancer patients
from gene expression data.
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Chapter 1
Introduction
1.1 Motivation
If one believes in the RNA world hypothesis (Gilbert, 1986), then proteins are a comparatively recent
addition in evolution. The interactions of these versatile biomolecules with DNA, with RNA, and among
themselves are vital for virtually all processes in a cell. Additionally, the nature of such interactions includes
a great range of events, from short transient interactions as for example in signalling to stable long-term
interactions as in many protein complexes.
For almost three decades, gene expression was thought to be mainly regulated at the transcriptional
level. Proteins known as transcription factors specifically bind to stretches of DNA in order to regulate the
expression of a gene. With the recent discovery of RNA silencing pathways, it is becoming increasingly
clear that a considerable fraction of human genes are co-regulated at the messenger RNA level. During
its entire lifespan, the messenger RNA acts as a platform for the binding of numerous proteins.
Changes of protein interactions can lead to disease by affecting the function of protein complexes
or by affecting gene regulation. The disease of cancer can arise by both errors in protein–protein and
protein–nucleic acid interaction. Constitutively active proteins such as a mutated Ras GTPase can drive
cells into uncontrolled cell division by constant signalling to other proteins. Transcription factors such as
myc oncogene are often found over-expressed in cancer cells, leading to uncontrolled growth. A better
understanding of these interactions on the molecular level gives rise to new methods to predict protein
interaction, and is critical for the rational design of new therapeutic agents that disrupt disease-causing
interactions.
This thesis addresses three open problems centered around protein interactions and their prediction
in the context of disease. First, we will address the problem of classifying and predicting protein–protein
interactions. Second, we will address the problem of predicting whether an RNA binding protein binds to
a certain messenger RNA. Third, we will address the problem of predicting survival of cancer patients
from putatively noisy microarray data. The algorithms devised to address these problems are used to
gain insight into diseases. Specifically, we predict protein interactions in osteoclasts, which are the bone-
digesting cells primarily causing osteoporosis. We predict messenger RNAs that interact with a RNA
binding protein in pancreatic beta cell in order to regulate insulin secretion, which is impaired in patients
suffering from diabetes. We study pancreatic cancer both on the protein-protein interaction and on the
regulatory level of gene expression. The open problems will be defined in the following.
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1.2 Definition of open problems
1.2.1 Open problem 1: Classification and prediction of protein–protein interactions
Motivation
Reliable interaction prediction is of growing importance for both medical and basic biological research.
High-throughput screening experiments such as microarray-based gene expression profiling studies or
genome-wide RNAi screens generate masses of data. In contrast to small-scale experiments, hundreds
of genes or proteins are revealed by such large-scale efforts. One fundamental question is how proteins
found in such studies can be linked to explain the observed phenotype. In addition, high-throughput ex-
periments for detection of protein interactions, such as yeast two-hybrid or complex purification, are still
error-prone. Telling which are the false negatives and false positives in interaction networks generated
with these methods is still not satisfactorily possible.
Investigations on the interfaces of protein–protein interactions are often based on structural data. In
many cases, the protein interaction is mediated by the interaction between two protein domains. Although
various interaction databases and prediction approaches exist, few have focused on the geometrical as-
pects of the domain–domain association. Detailed knowledge on the interaction interface, as it is available
in three-dimensional complex structures, helps to identify the key residues that are responsible for mediat-
ing the interaction. This knowledge is useful for the prediction of protein interactions, even in the absence
of structural data for the potentially interacting components.
Open problem
How can structural knowledge about protein interactions and their interfaces help to reliably predict
novel protein–protein interactions? How can it be combined and completed by exploiting sequence-based
sources of protein interaction that are commonly available?
1.2.2 Open problem 2: Prediction of protein binding sites on RNA
Motivation
Post-transcriptional control is an important mechanism by which cells can rapidly change gene expression.
PTBP1 is known to regulate the biosynthesis of insulin and components of the insulin secretory machinery.
To this end, it binds to the untranslated regions of messenger RNAs. Thus, PTBP1 regulates on the post-
transcriptional level, independent of gene transcription. Past studies showed that PTBP1 preferentially
binds to single-strand RNA regions with the sequence motif CYYYYCYYYYYG, where C denotes cytosine,
G denotes guanine, and Y denotes a pyrimidine base. In a recent screen by a collaborating group, a set
of 63 proteins in insulin-producing pancreatic beta cells were identified that changed their concentrations
while gene transcription was inactivated. This set is expected to be highly enriched in proteins that are
regulated by either PTBP1 or by other mRNA-binding proteins.
Open problem
Can we predict mRNAs as binding partners for PTBP1 based on their nucleotide sequence and the known
mRNA binding motif?
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1.2.3 Open problem 3: Prediction of clinical parameters from genomic data
Motivation
Pancreas cancer has an extremely poor prognosis, with a median patient survival time of 1 ½ years.
In some patients, however, much longer survival times are observed. A plausible explanation could be
that these patients have less aggressive types of pancreas cancer which, although histologically similar,
show different gene expression profiles. Predicting survival time based on gene expression profiles could
identify patients who would benefit from extensive therapy such as surgery and chemotherapy as opposed
to patients who would not. For the latter, less aggressive or different treatment could result in better quality
of their remaining lifetime.
Open problem
Can we identify genes whose expression in pancreas cancer tissue samples correlates with the survival
time of pancreas cancer patients? Can these genes be used as a molecular signature to reliably predict
the survival time of patients diagnosed with pancreas cancer?
1.3 Thesis outline
The outline of this thesis is shown in Figure 1.1. Each open problem will be addressed in one chapter.
The first chapter of this thesis deals with protein–protein interaction. Chapter 2 deals with open problem 1,
the classification and prediction of protein–protein interactions. Chapter 3 deals with open problem 2, the
prediction of protein–RNA interaction. Chapter 4 deals with open problem 3, the prediction of survival
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from tumor gene expression data in pancreas cancer patients. Here, we show that this prediction can
be considerably improved by adding background knowledge about which genes are regulated by which
transcription factors.
Chapter 2
Prediction and classification of
protein–protein interaction
Parts of this chapter were published in:
• Christof Winter, Andreas Henschel, Wan Kyu Kim, and Michael Schroeder. SCOPPI: A Structural
Classification of Protein–Protein Interfaces. Nucleic Acids Research 34: 310–314, 2006
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(GI), 2006
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2.1 Background
2.1.1 Protein–protein interactions
Protein–protein interactions are fundamental to cellular life. Nearly every major process in a cell is believed
to be carried out by assemblies of ten or more protein molecules (Alberts, 1998). Protein interactions are
responsible for the formation of large complexes such as ribosomes and play a critical role in biological
pathways relevant for cellular development, metabolism, and signal transduction. The infection of a virus,
for example, is mediated by the interactions between a viral coat protein and host protein receptors. The
immune system relies on protein interactions for the detection and the attack of pathogens by means of
antibodies and the complement system. Many human diseases are a result of aberrant protein interactions,
and often the modulation of an interaction provides the basis for a targeted therapy (Ryan and Matthews,
2005).
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As virtually all processes in a cell require cooperation of proteins, elucidation of their interactions is
of paramount interest, as this provides insight into how complex molecular machines are organised and
how their parts work together. Further, identification of protein interactions is a powerful means to infer
the function of uncharacterised proteins. The functional characterisation of a protein from its interaction
partners is referred to as guilt by association (Oliver, 2000).
Building genome-wide interaction maps has been a central problem in both experimental and compu-
tational biology in the post-genomic era. This problem is addressed by both small-scale and large-scale
experimental efforts, which are complemented by computational approaches, as will be described in the
following.
2.1.2 Experimental data on protein–protein interaction
Current knowledge on protein interactions originates from small scale studies as well as large scale high-
throughput studies. While the former are available in the biomedical literature, the latter are usually stored
in dedicated public databases.
An overview of experimental techniques for protein interaction detection is given in Shoemaker and
Panchenko (2007a).
Small-scale approaches
Biochemical methods. The gold standard biochemical assay for protein-protein interaction detection
is immunoprecipitation. Here, a protein of interest is isolated with a specific antibody, and its attached
interaction partners are subsequently identified by western blotting. Pull-down assays are a common
variation of immunoprecipitation, where a protein is engineered to be expressed with a tag attached at its
C- or N- terminal end. The tag is then used to capture the protein along with its binding partners. The use
of a tag avoids the need for an antibody that specifically targets the protein. Examples of tags in use are
the green fluorescent protein (GFP) tag, glutathione-S-transferase (GST) tag, and the FLAG-tag. While
using a tag to enable pull-downs is convenient, it raises some concerns since the tag itself might either
obscure native interactions or introduce artificial ones. It is important to note that immunoprecipitation or
pull-down experiments reveal direct interactions as well as indirect interactions via a bridging protein.
Structural data. The probably most detailed view on protein interactions can be obtained from X-ray
crystallography studies. These provide three-dimensional coordinates of all atoms in a protein complex
or a multi-domain protein. Atoms and amino acids that participate in the interaction interface can thus be
pinpointed. The SCOPPI database (Winter et al., 2006), which will be described in this chapter, is based
on such interfaces of known structure.
Recently, the advent of structural systems biology and structural genomic projects has provided a
large amount of three-dimensional structures (Chandonia and Brenner, 2006). Although crystal structures
of complexes are difficult to obtain, a fair number of protein-protein interactions are structurally solved and
available in the Protein Data Bank, PDB (Berman et al., 2000). As of May 2009,∼53,000 protein structures
were available in the PDB.
Further techniques. Further small-scale study techniques comprise fluorescence resonance energy
transfer (Yan and Marriott, 2003), surface plasmon resonance (Cooper, 2003), atomic force microscopy
(Yang et al., 2003), and electron microscopy (Baumeister et al., 1999).
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Figure 2.1 Experimental high-throughput methods for detecting protein-protein interactions. Left: The
yeast-two hybrid method (Fields and Song, 1989). (a) The GAL4 protein, which consists of a binding domain (BD)
and an activating domain (AD), can initiate transcription of the lacZ reporter gene via binding to an upstream activat-
ing sequence (UAS). Fusion proteins of the binding domain and a bait protein (b) as well as the activating domain
and a prey protein (c) are prepared. Neither of those can induce transcription on its own. (d) The interaction of bait
and prey results in transcription of the reporter gene. Right: The tandem affinity purification (TAP) method (Rigaut
et al., 1999). (e) Structure of the TAP tag. (f) Outline of the tandem affinity purification procedure.
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Large-scale approaches
Yeast two-hybrid and pull-down (co-purification and mass spectrometry) have been widely used for high-
throughput interaction screening.
Yeast two-hybrid. The yeast two-hybrid method was developed originally by Fields and Song (1989). It
is outlined in Figure 2.1, left. Using yeast cells, it relies on the activation of transcription of a reporter gene
(such as lacZ ) by binding of a transcription factor (such as GAL4) to an upstream activating sequence.
The transcription factor consists of two domains, a DNA-binding domain and an activating domain, neither
of which can initiate the transcription alone. To detect the interaction between a bait and a prey of interest,
the bait protein is fused to the DNA-binding domain (BD) of the transcription factor, and the prey protein
is fused to the activation domain (AD). If bait and prey protein interact, an active transcription factor (BD–
AD) is reconstituted by the mediation of the bait–prey interaction, resulting in the activation of the reporter
gene (Fields, 2005).
Two-hybrid genome-wide interaction maps have been generated for several species including yeast
(Uetz et al., 2000; Ito et al., 2001; Yu et al., 2008), Helicobacter pylori (Rain et al., 2001), fruit fly (Giot
et al., 2003; Formstecher et al., 2005), C. elegans (Li et al., 2004a; Boxem et al., 2008), the malaria
pathogen Plasmodium falciparum (LaCount et al., 2005), and the syphilis pathogen Treponema pallidum
(Titz et al., 2008). Two large-scale human interaction maps (Rual et al., 2005; Stelzl et al., 2005) have
been constructed as well, covering about 10% of the human interactome.
Affinity purification followed by mass spectrometry. For an affinity purification pull-down approach, a
series of bait proteins fused with an affinity tag is constructed (Figure 2.1, right). The tagged bait proteins
can be captured using a specific antibody in the following affinity-purification step. Proteins bound to each
bait are co-purified and identified by mass spectrometry. Accordingly, the pull-down method provides
information on the membership of a set of proteins in a complex, while most other interaction experiments
detect binary interactions. Therefore, some of the co-purified proteins may not directly interact with the
bait.
The first large-scale pull-down screenings were performed for yeast complexes. Gavin et al. (2002)
used endogenous bait proteins expressed from integrated genes in the host genome, while Ho et al.
(2002) used exogenous baits on plasmids. Using endogenous bait is shown to be more reliable than
exogenous ones probably because the proteins may be expressed in amounts similar to in vivo in the
former but over-expressed in the latter. Follow-up yeast studies were done by Gavin et al. (2006), Krogan
et al. (2006) as well as Collins et al. (2007). Species further covered are E. coli (Butland et al., 2005;
Arifuzzaman et al., 2006), C. elegans (Gunsalus et al., 2005), and human (Ewing et al., 2007).
Protein-fragment complementation assay. Recently, Tarassov et al. (2008) performed a genome-wide
in vivo screen for protein-protein interactions in yeast by means of a protein-fragment complementation
assay. Unlike the yeast two-hybrid approach, which requires additional cellular machinery that exists only
in specific cellular compartments, this assay uses two fragments of an enzyme which are linked to a bait
and a prey protein each. Only if there is an interaction between bait and prey, the enzyme is reconstituted,
resulting in a detectable increase of the enzymatic activity.
Quality of data
Two-hybrid and pull-down methods are prone to both false-positive and false negative rates. The earlier
versions of yeast two-hybrid data were estimated to contain about 50% of false positives (Mrowka et al.,
2001; Sprinzak et al., 2003). These may result from either the nature of the protein itself, which activate
the reporter without preys, or from the fact that bait and prey actually interact in the two-hybrid assay, but
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never in vivo due to localisation to distinct cellular compartments or differential expression (Walhout et al.,
2000b; Aloy and Russell, 2002; Fields, 2005). A similar error can occur in pull-down experiments. For
example, some so-called sticky proteins may non-specifically interact with many different proteins. Since
both methods require fusion or tagging of target proteins, such modifications can interfere with interactions.
In the comparison of various high-throughput interaction maps in yeast, only a small fraction of them was
found to overlap (Bader and Hogue, 2002; von Mering et al., 2002). This suggests that the interaction data
may cover only a small fraction of the total interactions, i. e. contain false negatives. Nevertheless, two-
hybrid and pull-down experiments are efficient tools for genome-wide interaction mapping. The reliability
of the two-hybrid system has been improved steadily, for example by a more stringent expression of the
reporter gene. The recent versions of both pull-down (Gavin et al., 2006; Krogan et al., 2006) and two-
hybrid (Rual et al., 2005) were shown to be significantly more reliable than the earlier ones. However, the
missing and falsely detected interactions, i. e. the false negative and false positive rate, do still represent
an unsolved problem.
2.1.3 Protein interaction interfaces
Protein interactions can be mediated by
• domain–domain interactions,
• domain–peptide interactions, or
• disordered regions of proteins.
A domain is a structurally defined compact globular portion of a protein molecule (Henderson and
Henderson, 1999). Whereas the majority of protein interactions are mediated by domain–domain con-
tacts, the involvement of peptide and disordered stretches has recently gained attention. Domain–peptide
interactions often involve linear motifs, which are 3–8 residue long stretches of a polypeptide. Especially
in eukaryotes, many important signalling interactions of proteins are facilitated by these short, linear mo-
tifs (Puntervoll et al., 2003; Neduva et al., 2005). Disordered or intrinsically unstructured proteins are
characterised by lack of stable tertiary structure. Intrinsic disorder was found to be a common feature of
eukaryotic hub proteins (Haynes et al., 2006).
This thesis chapter focuses on the domain–domain aspect of protein interaction, where interfaces
typically have an average size of ∼1,500 Å2. We will present a comprehensive classification of such
domain interfaces on structural level. In the following, we will mainly refer to domain interactions when
discussing protein interactions, unless stated otherwise.
Properties of protein domain interaction interfaces
Since the seminal work by Chothia and Janin (1975), a number of studies have been carried out on
the physico-chemical characterization of protein interfaces. The discovery of the characteristics of each
interface forms a basis to understand the rules of molecular recognition. General principles of protein-
protein interactions have been proposed (Hubbard and Argos, 1994; Jones and Thornton, 1996; Valdar
and Thornton, 2001; Gao et al., 2004; Bahadur et al., 2004). Many authors defined measures for interface
size, shape complementarity, protrusion, segmentation and secondary structure. It is important to notice
that in the vast diversity of protein interactions these characteristics differ strongly. Given the structure of
two interaction candidate proteins, these measures both help to determine the binding ability as well as to
identify the actual binding site. This knowledge driven approach has inspired many machine learning ap-
proaches. Further important aspects for protein interactions have been investigated, as will be discussed
in the following.
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Shape complementarity. Interacting proteins often have large surface patches that are in direct contact
with each other. Especially enzymes that select their substrates specifically exhibit a high degree of shape
complementarity with respect to their substrates. This phenomenon was observed by Emil Fischer, who
proposed the “lock and key” model in 1894 (Fischer, 1894). To account for conformational flexibility of
protein-protein interactions, Koshland (1958) proposed the “induced fit theory” as a modification to the lock
and key model. According to this theory, substrates are not rigidly docking to their enzymes, but constantly
perform small rearrangements of their side chains. Shape complementarity is a purely structural feature
and hence does not translate directly into sequence representations. Therefore, shape complementarity is
not directly usable in predictions, where only sequences are given. However, shape complementarity can
be the result of a long evolutionary process involving mutations on one side and compensatory mutations
on the opposite side of the interaction. These correlated mutations are detectable on sequence level.
Permanent versus transient interactions. A fundamental distinction between interactions is by their
duration, that is whether they occur in permanently or transient. Nooren and Thornton (2003) further dis-
tinguish between weak and strong transient interactions, where the former follow a principle informally
termed kiss and run, while the latter are in contact and their connection is disrupted through some trigger.
A slightly deviating definition, regarding the duration as well as the functional aspect, divides protein-
protein interactions into obligate and non-obligate. An obligate interaction is a permanent interaction be-
tween proteins which do not occur individually, but only as a complex. A prominent example are the alpha
and beta chains of hemoglobin, which are only fully functional upon complex formation.
Homo and hetero dimers. Protein dimers can be built from equal or different domains. Many proteins
occur as homo dimers, with two identical domains binding to each other. The distinction between homo
dimers and hetero dimers can be made on various levels, such as sequence level, family level, or su-
perfamily level. These factors influence the formation of protein-protein complexes. Jones and Thorn-
ton (1996) suggest a rough classification into four different types of protein-protein complexes: homo-
dimeric proteins, hetero-dimeric proteins, enzyme–inhibitor complexes, and antibody–protein complexes.
The comparison between the complexes highlights differences that reflect their biological roles. It will be
of great interest to determine the most relevant characteristics for the particular purpose of binding site
prediction. Elcock and McCammon (2001) found that interface conservation helps to correctly predict the
oligomerization state of a protein based on crystal structures.
Hydrophobicity. Surface patches with high hydrophobicity are energetically unfavourable in a watery
solution, but favourable when in contact with other hydrophobic surfaces. Hence, their occurrence can
be linked to binding sites. Gallet et al. (2000) proposed an interface detection method that predicts bind-
ing sites by analysing the hydrophobicity distribution in sequences. Especially permanent interactions
between globular proteins were found to involve more hydrophobic residues. The largest hydrophobic sur-
face patches were often found to participate in protein binding, at least to some extent. This approach has
been outperformed by several techniques that employed further features. According to Nooren and Thorn-
ton (2003), hydrophobicity has less discriminative power for transient interactions, as transient interactions
are often established by hydrogen bonds from polar side chains.
Evolutionary conservation. Structurally and functionally important residues are often well conserved.
It is reasonable to assume that key residues of a vital protein-protein interaction are spared from mutations,
as the loss of an interaction either has fatal consequences for the organism, or displays an evolutionary
disadvantage. Consequently, functional interfaces are commonly associated with a lower mutability than
other, non-functional parts of the protein surface. The identification of binding sites based on evolution-
ary conservation, however, remains controversial. While some authors claim a stronger conservation of
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interfaces than the rest of the surface (Nooren and Thornton, 2003; Bordner and Abagyan, 2005), others
question the statistical significance (Caffrey et al., 2004). A remaining problem is how to clearly identify
non-functional parts of the protein surface, as we are probably still far from complete knowledge about
all interactions. Surface parts considered non-functional could actually be important for yet unknown inter-
actions. It is hence not sufficient to base binding site detection solely on conservation scores. However,
selective pressure often leads to the conservation of important protein features, such as binding behaviour.
Therefore, it is generally beneficial to include evolutionary conservation scores, as for example employed
by Li et al. (2004b) as well as Bordner and Abagyan (2005).
Hot spots and hot regions. Hot spots are interface residues that dominantly contribute to the binding
free energy. Their identification requires experimental approaches such as alanine scanning (Bogan and
Thorn, 1998). Ma et al. (2003) found that structurally conserved residues distinguish between binding sites
and exposed protein surfaces. Halperin et al. (2004) showed that hot spots are often observed to couple
across two-chain interfaces. According to Keskin et al. (2005), who analysed computational hot spots
and their surroundings, hot spots reside in tightly packed, structurally conserved regions that contribute
dominantly to the stability of the interaction. Darnell et al. (2007) describe knowledge-based models that
allow to predict hot spots which make available online (Darnell et al., 2008).
Electrostatics. Calculation of the electrostatic potential of protein-protein complexes revealed that protein-
protein interfaces display electrostatic complementarity (McCoy et al., 1997). Electrostatic surfaces of pro-
teins can be calculated by solving the Poisson-Boltzmann Equation (Fogolari et al., 2002). Frequently,
binding sites are identified by opposite charges in opposite interfacing patches.
Hydrogen bonds and water bridges. The bonds formed by hydrogen atoms between a hydrogen-
donor and a hydrogen acceptor are, except for covalent bonds, the strongest contributors to binding
energies. Bridging water molecules are those forming two hydrogen bonds, one to each interface side.
A comprehensive analysis of so-called wet-spots can be found in the SCOWLP database (Teyra et al.,
2006).
Secondary structure. Interface residues can be classified according to the secondary structure they
are part of, that is alpha-helices, beta-strands, turns, and loops. Less common are 310 helices and pi-
helices. Secondary structure elements are commonly determined in protein structures using the DSSP
algorithm (Kabsch and Sander, 1983), which is based on an electrostatic definition to identify hydrogen
bonds. Further, less regular structural motifs exist (Milner-White et al., 2004). Preissner et al. (1998)
investigated protein interfaces from 351 selected protein complex structures. They classify binding sites
according to the participating secondary structure elements.
2.1.4 Prediction of protein–protein interaction
By predicting and assessing protein interactions, computational approaches can help in separating false
positive from true positive ones. Approaches to predict protein–protein interaction can roughly be divided
into
• homology-based,
• domain–domain interaction-based, and
• genomic methods.
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The homology-based approach is exemplified by Jonsson et al. (2006). It searches for existing inter-
actions among orthologous proteins from other organisms. If an orthologous interaction exists in many
other organisms, this interaction is assigned a high score. In addition, Mika and Rost (2006) as well as
Saeed and Deane (2008) suggested that paralogous interactions may provide even more information for
inferring interacting protein pairs.
In the domain interaction based approach, a protein interaction is inferred on the basis of domain
contacts. If a domain pair is frequently found in observed protein interactions, it is likely that other protein
pairs containing this domain pair might also interact. From the observed protein interaction network, the
probabilities of domain-domain interactions are estimated. Assuming that protein interactions occur inde-
pendently of each other, Deng et al. (2002) apply maximum likelihood estimation to infer interaction of
domains. The likelihood is then used to construct a probability score for a protein pair to interact. However,
the limited number of known domains may not be enough to describe the variety of protein interactions.
Further extensions, such as an improved scoring for domain interactions (Riley et al., 2005) and the inclu-
sion of other biological information (Lee et al., 2006) were proposed. The model of Liu et al. (2005b) is
an extension of the method of Deng et al. which integrates multiple organisms. In addition to S. cerevisiae,
two other organisms, C. elegans and D. melanogaster, are included.
Several computational methods based on genomic sequences have been developed for the predic-
tion of protein–protein interactions, among them gene fusion (Enright et al., 1999; Marcotte et al., 1999),
phylogenetic profile (Pellegrini et al., 1999), gene neighbourhood (Dandekar et al., 1998; Overbeek et al.,
1999), interacting domain profile pairs (Eisen et al., 1998), and co-evolution of gene expression (Fraser
et al., 2004). A comprehensive overview of prediction methods can be found in Aloy and Russell (2006)
and Shoemaker and Panchenko (2007b).
Predicting interactions through homology
As protein structure as well as function tend to be conserved between homologous proteins, interac-
tions may be inferred for protein pairs orthologous to known interacting pairs. The conserved interactions
across different organisms are termed interologs (Walhout et al., 2000a). Curated databases such as
COG (Clusters of Orthologous Groups) at NCBI (Tatusov et al., 2003), InParanoid (O’Brien et al., 2004b),
or OrthoMCL-DB (Chen et al., 2006) provide genome-wide ortholog mapping between different species.
Several genome-wide interolog maps for human have been generated using the interaction data from
other organisms (Lehner and Fraser, 2004; O’Brien et al., 2004a; Persico et al., 2005).
Homology-based interaction prediction provides useful information. Once an interaction map is con-
structed, other unknown interactions can be hypothesised and tested experimentally. The existence of
known interologs increases the reliability of high-throughput experiments in general. If the structure of an
interacting protein pair is known, 3D structural modelling is possible for homologous protein pairs. One
application presented in the results part of this chapter makes use of this fact.
There are a couple of limitations in practice. First, the critical step of ortholog identification can be
difficult. Non-orthologous multi-domain proteins may share common domains, showing a significant se-
quence similarity. Gene fusion or fission events can cause different domain architectures between or-
thologs. Second, genome-wide ortholog mapping may not be straightforward due to weak homology. This
holds particularly for human since the majority of currently available genome-wide interaction data are
from non-mammals such as yeast, worm, and fly. Third, there is the danger of inferring too many inter-
actions when many candidate orthologs or homologous domains exist, as for example in the case of
G-proteins, G-protein coupled receptors, or SH2/SH3 domains. The prediction of interaction specificity
between the members of two interacting families is still a critical problem in any homology-based method.
C H A P T E R 2 . P R E D I C T I O N A N D C L A S S I F I C AT I O N O F P R O T E I N – P R O T E I N I N T E R A C T I O N 27
Predicting interactions through domain–domain interactions
Domains are regarded as the structural and functional units of proteins as they tend to fold independently.
The natural repertoire of distinct domain families is limited (Chothia, 1992; Finn et al., 2005). Domains
appear in various combinations in multi-domain proteins as a result of gene rearrangement and duplication
in the course of evolution (Teichmann et al., 1998; Koonin et al., 2002). Domain combination is not entirely
random since certain functions require cooperative action of multiple domains. For example, the enzyme
active site of phosphoglycerate kinase is located at the interface of its two domains (Banks et al., 1979).
Only a small fraction of possible domain combinations are believed to actually exist in nature (Vogel et al.,
2004).
Domain-domain interactions can be extracted from a set of protein interaction data including yeast
two-hybrid. The inference is generally based on the identification of statistically over-represented domain
pairs among a set of interaction data. Several methods have been developed using different techniques
and scoring schemes (Sprinzak and Margalit, 2001; Wojcik and Schächter, 2001; Deng et al., 2002; Ng
et al., 2003). Using structural data, the construction of a domain interaction map is made straightforward
by collecting domain-domain contacts from PDB.
Domain-level interaction mapping has a couple of advantages over homology-based maps. First, in-
teraction analysis can focus only on the domains at the interface without being distracted by irrelevant
domains. Second, the interaction types in a domain interaction map should be smaller than in a homology-
based map. The reason is that the protein pairs of different domain architectures are merged into a single
domain-domain pair if the protein interactions are mediated by the same domain pair. The smaller size
makes the domain interaction map easier to understand by providing a higher level of abstraction. Finally,
the domain interaction map provides a framework to engineer novel interaction modules. For example, a
signalling circuit can be re-engineered by combining different interaction modules (Dueber et al., 2004).
Integrative genomic approaches
Genome analysis methods predict protein-protein interactions and functional associations between pro-
teins based primarily on genome context and not directly relying on sequence homology. The availability
of many genome sequences provides a deep insight on the functional diversity and the evolution of life.
To date, hundreds of prokaryotic and dozens of eukaryotic genome sequences are complete or near com-
plete including human (Lander et al., 2001; Venter et al., 2001). The methods described below aim to
predict functionally related proteins but not necessarily physical interactions. Still, functional linkage is
often correlated with physical interaction, as shown in many biological pathways.
Phylogenetic profiles. Phylogenetic profiling finds pairs of proteins with similar patterns of presence
or absence across large numbers of species (Figure 2.2a). It identifies pairs likely to act in the same
biological process, but does not necessarily imply physical interaction. One drawback is that this method
requires complete genome sequences. A refined phylogenetic profile method was proposed by Sun et al.
(2005), and Pagel et al. (2004) presented a domain interaction map based on phylogenetic profiling.
Gene fusion. The gene fusion method presumes interaction when two proteins in one species appear
as a single fused protein in another (Enright et al., 1999; Marcotte et al., 1999) (Figure 2.2c). The basic
assumption is that fusion is maintained by selection only when it facilitates functional interaction between
proteins such as coupling of consecutive enzymes in pathways. Especially metabolic enzymes are often
found in both fused and separate forms (Tsoka and Ouzounis, 2000). Therefore, proteins that are fused in
some species are likely to interact in other organisms. Such fusion proteins have also been called Rosetta
stone proteins as they might be able to reveal the mystery of the function of their components. Several
advantages of gene fusion have been mentioned (Long, 2000). First, the expression of functionally related
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Figure 2.2 Methods for mapping protein-protein interactions by integrative genomics approaches. (a) Phy-
logenetic profile: The phylogenetic profile of a gene is the pattern of its presence (black) and absence (white) across
different organisms. Two genes (A and C) showing similar patterns suggest a physical or functional linkage. (d) Gene
fusion: Two proteins in one organism (E. coli) appear as a fused single protein in another (yeast). (c) Conserved
gene order: The two neighbouring genes appear in the same order in the genomes of different organisms, particu-
larly in prokaryotes. (d) Co-expression: Interacting proteins tend to show a similar expression pattern (gene A and
D).
proteins is co-regulated. Second, multi-functional enzymes do not dissociate even at low concentration.
Gene fusion is considered the most direct evidence of physical interaction among the integrative genomic
methods.
Gene context conservation. An approach which is analogous to the Rosetta Stone methodology, and
can be useful to complement it, is based on the analysis of gene neighborhoods in genomes (Dandekar et
al., 1998; Overbeek et al., 1999). The central assumption is quite basic. In prokaryotes, functionally related
genes are often located together, forming an operon. Since the composition of operons is evolutionarily
variable, the presence of such an operon in one or several genomes can be used to predict a functional
association for other organisms, even if the corresponding genes are scattered (Figure 2.2b). Dandekar
et al. (1998) compared nine bacterial and archaeal genomes and identified about one hundred genes as
conserved neighbours or clusters. For closely related species, the conservation of gene order may be
a result of the lack of chance for extensive recombination. Therefore, the genomes should be selected
appropriately such that they are not too close, but still share a significant number of orthologs.
Co-expression. Transcriptional co-expression patterns have proved useful for inferring physical protein
interactions (Deane et al., 2002; Jansen et al., 2003), with strongly co-expressed mRNAs more likely to
indicate long-lived interactions Figure 2.2d. The correlation of gene expression and protein-protein inter-
action was first studied in the T7 bacteriophage and in yeast (Grigoriev, 2001; Ge et al., 2001). Large
complexes of cellular machines such as ribosomes and proteasomes were shown to have a strong corre-
lation in yeast (Jansen et al., 2002). For complexes, strong co-expression is rationalised by the fact that all
complex subunits should be present at the same time and in balanced amounts. However, not all subunits
of a complex may be co-expressed. A recent analysis of cell-cycle related complexes in yeast suggests
that many complexes contain both periodically and constitutively expressed subunits (Lichtenberg et al.,
2005). By adding or removing crucial components, a just in time complex assembly can be achieved
(Jensen et al., 2006b). Recently, a map of human protein interactions derived from co-expression of hu-
man mRNAs and their orthologs was created by Ramani et al. (2008).
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Mirror tree. Pazos and Valencia (2001) proposed similarity of phylogenetic trees as an indicator of
protein-protein interaction. In the mirror tree method, the intensity of the co-evolution between a pair of
proteins is evaluated by Pearson’s correlation coefficient between a pair of distance matrices of the pro-
teins. However, it has been recognised that predictions by the mirror tree method include many false pos-
itives. Recently, Juan et al. (2008) presented a high-confidence prediction of global interactomes based
on genome-wide coevolutionary networks.
Conclusion. All the integrative genomic methods provide information correlated to physical interaction.
Therefore, they are useful to validate noisy high-throughput interaction data (Deane et al., 2002; Kem-
meren et al., 2002). Further, they can be integrated to predict interactions. In combination, these methods
were shown to be highly useful to infer unknown function or interaction (Huynen et al., 2000; Marcotte
et al., 1999). Various other types of data are integrated further to predict unknown functions or interac-
tions such as genetic interaction, localisation, phenotypes, transcription factor binding sites as well as
interologs (Walhout et al., 2002; Date and Marcotte, 2003; Jansen et al., 2003; Troyanskaya et al., 2003;
Lee et al., 2004; Kelley and Ideker, 2005).
Machine learning approaches
Bock and Gough (2001) used support vector machines for the prediction of protein–protein interactions
based on protein sequence and associated physicochemical properties. Further methods for predicting
protein–protein comprised random decision forest frameworks (Chen and Liu, 2005), Kernel methods
(Ben-Hur and Noble, 2005), signature products (Martin et al., 2005), and an ensemble of K-local hyper-
plane distance nearest neighbor classifiers (Nanni and Lumini, 2006). Choosing negative examples for
the prediction of protein-protein interactions was proposed by Ben-Hur and Noble (2006).
2.1.5 Protein and domain interaction databases
A number of databases exist collecting protein interaction data from the literature. Major interaction
databases comprise HPRD (Mishra et al., 2006), DIP (Salwin´ski et al., 2004), BIND (Bader et al., 2003),
MINT (Chatr-aryamontri et al., 2007), MIPS (Pagel et al., 2005), and IntAct (Kerrien et al., 2007). They
are listed in Table 2.1.
The data format was not standardised until the Human Proteome Organization proposed PSI-MI, the
Molecular Interaction (MI) language of the Proteomics Standards Initiative (PSI), an extensible markup
format in XML (Hermjakob et al., 2004). One aim of the PSI-MI is to allow data synchronisation between
different databases such as the nucleotide databases from EMBL, the DNA Data Bank of Japan, and
GenBank. (Kanz et al., 2005; Tateno et al., 2005; Benson et al., 2003).
Databases on domain–domain interactions are often based on structural data. Domain definitions are
taken from SCOP, the structural classification of proteins (Murzin et al., 1995), from Pfam (Bateman et al.,
2004), or from the conserved domain database, CDD (Marchler-Bauer et al., 2005). Although various
interaction databases and prediction servers exist — such as 3did, PIBASE, STRING, IntAct, ProMate,
InterPreTS, and PSIMAP (Stein et al., 2005; Davis and Sali, 2005; von Mering et al., 2007; Kerrien et al.,
2007; Neuvirth et al., 2004; Aloy and Russell, 2003; Park et al., 2001; Gong et al., 2005b) —, few focus
on the geometrical aspects of the domain–domain association.
The advances of X-ray crystallography resulted in a fast growth of multi-domain and multisubunit struc-
tures. To thoroughly understand the nature of protein interactions, investigations at multiple resolutions are
necessary from the atomic details at interfaces to pathways and genome-wide networks (Aloy and Russell,
2005).
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Table 2.1 Databases of protein–protein and domain–domain interactions. Protein interaction databases are
often manually curated. For small scale studies, this involves careful reading of the literature. Large scale studies
are usually imported in an automated manner without assessing their quality. Domain interaction databases are
often based on structural evidence. They employ different definitions for identifying domains, among them Pfam,
SCOP, and CATH.
Database Number of
interactions
Curation † Domain definition Reference
PROTEIN-BASED
BIND 83,517 M Protein level Bader et al. (2003)
MIPS 9,103 M Protein level Pagel et al. (2005)
DIP 57,099 A Protein level Salwin´ski et al. (2004)
BioGRID 99,104 M Protein level Stark et al. (2006)
STRING 730,000 A Protein level von Mering et al. (2007)
MINT 111,847 M, A Protein level Chatr-aryamontri et al. (2007)
HPRD 3,710 M Protein level Mishra et al. (2006)
NetPro 22,000 M Protein level Molecular Connections (2005)
IntAct 192,887 M, A Protein level Kerrien et al. (2007)
DOMAIN-BASED
iPfam 3,019 A Pfam Finn et al. (2005)
3did 3,304 A Pfam Stein et al. (2005)
SCOPPI 3,358 A SCOP Winter et al. (2006)
SCOWLP 60,664 ‡ A SCOP Teyra et al. (2006)
CBM 2,784 A Conserved Domain
Database
Shoemaker et al. (2006)
PIBASE 2,387 A SCOP, CATH Davis and Sali (2005)
PSIMAP 93,000 ‡ A SCOP Gong et al. (2005b)
PRISM 21,684 (clus-
tered: 3,799)
A Interface-similarity Ogmen et al. (2005)
InterPare 44,378 ‡ A SCOP Gong et al. (2005a)
DIMA A Pfam Pagel et al. (2006)
SNAPPI-DB 4,217 A SCOP, CATH, Pfam Jefferson et al. (2007)
DOMINE 20,513 A Pfam Raghavachari et al. (2008)
† M—manual, A—automatic
‡ not clustered
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2.2 Definition of open problem
Motivation
Investigations on domain–domain interactions are often based on structural data. Although various inter-
action databases and prediction approaches exist, few focus on the geometrical aspects of the domain–
domain association. Detailed knowledge on the interaction interface, as it is available in three-dimensional
complex structures, helps to identify the key residues that are responsible for mediating the interaction.
This knowledge could be used to predict protein interactions even in the absence of structural data.
Reliable interaction prediction is of growing importance. High-throughput screening experiments such
as microarray studies or genome-wide RNAi screens generate masses of data. In contrast to small-scale
experiments, hundreds of genes or proteins are revealed by such large-scale efforts. One fundamental
question is how these proteins interact in order to create the phenotype that was screened for in the study.
In addition, high-throughput experiments for detection of protein interactions, such as yeast two-hybrid
or complex purification, are still error-prone. Telling which are the false negatives and false positives in
interaction networks generated with these methods is still not sufficiently possible.
Open problem
How can structural knowledge about protein interactions and their interfaces help to predict protein–
protein interactions? How can it be combined and completed by sequence-based sources of protein
interaction that are commonly available?
2.3 Results
The results of this chapter are structured as follows. First, the SCOPPI database is presented. SCOPPI,
the Structural Classification of Protein–Protein Interfaces, classifies and annotates domain interactions in
all known protein structures. It is available online, providing various views on the data and query options.
Several examples are presented where SCOPPI is a useful tool to analyse viral mimicry of human interface
binding sites, gene fusion events, conservation of interface residues, and diversity of interface localisations.
The classification of interfaces is based on sequence as well as structural similarity. The classification
algorithm and its validation are described.
Three use cases are presented that utilise SCOPPI in different ways to induce and predict interaction
networks for deregulated pancreas cancer proteins in human, for meiotic microtubule-associated proteins
in Xenopus, and for osteoclast differentiation in mouse.
2.3.1 A classification of structural domain–domain interactions: SCOPPI
Idea
The idea of SCOPPI is to investigate domain–domain interfaces in proteins of known structure. Domains
are defined according to the SCOP, the Structural Classification of Proteins (Murzin et al., 1995). SCOP is
a comprehensive ordering of all proteins of known structure, according to their evolutionary and structural
relationships. The SCOP hierarchy comprises, from bottom to top, the levels of protein domain, family,
superfamily, fold, and class. Domain members of one family have similar sequences, and superfamily
members originate from a common evolutionary ancestor.
In SCOPPI, we define two domains to interact if they have at least 5 residue–residue contacts within
5 Å (Gong et al., 2005b). This distance-based interaction criterion is in accord with other interface defi-
nitions such as burial of accessible surface area, interatomic distances, or van der Waals energy, which
were all shown to be consistent with each other (Tsai et al., 1996).
32 C H A P T E R 2 . P R E D I C T I O N A N D C L A S S I F I C AT I O N O F P R O T E I N – P R O T E I N I N T E R A C T I O N
Rac1
DH domain PH domain
Tiam1
BA
Figure 2.3 The most detailed knowledge on protein interactions can be gained from structures. (A) The
interaction of small GTPase Rac1 (blue) with the DBL homology (DH) domain of the Guanine nucleotide exchange
factor Tiam1 (red) is shown, as obtained from X-ray crystallography. Tiam1 has a second domain, a Pleckstrin
homology (PH) domain (light brown), which does not interact with Rac1, but rather functions as a membrane anchor
by interacting with membrane lipids. (B) The atoms that mediate the interaction are shown as spheres. They are
defined as those atoms of one domain that are within 5 Å distance of the other domain.
Figure 2.3 shows an example of a protein–protein interaction which is mediated by a domain–domain
interaction: the small GTPase Rac1 (blue) interacting with its guanine nucleotide exchange factor Tiam1.
Tiam1 consists of two domains — a DBL homology domain which interacts with Rac1, and a Pleckstrin
homology domain, which does not participate in the interaction. On the left in Figure 2.3, the full complex
is shown. On the right, the atoms that are interacting according to the 5-Å-rule are highlighted as spheres.
Two faces constitute an interface
We use the term face for a binding site on a single domain and interface for the interacting faces of two
domains. The notion of a face allows us to investigate how different faces of domains that belong the
same SCOP family relate to each other. Faces that show high similarity, for example by sufficient overlap,
are clustered together, forming a face type. A detailed description of the clustering and classification
procedure is given on page 41. As face types define similar binding sites for members in a SCOP family,
the combination of two face types forms an interface type. In the examples section (page 35), we will see
how face types allow to study cases of gene fusion and molecular mimicry.
Multiple sequence alignments of SCOP family members
To better analyse and visualise domains, SCOPPI creates a multiple sequence alignment of domains
within a SCOP family. Interface residues are highlighted in the aligned sequences. Figure 2.4 shows an
example for interactions of the Myosin S1 fragment, N-terminal domain. Each row of the tabular repre-
sentation corresponds to a domain–domain interaction. Interacting face residues are depicted in upper
case and highlighted in yellow. Already in the sequence alignment, one can identify three face types of
the Myosin fragment domain. For interaction with Calmodulin-like domains, displayed in the first row, dif-
ferent residues are used as compared to the interaction with Motor protein domains. For the latter, most
domain–domain pairs have a similar pattern of face residues, except for the one in the last row, where
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Figure 2.4 A typical SCOPPI query result. Here, all interactions of domains of the Myosin S1 fragment fam-
ily (SCOP identifier b.34.3.1) with domains of other families are shown, with one interaction per line. Interacting
residues are displayed in uppercase and highlighted in yellow. The source PDB file and its resolution are listed on
the left.
most domain residues are participating in the interaction. Accordingly, SCOPPI lists three face types for
this family (not shown).
Interface characteristics
Various interface characteristics are determined. They are defined as follows.
Intra and inter chain interactions. The interaction type of intra is assigned to the domain pairs from
the same polypeptide chain and inter to the pairs from different chains.
Homo and hetero dimers. If two interacting domains belong to the same family, the interaction is clas-
sified as homo dimer. If they are from different families, it is classified as hetero dimer.
Permanent and transient interactions. Following Kottha and Schroeder (2006), each domain–domain
interaction is classified as permanent or transient. The classification is based on criteria including the
homo or hetero dimeric state of the protein, Swiss-Prot and PDB molecule annotations, and enzyme
class numbers. The exact rules are given in the Materials and Methods (page 63).
Non-redundant sets of interfaces
Since the very same protein can be present multiple times in the PDB, for example in the case of
hemoglobin, such redundant sequences can be filtered out. To this end, a series of non-redundant in-
terface sets are available at different sequence identity thresholds from 50% to 100% in 5% intervals.
Sets of non-redundant sequences were generated for each SCOP family using CD-HIT (Li et al., 2001).
All domains within a family are then represented by the non-redundant domains at a given threshold. Intra
and inter chain interfaces are not merged but treated separately.
Statistics
SCOPPI contains some 73,000 domain–domain interactions and their interfaces (see Table 2.2). The
majority of these, ∼44,000, are homo dimers between separate polypeptide chains. Considering only
sequences that are not more than 90 % identical, there are∼10,000 distinct domain–domain interactions.
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Table 2.2 Statistics of domain–domain interactions in SCOPPI. The majority of interactions are homo dimers
between separate polypeptide chains (inter chain). Classification into interface types reveals that 40% of the family
interactions associate in multiple orientations.
Intra chain† Inter chain† Total
Homo ‡ Hetero ‡ Intra
total
Homo Hetero Inter
total
Total domain pairs 3,562 13,665 17,227 43,939 11,690 55,629 72,856
NR90 domain pairs ? 511 1,689 2,200 6,313 1,567 7,880 10,080
Superfamily pairs 147 565 712 966 693 1,659 2,081
Family pairs 189 672 861 1,613 783 2,396 2,934
Family pairs of multiple
interfaces (%)
34
(18%)
112
(17%)
146
(17%)
737
(46%)
191
(24%)
928
(39%)
1,172
(40%)
Interface type 256 830 1,086 3,612 1,090 4,702 5,727
Interfaces/family pair 1.4 1.2 1.3 2.2 1.4 2.0 2.0
† Intra chain, domains are on the same polypeptide chain; inter chain, domains are on separate
polypeptide chains
‡ Homo dimer, domains belong to the same family; hetero dimer, domains belong to different families
? NR90, non-redundant set with maximum of 90% sequence identity
At the SCOP family level, this corresponds to ∼3,000 family–family pairs. Since one family can exhibit
one to many face types, we observe ∼5,700 interface types in SCOPPI. These represent the current
knowledge on how two domain structures can associate in three-dimensional space. Whereas 60% of
family pairs have only one known orientation of interaction, 40% can associate in multiple orientations.
As we will see later, this has an impact on the problem of docking. On average, there are two possible
associations, i. e. interfaces, per domain family pair.
2.3.2 The SCOPPI web interface
SCOPPI is available online at http://www.scoppi.org. In the following, the web-based user interface is
described.
Query options. SCOPPI can be queried for a SCOP family, superfamily, one or several PDB identi-
fiers or a keyword. For keywords entered, SCOP family and superfamily description, PDB headers and
InterPro abstracts (Apweiler et al., 2000) are searched. SCOPPI can be further browsed by SCOP fam-
ily descriptions alphabetically and by the Gene Ontology hierarchy (Ashburner et al., 2000). All queries
will finally result in the display of sequences or screenshots of interacting domains along with interface
characteristics.
Data view. A typical query result is presented in Figure 2.5. The data is organised in a table: Each
row represents one domain–domain interaction, and each column depicts one property of this interaction.
In the default view, SCOPPI shows resolution and 4-letter PDB identifier of the source file, sequences
of the two domains in full length with highlighted interacting residues, the face types for both domains,
the interaction type and a link to GoPubMed (Doms and Schroeder, 2005). Both sequence columns are
grouped by SCOP family. If SCOPPI was queried for a family and not for a PDB identifier, this family always
appears on the left. The View selector to the very left above the result table is used to obtain different
views on the data: To access all interaction properties including the SCOP unique identifier for each
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domain, it can be changed to All. Structures presents a view without sequences, but with screenshots for
each interaction. Images are clickable to obtain a larger version.
Various other interface characteristics such as permanent or transient nature of the interaction, in-
terface size (the loss of accessible surface area upon complexation, ∆ASA), domains on the same or
different polypeptide chains and number of interacting atoms and residues are available.
Display of sequences. Interacting residues are displayed in upper case letters, non-interacting in lower
case. The default coloring highlights interacting residues for better identification. It can be changed with
the Color selector to assign different colors to different face types. A simple conservation overview is
provided by assigning a color to each residue depending of the frequency in the column of the multiple
sequence alignment. Residues can be further colored by physicochemical type. Sequence display facili-
tates switching between aligned sequences, raw sequences without gaps, and only the aligned interfaces,
where 3 dots indicate 4 or more left out non-interacting residues.
Filter options. Since lots of identical sequences exist among SCOPPI’s domain interactions, we pro-
vide non-redundant sets at various sequence identity levels. A default 90% cut-off leads to around 10,000
different domain–domain contacts. Non-redundant sets are available via the Redundancy cut-off (%) se-
lector. To filter out small interfaces, we calculate the change in accessible surface area∆ASA and provide
an interface size cut-off selector for 600, 1400, and 2000 Å2.
Interface screenshots. For each domain–domain interaction in SCOPPI, interface screenshot were
pre-generated with PyMOL (DeLano, 2002) and stored (see Figure 2.5, bottom).
2.3.3 Examples of SCOPPI usage
SCOPPI provides a multiple sequence alignment of domains and their interacting residues within a family.
The multiple alignment of these interaction interfaces in combination with the clustering and classification
of binding sites is a unique feature of SCOPPI. The following examples will illustrate how this feature can
provide interesting insight into various fields. In the following, IDs such as 1kim refer to PDB structures
(Berman et al., 2000), and a.48.1.1 to SCOP families (Murzin et al., 1995).
Binding site similarity: Viruses mimic interfaces
Chemokines play a key role in leukocyte recruitment and migration. A query for the term chemokine in
SCOPPI finds, among others, the Interleukin-8 like chemokines family (d.9.1.1). Following the family link
in the results lists all interactions of chemokine family members with other domains: SCOPPI shows that
IL-8 like chemokine domains can associate with domains of the same family, forming homodimers, and
that they can associate with members of the viral chemokine binding protein M3 family (b.116.1.1). The
Face type family 1 column reveals that the viral protein binds to the same face type of the chemokine
that is used for homodimerisation. Alexander et al. (2002) report that viral protein M3 indeed employs
structural mimicry to sequestrate chemokines.
Knowing that the binding occurs at the same binding site, interface similarities between the ligands
are expected. Indeed, as seen in Figure 2.6, there is an optimal fitting to a binding site that is utilised by
chemokines to form homodimers. To achieve this, the virus has evolved the SVSPLP motif which can play
the role of the native motif SSDTTP.
Another example, which was found in a systematic screen by Henschel et al. (2006), is shown in
Figure 2.7. The caspase catalytic domain of human caspase (c.17.1.1, blue), interacts with its its natural
inhibitor, the inhibitor of apoptosis (IAP) protein (g.52.1.1, red). Interestingly, the same face type of the
caspase domain is also used for the interaction with the Baculovirus p35 protein (b.28.1.1, yellow). IAP
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Figure 2.5 The SCOPPI web interface. Top: SCOPPI displays sequences of interacting domain pairs, aligned
by families. Each row represents one interaction, while columns describe various aspects of that interaction. Views
on the data, filters and coloring can be changed. Here, residues are colored by conservation within the family.
Bottom: When switching to the structure view, SCOPPI shows screenshots of two interacting domains (left) and their
interface (right). Various interface characteristics such as size of interface, number of involved residues, permanent
or transient nature of the interaction are further available. Explanations for these characteristics appear as the
mouse is moved over the column headers.
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Figure 2.6 Viral proteins mimic host chemokine interfaces. Left: The viral protein M3 (yellow) adapting to hu-
man chemokine (blue), mimicking the native chemokine homodimer (green). The backbone of M3 between Ser269
to Pro274 (motif SVSPLP) fits nicely to Ser4 to Pro9 (motif SSDTTP) in chemokine. Both faces utilise proline to fill
the cleft (source: PDB structures 1ml0 and 1b3a superimposed).
and p35 both block the active site of the caspase (orange). To do so, they use quite similar faces, although
they belong to completely different SCOP classes. It seems that the viral has evolved to mimic the face
of the natural inhibitor. Since there is no common ancestor between IAP and p35, and also the residues
participating in the interaction are completely different, this can be seen as an example of convergent
evolution.
Binding site diversity: Where do cytokines bind to their receptors?
Some families’ members display a considerable variety of face types when interacting with members
of another family. Querying SCOPPI for the Long-chain cytokines (a.26.1.1) reveals such an example.
Domains of this family appear as part of human cytokines, human growth hormone and prolactin. When
interacting with their receptors, the ligand’s cytokine domain binds to the fibronectin type III domain of the
receptor. SCOPPI reports that there are 10 different interface types for this interaction (Face type family 1
column on the right). To confirm this, we superimpose 3D interactions of several examples structurally
aligning the cytokine domain (Fig. 2.8). The cytokine domains are shown in black, with the associated
fibronectin domains in various colors. There are clearly numerous different interaction sites (face types)
on the cytokine domain surface.
Binding site conservation: How well conserved is the trypsin pocket?
Consider trypsin-like serine proteases that are found in the family of eukaryotic proteases (b.47.1.2). The
active site of these enzymes is formed by a catalytic triad of three residues: histidine, aspartic acid and
serine (in sequential order). Due to the obvious importance of these three residues, we expect them to be
conserved throughout all members of the serine protease family. To verify this, one can enter b.47.1.2 in
SCOPPI, apply a redundancy level of 50% for a better overview and select Conservation from the color
selector. The result is depicted in Figure 2.9. The conservation percentage is simply calculated by counting
the number of residues of the same type in that column divided by all residues in that column. Residues
with a value above 90% will display in red, those with a value below 10% in purple. A color legend pop-up
is available through a hyperlink next to the selectors. For the serine proteases, SCOPPI reveals a highly
conserved region AAHC with the catalytic histidine residue. Asp (D) is also well conserved (DIxLxxL motif).
Serine (S) is found inside a conserved GDSGGP motif. It is striking, however, that the serine is not fully
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Figure 2.7 Viral mimicry of host binding site. Baculovirus protein p35 (yellow) mimics the binding site of human
inhibitor of apopotosis (red) in order to bind to human caspase (blue, active site in orange). Although structurally
similar, there is no apparent sequence similarity present at the binding site—a fine example of convergent evolution.
Figure 2.8 Binding site diversity. The cytokine domain (grey) can associate with the fibronectin domain (various
colors) in eight different orientations, each using a different binding site on the cytokine domain surface.
Binding site diversity: Superimposed examples of an interaction between a cytokine domain (black) and a fibronectin
domain (various colors). The examples were structurally aligned to the cytokine domain. According to SCOPPI, a
total of 10 different face types are identified on the cytokine domain surface for this interaction.
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Figure 2.9 Conservation of the trypsin-like serine proteases. The conservation coloring of the multiple se-
quence alignment of trypsin-like serine proteases (b.47.1.2) in SCOPPI reveals highly conserved residues. Conser-
vation is color-coded, with violet corresponding to low, and red corresponding to high conservation. The catalytic
triad of histidine, aspartate, and serine is marked.
conserved — between 10% and 20% of the family members are missing the serine at this position. Closer
examination reveals that in these cases serine had been subject to site-directed mutagenesis studies and
was changed to alanine.
Binding site orientation: Gene fusion
The interface type classification of SCOPPI defines groups of pairs of domains that associate in the same
geometric orientation (i. e. clusters of domain pairs with the same interface type). In addition, SCOPPI
provides the information if two interacting domains reside on the same or on separate polypeptide chains
(i. e. if the interaction type is intra or inter ). If two domain pairs interact in the same orientation, but the
interaction type is intra in one and inter in the other case, the reason behind this observation might be a
gene fusion event.
Such an example is found among domains of the c.1.2.1 family (Histidine biosynthesis enzymes)
interacting with domains of family c.23.16.1 (Class I glutamine amidotransferases). SCOPPI’s face type
column on the right informs that there are inter and intra cases displaying the same two face types.
The matching face types can also be identified just by looking at the highlighted interacting residues of the
aligned sequences. Taking two PDB files of the listed cases, 1gpw and 1ox4, and displaying the interacting
domains confirms the above finding at structural level (see Figure 2.10). Both PDB files describe the
crystal structures of Imidazole Glycerolphosphate Synthase, which catalyses formation of the imidazole
ring in histidine biosynthesis. The functional enzyme consists of a glutamine amidotransferase domain
(top), and a cyclase domain (bottom). In Thermotoga maritima, a hyperthermophile bacterium, these
domains are located on two separate polypeptide chains, forming a heterodimeric protein. In yeast, the
two domains are fused together, as it is common in plants and fungi (Chaudhuri et al., 2003). SCOPPI
nicely picks up this example by its classification of geometrically distinct interface types. In total, we identify
59 of such examples. In two thirds of these, the orientation of the association is preserved after fusion or
fission, whereas in one third of the cases a new association arises.
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Figure 2.10 Binding site fusion. In the bacterium Thermotoga maritima (left), the amidotransferase domain (top)
and the cyclase domain (bottom) of Imidazole Glycerolphosphate Synthase are located on two separate polypeptide
chains, whereas in yeast (right) they are fused together. Note that the binding orientation is conserved after fusion.
Genuine versus non-genuine gene fusion. We define genuine gene fusion cases, in which the bind-
ing orientation of the fused and non-fused domains is preserved, as opposed to non-genuine gene fusion
cases, in which the binding orientation is not preserved. A systematic screen among all SCOPPI inter-
actions revealed that two-thirds of gene fusions associate in the same orientation, while the remaining
one-third interacts differently. Conventionally, gene fusions or domain fusions are identified by sequence
similarity search for two separate proteins in one organism appearing as a single homologous fusion pro-
tein in another organism. However, there has been study to check how often the binding orientation is
conserved.
Ancient interfaces are dominated by symmetric homodimers
How did different interface types evolve, and how many of them are common among species or lineage-
specific? The questions of the evolutionary history and the taxonomic distribution of interfaces are highly
interesting but difficult to answer due to the bias and the low coverage of structures available. Gene dupli-
cation followed by differentiation is an important mechanism to develop complex protein functions in higher
organisms. In order to gain insight into the evolution of interfaces, we analyzed the taxonomic distribution
of interactions and interfaces in the three major kingdoms of life: archaea, bacteria, and eukaryotes.
In terms of family pairs, archaea have the most overlap with other kingdoms, probably because they
are the most primitive form of life. There are 75 family pairs that have member domain pairs from all the
kingdoms. For a statistical interpretation, 23 family pairs were selected out of the common 75 family pairs,
each with a taxonomic diversity of ten or more species. These core 23 family pairs consist of 127 inter
chain and ten intra chain interfaces originating from a total of 160 species.
We assumed that an interface type is ancient if it is common to all three kingdoms. The taxonomic dis-
tribution of the 127 inter-type interfaces is shown in Figure 2.11. Interestingly, the common or ancient 20
interfaces all belong to symmetric homodimers, with only two exceptions (one hetero and one asymmetric
homo). Asymmetric homo and hetero dimer types are enriched in the lineage-specific category, though
not as strongly as in the ancient category. This observation supports the trend of interface evolution from
symmetric to asymmetric or hetero. In contrast to ancient types, the identification of lineage-specific types
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Figure 2.11 Ancient interfaces are dominated by symmetric homodimers. The venn diagram shows the dis-
tribution of 127 interfaces and their categories from 23 family pairs common to all three kingdoms and having ten
or more species diversity. The category of the interfaces are divided as homo and hetero. Symmetric homodimers
associate using the faces of the same type, and asymmetric homodimers using the faces of different types. The 20
common or ancient interfaces are mostly symmetric homodimeric.
is always ambiguous because the structures may simply not be available across multiple kingdoms. Here,
90 of the 127 interfaces were found to be lineage-specific to a single kingdom. However, only five of these
were estimated significantly lineage-specific (p < 0.01): four symmetric and one asymmetric homo-types.
The significance was calculated as the probability of sampling N times only the species of the single king-
dom out of the total species found in the corresponding family pair, where N is the number of member
domain pairs of the interface type. In the ten intra-type interfaces, there were one symmetric, two asymmet-
ric, and five hetero-types, where five hetero-types were ancient. None of the lineage-specific interfaces
were significant because of the small amount of data. Overall, this analysis supports the hypothesis stated
by Ben-Shem et al. (2004) that ancient interactions are symmetric homodimers.
2.3.4 Face type classification procedure
The classification of interfaces in SCOPPI is a two-step procedure. It involves a sequence-based followed
by a structure-based clustering of similar faces into face types, which is described in detail in Kim et al.
(2006).
Sequence measure of similarity
The geometry of interfaces is first classified using interface tags (IFTs), which represent sequence pat-
terns of interface residues on the aligned sequences. The interface tags (IFTs) of each family are gener-
ated as follows. The face residues are defined as the residues containing at least one atom contacting
with the other domain within 5Å of distance cut-off. The interface tag (IFT) is generated by mapping the
face residues onto the aligned sequences for each family. After the alignment, the interface residues are
converted to 1’s and non-interface residues to 0’s (see Figure 2.12). The resulting IFT becomes a vec-
tor of 1’s and 0’s with gaps, for example 10-01110-00 for an aligned sequence Ms-aHCWk-im (interface
residues in uppercase and non-interface residues in lowercase). Since all the domain sequences are
aligned simultaneously in a family, the lengths of IFTs are the same within the same family.
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The similarity of IFT patterns is measured using the cosine distance of the two IFT vectors, where the
positions containing gaps on either of the two IFTs are ignored.
DIFT (u,v ) = 1− u · v|u||v |
As the elements of each vector consist of only 1’s and 0’s, the distance becomes 0 between identical
IFT pairs and 1 between IFT pairs without any common interface residue.
Structural measure of similarity
To measure the similarity of two faces, two geometric features — face overlap and face angle — are intro-
duced in addition to the sequence-based interface tag (Figure 2.12). The scale of measurement is set
to decrease for more similar faces so that the features are appropriate for clustering. The two geometric
features are calculated after the structural alignment of the two domains. The face overlap distance DO
measures the spatial overlap of the interface atoms between two faces (Figure 2.12c). The face angle DA
measures the angle between the two centroids of the faces and the common centroid of the two domains
(Figure 2.12d). The full descriptions of DIFT , DO , and DA are given in Materials and Methods on page 63.
Interface classification by a hybrid approach
Hierarchical clustering can be applied at a specified face overlap or face angle cut-off. However, clustering
all the faces solely based on geometric features needs enormous computation. Several SCOP families
contain more than one or two thousand domains, where each requires about 0.5–2 million structural com-
parisons. Multi-faced domains add more complexity as each face should be compared independently. As
the known structures are highly redundant, a hybrid approach is applied to reduce the amount of computa-
tion. First, faces of highly similar IFT patterns are merged into stage I face clusters at DIFT < 0.1 to remove
redundancy. A representative face is chosen in each stage I face cluster. Second, the representative faces
are clustered using the geometric feature of face overlap distance (DO) or face angle (DA), resulting in
stage II face clusters. The types of the non-representative faces are assigned those of their representa-
tives. The hybrid method saves considerable computation but still achieves a comparable accuracy to a
fully structural method. The quality of classification critically depends on the accuracy of sequence align-
ment. In families containing remote homologs, the alignment is not accurate enough and thus results in
erroneous classification. Here, the IFT-based method is improved by using structural alignment.
Accuracy of classification
The classification accuracy was tested using 416 manually classified interfaces between 28 family–family
pairs. To make the test challenging and rigorous, the family pairs were chosen from family pairs with highly
diverse binding orientations, and the interfaces were made non-redundant. On average, the family pairs in
the benchmark shows 5.4 distinct binding orientations, or interface types. The benchmark set was made
non-redundant by collating domain pairs of similar interface patterns (DIFT < 0.3) for both faces.
A series of hierarchical clustering conditions are tested using DA ranging from 0° to 60° in 5° intervals
and DO ranging from 1% to 100% in 5% intervals as cutoffs. The recall and the precision were calculated
for each interface type. The classification by face overlap consistently showed better accuracy than the
face angle method. In comparison with the IFT clustering method, the face overlap method showed nearly
10% better recall at the same precision, while the face angle method shows the lowest accuracy. The fully
structural method has a classification accuracy of 91% recall and 92% precision. The hybrid procedure has
83% recall and 95% precision, showing a significant improvement from 78% and 90% by IFT clustering
alone. The hybrid procedure achieves an accuracy rate close to that of the purely structure-based method
with far less computation.
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Figure 2.12 Different measures of face similarity used for clustering. To determine the similarity of two faces
(a), three distance measures are employed. A sequence based interface tag distance is computed from the aligned
domain sequences by representing interface residues by 1’s and other residues by 0’s, and calculating the cosine
distance of the corresponding vectors (b). After structural alignment, geometrically overlapping face residues can
be determined, resulting in the face overlap distance (c). The angle between the two centroids of the two faces and
the common centroid of the two domains yields the face angle distance (d).
Face overlap and IFT clustering use a set of atoms or residues, while the face angle method uses only
a single point to represent a face. Accordingly, the face angle method loses the information about shape
or volume when the distance is measured. The observed accuracy reflects the order of how well the face
definition represents the 3D shape of each face (overlap > IFT > angle).
2.3.5 SCOPPI use case 1: The pancreas cancer proteome
Given the knowledge of structural interfaces, we now address the open problem of how structural knowl-
edge about protein interactions and their interfaces can help to predict protein–protein interactions. In the
following use case, SCOPPI interactions are used as structural templates to predict interactions between
proteins deregulated in pancreatic cancer. Parts of this were published in
Gihan Dawelbait, Christof Winter, Yanju Zhang, Chrisitian Pilarky, Robert Grützmann, Jörg-
Chrisitan Heinrich, and Michael Schroeder. Structural templates predict novel protein inter-
actions and targets from pancreas tumour gene expression data. Bioinformatics 23:i115–24,
2007
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Introduction
Pancreatic cancer is the fourth leading cause of death due to cancer in virtually all industrialised countries.
It accounts for approximately 100,000 deaths per year in the United States and Europe. Pancreatic ductal
adenocarcinoma is the most common pancreatic neoplasm and is found in about 80% of pancreatic tumor
cases (Hezel et al., 2006). Since pancreatic cancer is not only difficult to detect, but also difficult to treat, it
has an extremely poor prognosis. To improve this prognosis, novel molecular markers for earlier diagnosis
and targets for adjuvant or neoadjuvant treatment need to be identified.
Data set
The data set used for this case was pooled from previous studies (Grützmann et al., 2003a; Grützmann
et al., 2003b; Grützmann et al., 2004b; Grützmann et al., 2005) and contains 1,612 genes differentially
expressed in pancreatic ductal adenocarcinoma (PDAC) compared to normal pancreas tissue. Of these,
944 were up-regulated and 668 were down-regulated in the cancer tissue.
Approach
Protein interactions provide an important context for understanding protein function. We aim at using
structural information to predict novel interactions among the PDAC proteins. Our interaction prediction
approach is based on structural templates from SCOPPI. The idea of predicting new interactions from
these known ones is outlined in Figure 2.13. First, we assign SCOP domain structures to all proteins in
our data set by threading (McGuffin et al., 2004). Threading is a fold recognition technique that allows
structure prediction for sequences that are related to known structures, but where no stucture exists yet.
For every protein pair, we check if we find two assigned domains that are known to physically interact. If
we find such evidence, we infer an interaction between the two proteins. This initial interaction prediction
is further refined. Since our predicted interactions are based on existing complex structures, we know the
residues that are part of the binding site. After determining the amino acid sequence conservation at the
binding site, we consider only proteins with interface sequence identity of more than 50% compared to
the structural template. The initial prediction (Figure 2.13) yields ∼1,000 potential interactions among the
PDAC microarray data set out of 300,000 protein pairs with assigned domains. Filtering out predictions
with less than 50% interface identity as well as medium or low threading confidence results in a set of
40 confident, novel interactions. Table 2.3 contains the subset of 29 interactions where only interactions
between a pair of up–up or up–down regulated genes are shown in addition to two literature confirmed
interactions which are down–down regulated.
Results and discussion
A pancreas cancer map. Combining known interactions and predicted interactions and adding local-
isation information from the Gene Ontology cellular component annotation, we obtain the hallmarks of
pancreatic cancer map (Figure 2.14). The map illustrates the gene products of the PDAC data that are
involved in the 40 novel predicted interactions. Figure 2.14 shows the complete picture of the integrated
circuit of the cell progress which we annotate with the PDAC genes. The genes are located inside the map
according to their cellular localisation. The colours of the genes encode their regulation level (green for
down-regulated and red for up-regulated). Edges linking genes represent interactions among the genes
where red edges indicate confirmed interactions and blue edges indicate the predicted ones.
Our data confirm several of the classical cancer alterations. In addition, we complement these by
known and predicted interactions. Most notably, we find many extracellular proteins to be deregulated.
Table 2.3 lists 29 structure-based interactions predictions after filtering. These interactions have a high
confidence with respect to the threading structure prediction method. Furthermore, they have a sufficient
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Table 2.3 Twenty-nine predicted interactions based on structural evidence between proteins deregulated
in pancreatic cancer. Protein 1 is the interaction partner of Protein 2. The arrow next to the protein symbol indicates
whether the corresponding gene was up- (↑ ) or down-regulated (↓ ). The complex column shows the PDB ID of
the structural template that was used for modelling of the interaction. The interface conservation is indicated as
percentage identity of the interface residues between protein and structural template. All predictions were manually
checked in the literature. Verified predictions are marked with X, and × represents an explicit negative literature
confirmation (Lolli et al., 2004).
Protein 1 Description
Interface
conser-
vation
Complex
PDB
ID
Protein 2 Description
Interface
conser-
vation
Confirmed
by liter-
ature
MLRM ↑ Myosin regulatory light
chain 2, nonsarcomeric
63% 1b7t MYH9 ↑ Cellular myosin heavy
chain, type A
57%
TFPI2 ↓ Tissue factor pathway
inhibitor 2
62% 1taw KLK10 ↑ Kallikrein 10 59%
TFPI2 ↓ Tissue factor pathway
inhibitor 2
61% 1brc TMPRSS4 ↑ Transmembrane protease,
serine 4
63%
TMPRSS4 ↑ Transmembrane protease,
serine 4
64% 1ezx SERPINI2 ↓ Serpin I2 50%
TMPRSS4 ↑ Transmembrane protease,
serine 4
58% 1sgf NTF5 ↓ Neurotrophin-5 80%
RHOA ↑ Transforming protein
RhoA
89% 1am4 DLC1 ↓ Deleted in liver cancer 1,
isoform 1
58%
RHOA ↑ Transforming protein
RhoA
80% 1kzg PLEK2 ↑ Pleckstrin-2 50%
FYN ↑ FYN Tyrosine Kinase
protooncogene
77% 2src EPS8L1 ↓ Epidermal growth factor
receptor kinase substrate
8-like protein 1
50%
FYN ↑ FYN Tyrosine Kinase
protooncogene
77% 2src BIN1 ↑ Myc box-dependent-
interacting protein 1
50%
C2 ↑ Complement component 2 64% 1ezx SERPINI2 ↓ Serpin I2 50%
C2 ↑ Complement component 2 50% 1sgf NTF5 ↓ Neurotrophin-5 80%
KLK10 ↑ Kallikrein 10 57% 1ezx SERPINI2 ↓ Serpin I2 50%
RAB25 ↑ Ras-related protein Rab-
25
56% 1cjt ADCY9 ↓ Adenylate cyclase type 9 50%
RAB25 ↑ Ras-related protein Rab-
25
56% 1cjt ADCY3 ↑ Adenylate cyclase type 3 50%
RRAS ↑ Ras-related protein R-Ras 100% 1wq1 RASAL2 ↑ RAS protein activator-like
2
59%
MYL9 ↑ Myosin, light polypeptide
9, regulatory
61% 1b7t MYH9 ↑ Cellular myosin heavy
chain, type A
57%
KRAS2 ↑ GTPase KRas 100% 1wq1 RASAL2 ↑ RAS protein activator-like
2
59%
RGS2 ↓ Regulator of G-protein
signalling 2, 24kDa
53% 1fqj RAB22A ↑ Ras-related protein Rab-
22A
50%
RGS5 ↑ Regulator of G-protein
signalling 5
53% 1fqj RAB22A ↑ Ras-related protein Rab-
22A
50%
RGS16 ↑ Regulator of G-protein
signalling 16
53% 1fqj RAB22A ↑ Ras-related protein Rab-
22A
50%
CDC2L1 ↑ Cell division cycle 2-like 2 67% 1fq1 CDKN3 ↑ Cyclin-dependent kinase
inhibitor 3
100%
RAB22A ↑ Ras-related protein Rab-
22A
56% 1jx2 KIF20A ↑ Kinesin family member
20A
60%
CDC2 ↑ Cell division control pro-
tein 2 homolog
83% 1fq1 CDKN3 ↑ Cyclin-dependent kinase
inhibitor 3
100% X
CDK7 ↑ Cyclin-dependent kinase 7 58% 1fq1 CDKN3 ↑ Cyclin-dependent kinase
inhibitor 3
100% ×
ARHGDIA ↑ Rho GDP dissociation
inhibitor(GDI)alpha
100% 1cc0 RHOA ↑ Transforming protein
RhoA
100% X
EPS15L1 ↓ Epidermal growth factor
receptor pathway sub-
strate 15-like 1
50% 1dfk MYH9 ↑ Cellular myosin heavy
chain, type A
59%
TAPBP ↓ TAP binding protein 67% 2ig2 CD58 ↑ Lymphocyte function-
associated antigen 3
100%
TFPI2 ↓ Tissue factor pathway
inhibitor 2
62% 1taw F11 ↓ Coagulation factor XI 66% X
TFPI2 ↓ Tissue factor pathway
inhibitor 2
62% 1taw KLKB1 ↓ Kallikrein B, plasma
(Fletcher factor) 1
66% X
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Figure 2.13 Interaction prediction with structural templates.
conservation of the putative interacting residues when compared to the known structural template that
was used to model this interaction. One interesting example of two extracellular proteins that might play a
major role in tissue infiltration and metastasis of pancreas cancer is discussed below.
Some of the identified genes were investigated as therapeutic targets. Fleming et al. (2005) provided
support that silencing mutant K-ras through RNA interference results in alteration of tumor cell behaviour
in vitro and suggests that targeting mutant K-ras specifically might be effective against pancreatic cancer
in vivo. Lebedeva et al. (2006) as well targeted K-ras by using an adenovirus expressing a novel cancer-
specific apoptosis-inducing cytokine gene. Taniuchi et al. (2005) identified KIF20A as a candidate for
development of drugs to treat PDACs. Knockdown of endogenous KIF20A expression in PDAC cell lines
by small interfering RNA drastically attenuated growth of those cells, suggesting an essential role for the
gene product in maintaining viability of PDAC cells. From our data, we can predict a potential interaction
of KIF20A and RAB22A.
TFPI2 is a potential inhibitor of TMPRSS4. The interaction between the upregulated transmembrane
protease, serine 4 (TMPRSS4) and the downregulated tissue factor pathway inhibitor 2 (TFPI2) marks
an interesting example. In pancreas cancer cells, TMPRSS4 is involved in the process of metastasis
formation and tumor invasion, and its expression is correlated with the metastatic potential (Wallrapp et
al., 2000). TFPI2 is an extracellular protein that belongs to the small Kunitz inhibitor family. It is known to
be downregulated in PDAC.
Figure 2.15 shows how our structure-based method predicts and models an interaction between TM-
PRSS4 and TFPI2. The structures are predicted according to the domains found by Threader. Searching
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Figure 2.14 A comprehensive map of pancreas cancer relevant interactions. The underlying picture was
taken from (Hanahan and Weinberg, 2000) and updated with our findings. It depicts integrated circuit of the cell
progress annotated with the PDAC genes that are involved in the 40 novel predicted interactions. Proteins are
shown according to their cellular localisation. Genes coloured green are down-regulated while genes coloured red
are up-regulated. Lines linking genes represent interactions among the genes. Interactions confirmed by literature
shown in red, and predicted interactions shown in blue.
the SCOPPI database for interactions of related domains, we find the complex of trypsin (light blue)
and amyloid beta-protein precursor inhibitor (dark blue). The modelled structures (red and yellow in Fig-
ure 2.15a) are superimposed with the template of known interaction (blue) to model the putative interaction
between them. This interaction is shown again from a different angle in Figure 2.15d. TMPRSS4 residues
that are part of the interface are colored orange, and the catalytic triad of serine, aspartate and histi-
dine is colored blue. After energy minimisation of the complex, the pocket around the active site slightly
opens (Figure 2.15e) and minor clashes that were present before disappear. The sequence alignments of
TMPRSS4 and TFPI2 with the sequences of their threading-assigned structures as well as the SCOPPI
structural template are shown in Figure 2.15b and c. Sequence similarity is reflected by shades of color.
We find the interface regions (orange/red) to be well conserved.
This interaction could explain the mechanism of metastasis that makes PDAC a very aggressive type
of cancer. TFPI2 is an extracellular matrix associated serine protease inhibitor (Rao et al., 1996) that plays
a major role in extracellular matrix degradation during tumor cell invasion and metastasis, wound healing,
and angiogenesis. It has been shown that TFPI2 inhibits plasmin, trypsin, chymotrypsin, cathepsin G, and
plasma kallikrein but not urokinase-type plasminogen activator, tissue plasmin and thrombin (Konduri et
al., 2001). It plays a major role in negative regulation of the coagulation cascades and its down-regulation
is associated with malignant pancreas tumors. On the other hand, TMPRSS4 is known to be up-regulated
in pancreas cancer, which may be of importance for processes involved in metastasis formation and tumor
invasion (Wallrapp et al., 2000). We thus hypothesise that TFPI2 acts as a natural inhibitor of TMPRSS4.
Since TFPI2 is down-regulated, the up-regulated TPRSS4 is no longer inhibited and might facilitate tissue
invasion.
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(a) Structural template and predicted interaction (b) Sequence alignment of TMPRSS4 and templates
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(d) (e) (f) Conservation of surface residues
Figure 2.15 Example for a predicted interaction based on structural templates. Transmembrane protease,
serine 4 (TMPRSS4) is up-regulated in pancreatic cancer, and tissue factor pathway inhibitor 2 (TFPI2), is down-
regulated. (a) The known complex of trypsin (light blue) and amyloid beta-protein precursor inhibitor (dark blue)
serves as a template to predict and model the interaction between TMPRSS4 (yellow) and TFPI2 (red). (b) Alignment
of the sequence to model the TMPRSS4 structure and the sequence of the template. Interface residues are shown
in orange, the catalytic triad is shown in blue. Sequence similarity is shown in shades of color. (c) Alignment of the
sequence to model the TFPI2 structure and the sequence of the template. Interface residues in red. (d) Close-up
view of the predicted interaction of TMPRSS4 and TFPI2. The interface region of TMPRSS is shown in orange, with
catalytic triad of the active site shown in blue. (e) After molecular dynamics energy minimization, the pocket slightly
opens and initial minor clashes can be resolved. (f) Amino acid conservation coloring of the predicted TMPRSS4
structure shows a well-conserved pocket.
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RAB22A is a potential interaction partner of KIF20A. A second example is the predicted interaction
between RAS oncogene family member RAB22A, and kinesin family member KIF20A, both upregulated.
Rab proteins are small Ras-related GTPases that act as key regulators that ensure the specificity of
intracellular membrane traffic (Waters and Pfeffer, 1999). Kinesins are motor proteins which play a wide
variety of roles, being involved in processes as diverse as formation of the mitotic spindle and chromosome
partitioning and the intracellular movement of organelles and vesicles (Hirokawa et al., 1998). KIF20A is
also known to be involved in pancreatic carcinogenesis (Taniuchi et al., 2005). Moreover, Taniuchi et al.
(2005) report that KIF20A is a promising target for development of new therapeutic strategies for PDACs
and its down-regulation can attenuate growth of pancreatic cancer cells. In Table 2.3, one can see that
RAB22A and KIF20A have a 56% and 60% interface conservation compared to the existing complex (PDB
ID 1jx2). Our data suggest that the interaction between these two proteins could play an important role for
PDAC tumorigenesis. Thus, its inhibition might provide a promising approach for drug therapy.
Validation of candidates. Molecular Dynamics simulations confirmed that the predicted TMPRSS4–
TFPI2 interaction remains stable. We used homology modelling and docking to further test our results.
For the homology modelling we use the MODELLER software for homology or comparative modelling of
protein three-dimensional structures (Martí-Renom et al., 2000). The Modeller results for the TMPRSS4–
TFPI2 interaction strongly supports our prediction. As input we provide an alignment of the TMPRSS4
sequence to be modelled with known related structures and the output is the modelled structure of the
input sequence.
2.3.6 SCOPPI use case 2: Microtubule-associated proteome in Xenopus meiosis
Parts of this will be published in
Vincent Gache, Patrice Waridel, Christof Winter, Aurelie Juhem, Michael Schroeder, Andrej
Shevchenko and Andrei V. Popov. Xenopus meiotic microtubule-associated protein interac-
tion network. Submitted to Journal of Cell Science, 2009
Introduction
In metazoan cells, a microtubule-based spindle ensures the correct ploidy of the resulting daughter cells.
Proper meiotic spindle assembly depends on the activity of a large number of accessory non-tubulin
proteins, many of which remain unknown. Fidelity of spindle assembly and function is of vital importance
for the fate of resulting daughter cells. In mitosis, improper chromosome segregation often leads to cell
death through mitotic catastrophe (Castedo et al., 2004) and has also been linked to cancer through
formation of aneuploid cells (Shi and King, 2005; Fujiwara et al., 2005).
Uncovering novel components of the meiotic microtubule proteome should therefore not only pro-
vide clues to pathways common to both mitotic and meiotic spindle, but may reveal factors specific to
microtubule-related processes in meiosis.
Data set
The data set was obtained experimentally from our collaborators. It consists of microtubule-bound proteins
isolated from Xenopus eggs. Using mass spectrometry, 318 proteins were identified, only 43 of which are
already known to bind microtubules.
Approach
To understand how these proteins could be connected to microtubules and what modules in form of protein
complexes they might form, we aimed to compile the first network of the meiotic microtubule-related
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interactome. To this end, an initial core map was created based on text-mined, curated protein interactions.
This core map was extended by adding data from the protein-protein interaction databases BIND, DIP,
HPRD, IntAct, MINT, NetPro, and from SCOPPI. Since far more interactions are available for human
than for Xenopus, human orthologues were identified and mapped to the Xenopus proteins. Orthologous
interactions were added as well. We also grouped all identified proteins into fourteen functional categories.
Results
A network of the microtubule-associated interactome in meiosis. To evaluate functional connec-
tions of proteins with microtubules and with each other, we created a network of the microtubule-associated
interactome. We first used all 290 identified known proteins (a total of 318 proteins minus 28 uncharac-
terised ORFs) to find all direct links with the microtubule cytoskeleton. As a result, we compiled a core map
containing 50 proteins in direct binding relations, previously shown either in somatic cells or in oocytes.
Second, we related all identified known proteins between themselves and fused the resulting assembly
with the core map to obtain a network of 218 proteins (75% of the identified annotated proteins) and 51
complexes with 438 functional interactions (Figure 2.16). Note that EF1-α, CKI-α, Need1, tubulin ε and
Plectin 1 are shown as MAPs because they can bind to microtubules directly. Novel spindle components
identified in the experiment (Mgc68500, TSGA14/CEP41, LSM14A/RAP55A, Mgc80361, Mgc81475) are
linked to the microtubule using a dashed line, since their binding may be indirect. Similarly, a dashed line
is used to show the interaction of LRRFIP2 with actin.
Online cytoscape version of the network. We then compiled the layout of the network in Cytoscape,
an open source software platform for visualizing molecular interaction networks (Shannon et al., 2003).
Within the Cytoscape session file, we provide links to UniProt, GeneCards, BioGrid and Entrez databases
for each protein, and PubMed literature references for each protein relationship or protein complexes
(http://www.biotec.tu-dresden.de/schroeder/group/cytoscape/mempin.jnlp).
Discussion
We assembled the identified proteins into the first literature-curated network of the Meiotic Microtubule-
associated Protein Interaction Network, to show interactions of proteins complexes and individual proteins
with microtubules. The map also highlights a number of proteins and their complexes absent from the mi-
totic spindle proteome, suggesting that some of them may have a specific microtubule-related role during
oogenesis. The resulting network is depicted in Figure 2.16. It reveals numerous interactions between
spindle microtubules and the newly identified non-tubulin spindle components and highlights proteins ab-
sent from the mitotic spindle proteome.
Microtubules are at the heart of the complex cell division machinery, which ensures equal distribution
of daughter chromosomes, organelles and cytoplasm. Therefore it is not surprising that hundreds of pro-
teins are associated with microtubules either directly, or via organelles such as centrosomes (Andersen
et al., 2003), chromosomes (Gassmann et al., 2005) or ribosomes (Liska et al., 2004; Suprenant et al.,
1993).
Apart from the generally known spindle components such as dynein/dynactin and tubulins, several
other “hubs” are connected with a large number of entries. These are: importin (12), CDK/cyclin (22),
F-actin (12), PARP1 (13), ATM (11), ATR (6), proteasome (14), with the number of nearest connecting
neighbours for the hub shown in parenthesis. Interestingly, most of the ribosomal proteins found belong
to the small, 40S ribosomal subunit, which is known to associate with another multiprotein factor that we
have identified, the cap-binding complex eIF4F (Pestova et al., 2001). Finally, the map shows multiple
complexes implicated in RNA and DNA transcription, DNA replication and structure maintenance.
Furthermore, we found a number of proteins involved in post-transcriptional events: these proteins
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Figure 2.16 The meiotic microtubule-associated protein interaction network. The network shows 218 pro-
teins, 51 protein complexes, and 438 interactions. Proteins are colored by function, protein complexes are shown in
grey. Interactions were obtained from high-confidence interaction databases and checked manually. A Cytoscape of
the netork is available online.
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are shown on the Network as part of the following complexes: spliceosome, mRNPs, exon junction and
THO/TREX. Most of these proteins are absent from MSP and their main functions in oocytes relate to
mRNA processing, storage and translational repression. These proteins dynamically interact with mRNA
and with each other and some of them are known to participate in more than one type of the ribonucleo-
protein complexes (Merz et al., 2007; Blower et al., 2007; Eulalio et al., 2007).
We propose that such networks may further evolve to describe not only the microtubule-associated
interactome, but also the mitotic spindle of metazoan organisms with its much more complex apparatus,
including kinetochores, centrosomes and chromosomes. Indeed, the respective proteomes of the mitotic
spindle (Sauer et al., 2005), centrosomes (Andersen et al., 2003) and mitotic chromosomes (Gassmann
et al., 2005) have recently been elucidated, paving the way towards integration of these data. Moreover,
future challenges lies with making microtubule-related networks dynamic, to provide a measure of the
quantitative and qualitative changes of the microtubule-related proteome in different stages of the cell
cycle and in different cell types.
2.3.7 SCOPPI use case 3: The osteoclast differentiation proteome
We now investigate how structural knowledge can be combined and completed by sequence-based
sources of protein interaction that are commonly available. To this end, we combine SCOPPI with other
non-structural sources of evidence. By maximising the information from text mining of the biomedical lit-
erature, data from interaction databases, and from available protein structures, we aim at generating a
comprehensive picture of known and novel potential interactions between a given set of proteins.
Parts of this were published in
Christof Winter, Thorsten Baust, Bernard Hoflack, and Michael Schroeder. A novel, com-
prehensive method to detect and predict protein-protein interactions applied to the study of
vesicular trafficking. In: Oliver Kohlbacher and Andrei Lupas, editors, Proceedings of German
Conference on Bioinformatics, Lecture Notes in Informatics (LNI) – Proceedings Series of the
Gesellschaft für Informatik (GI), 2006
Introduction
Vesicle coats and adaptor proteins. Vesicles are small, membrane-enclosed containers that mediate
transport between cellular compartments. The formation of vesicles and the selective incorporation of
cargo molecules are both mediated by protein coats, which are recruited onto the cytosolic side of the
forming vesicle. In the case of clathrin-coated vesicles, the cargo transmembrane proteins are linked
via adaptor proteins (APs) with structural coats such as clathrin (Owen et al., 2004). AP-1 mediates the
transport of selected transmembrane proteins that cycle between the trans-Golgi network, endosomes
and the plasma membrane. How APs interact with other molecular components of the complex coat
machinery remains largely unclear.
Data set
The data set of proteins used in our study was obtained experimentally by a collaborating group (Baust
et al., 2006). Aim of this study was to identify cytosolic proteins that are involved in the adaptor protein 1
(AP-1) coat assembly. The result comprises 35 murine proteins that could be selectively recruited onto
liposomes that exhibit cytoplasmic domains of AP-1 cargo molecules. Among these, the AP-1 complex,
clathrin, several GTPases and their effectors as well as an actin nucleation machinery were found. Ta-
ble 2.4 shows the 35 proteins identified by mass spectrometry. How these proteins spatially arrange on
liposome membranes is still speculative. Here, our method can help to suggest possible interactions and
thus aid to formulate hypotheses concerning the recruited molecular machinery.
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Table 2.4 Proteins on AP-1A-coated liposomes as found by mass spectrometry. For proteins which have a
known structure, the Protein Data Bank identifer is given. The list of proteins was obtained from Baust et al. (2006).
Protein NCBI Protein
GI number
Known struc-
ture (PDB ID)
COAT COMPONENTS
Clathrin heavy chain 66773801 1xi5, 1xi4
Clathrin light chain B 62510439 1xi5, 1xi4
Clathrin light chain A 2493731 1xi5, 1xi4
AP1 beta 1 21541948 1w63
AP1 gamma 1 113349 1w63
AP1 mu 1 543817 1w63
AP1 sigma 1B 21541960 1w63
AP1 sigma 1A 48428720 1w63
AP1 gamma subunit binding protein 1 (gamma-synergin) 34996507
ARF-1/ARF-3 51316986 1r8q
47117658
ARF-GEF 2 (Brefeldin A-inhibited) 63492672
G protein-coupled receptor kinase-interactor 1 (ARF-GAP Git1) 58864889
G protein-coupled receptor kinase-interactor 2 (ARF-GAP Git2) 18203126
Arfaptin 1 63501125
Arfaptin 2 67460562
ACTIN POLYMERIZATION
Nck-associated protein 1 (HEM-2) 26986194
SH3 adapter protein SPIN90 57015413
WASP-family protein member 1 16877274
WASP-family protein member 3 20071942
CYFIP2 19526988
Abi-1 50400517
Abi-2 50400259
ARP2/3 complex subunit 1A 59797974 1u2v
ARP2/3 complex subunit 2 23621467 1u2v
ARP2/3 complex subunit 4 38372626 1u2v
ARP2/3 complex subunit 3 62899893 1u2v
p21-Rac1 51702788 1i4l
Cdc42 homolog 46397379 1grn
SLIT-ROBO Rho-GAP 3 (WAVE-associated Rac-GAP) 48428625
Rho-GEF 7 (PAK-interacting exchange factor beta) 18202873
PAK 3 47117898 1yhw
MEMBRANE FUSION
Rab-11B 1172815 1oiv
Rab-14 46577103 2aed
Rab-4 15986733 2bme
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Figure 2.17 A three-step approach to gather all knowledge about protein–protein interactions. (a) First, text
mining is used to collect interactions from the literature. Sequences of the involved proteins are stored in a database.
In a similar manner, available interaction databases are integrated and their protein sequences stored. (b) Second,
for a given protein pair A and B, a search for homologous interactions is performed using orthologue information
and BLAST. Thus, interactions between homologous proteins in other species or similar proteins can serve as
templates to predict an interaction between the original proteins A and B. (c) Third, similarity to structural templates
of interacting domains is used to predict interactions. To this end, we employ both sequence similarity (BLAST) and
structural similarity (Threading) measures.
A comprehensive method to detect and predict protein–protein interactions
We combine protein–protein interactions derived from text mining of the biomedical literature, available
protein interaction databases, and structural domain interactions. Aim of our method is to obtain all known
interactions between a given set of proteins, and to further predict new interactions that are likely to be
present within this set. The overall approach is a procedure of three steps. It is summarised in Figure 2.17
and described in detail below.
Collection of literature-based interactions. In the first step, we start collecting known interactions from
the literature. We use NetPro, an expert curated and annotated database containing ∼100,000 protein–
protein interactions (Molecular Connections, 2005). These were extracted from PubMed abstracts by a
semi-automated method and then cross-checked by human experts. For every interaction, NetPro lists the
two involved gene identifiers, species, the abstract sentences documenting the interaction, an interaction
verb and an interaction nature. The interaction nature can be direct or indirect, where interactions verbs
such as binds to classify an interaction as direct, and verbs such as colocalises with as indirect. For every
protein in NetPro, we collect its sequence from the NCBI Protein Database (Figure 2.17a).
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Collection of interactions from interaction databases. We complement our collected literature-derived
interactions with data from various interaction databases. Protein–protein interaction sets are obtained
from HPRD (Mishra et al., 2006), DIP (Salwin´ski et al., 2004), BIND (Bader et al., 2003), MINT (Chatr-
aryamontri et al., 2007), MIPS (Pagel et al., 2005), and IntAct (Kerrien et al., 2007). Again, sequences of
the interacting proteins are collected and stored (Figure 2.17a). We are aware of potential false positives
introduced by high-throughput interactions screens (von Mering et al., 2002). Since our approach aims at
maximum sensitivity, we do not apply any filter, but rather record the experimental origin of an interaction
finding as confidence criterion.
Identification and prediction of interactions for a given data set. To identify known interaction in a
given data set, we simply query our databases of collected interactions. The result is a protein–protein
interaction network where an interaction either was described in the literature or stored in an interaction
database. In a second step, we expand this network. Orthologues, i.e. homologues in other species, of
proteins in our given data set are identified using the NCBI HomoloGene Database (Release 46.1). Our
collected interactions are again checked for the orthologues. Following the idea of interologs described
in (Walhout et al., 2000a), we predict a putative interaction between two proteins if they have interacting
homologues in another species. We further extend this idea of homologous interactions by performing
a BLAST search with our data set against the collected interaction sequences. Thereby, we are able to
find a template protein pair A’ and B’ known to interact, where A’ and B’ are similar to two proteins A
and B from our data set (Figure 2.17b). If the similarity (e.g. measured in sequence identity) is sufficient,
we infer a putative interaction between A and B. In order to obtain a score reflecting the reliability of the
prediction, we calculate the joint percentage identity. For a protein pair (A,B), this score is defined as
min(IA, IB) where IA, IB are the sequence percentage identities between the protein pair and the template.
In this study, we require a joint percentage identity of at least 40%.
Structure-based interaction prediction. The third step of our approach is shown in Figure 2.17c. To
predict interactions on the basis of known structures, we use SCOPPI. As structural interaction templates
for our predictions, we use a subset of SCOPPI obeying the following filter criteria: 1) interacting domains
are required to be on different polypeptide chains, 2) interface size (defined as change in accessible
surface area,∆ASA, calculated with Naccess) ≥ 600 Å2 to filter out unspecific interfaces, 3) exclusion of
homo-dimers to avoid false positive predictions between highly similar proteins. Two proteins are predicted
to potentially interact if they contain domains that are known to interact structurally, according to the
SCOPPI subset described above. To assign these domains to a given protein sequence, we employ
both sequence similarity and structure prediction methods: First, we perform a BLAST search against a
database containing the defined SCOPPI subset. By using a sequence identity cut-off at 40%, we ensure
that the assigned domains have a similar structure to our structural interaction templates. Second, all
protein sequences are threaded with GenTHREADER (Jones, 1999), considering hits with p-values <
0.001 only. This procedure assigns probable SCOP domains being part of GenTHREADER’s fold library
to each protein sequence. As above, we assign a score of min(IA, IB) for the sequence identities between
the protein pair and the template, and max(pA,pB) where pA,pB are the threading p-values, respectively.
Results and discussion
Construction of an interaction network for proteins from clathrin-coated vesicles. We apply our
method to the data set described above, which consists of 35 proteins shown in Table 2.4. Figure 2.18
shows the putative spatial arrangement of a subset drawn by the collaborating expert biologist.
Figure 2.19 shows the resulting network after taking the steps described in detail above. Interactions
that could be found from the literature or interaction databases are shown in red. Homologous interactions
in close species (human, rat) are also red. Predicted interactions, inferred by orthology in remote species
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Figure 2.18 Theoretical model of the adaptor protein 1 (AP-1) related machinery. Several small GTPases
along with their GAP and GEF effectors are involved. Some of the depicted interactions are known, while others are
still presumptions (Hoflack, 2006).
or by sequence similarity, are depicted in yellow. In addition, indirect literature interactions are dashed,
whereas direct ones are solid lines. Blue lines indicate predictions based on structural templates. In case
of yellow and blue lines, numbers specify the joint sequence identity percentage score of the prediction.
The result allows for the generation of several new hypotheses about the molecular machinery around
AP-1. In the following, three predicted examples will be discussed in detail.
Literature- and interaction databases approach. The ability to blast against a multitude of literature
interactions represents a quite powerful tool. First, it allows for the detection of seamless grades of sim-
ilarity. Second, it deals with the problem of synonyms in a very elegant way. Once text mining matched
a protein name to a protein entity, we do not further rely on synonyms but on the sequence which—in
combination with the species—unambiguously described the protein entity.
PAK3 is a potential interactor of the Arp2/3 complex subunit 1A. The literature-derived search pre-
dicts, for example, the interaction between murine p21-activated kinase 3 (PAK3) and the Actin-related
protein 2/3 complex subunit 1A. Basis of this prediction is a literature-documented interaction between
human p21-activated kinase 1 (PAK1) and human Arp2/3 subunit 1B, reported in (Vadlamudi et al., 2004).
Overall sequence identity is 69% between the kinases, and 83% between the Arp2/3 subunits. We cannot
be sure if this interaction is indeed true, but our method provides evidence that an interaction is likely. This
would suggest that PAK3 functions in the given data set of mouse proteins in a similar manner as PAK1,
namely by phosphorylating the Arp2/3 complex, thus influencing vesicle motility. Further inspection of this
example reveals additional support for the prediction. In the abstract of (Vadlamudi et al., 2004), we learn
that PAK1 phosphorylates p41-Arc (another name for the Arp2/3 subunit) on threonine 21. As we check
the alignment, we find threonine 21 present in a well-conserved region in both proteins:
1         11        21        31        41        51
Arp2/3 1B  MSLHQFLLEPITCHAWNRDRTQIALSPNNHEVHIYKKNGSQWTKAHELKEHN
p41-Arc    -AYHSFLVEPISCHAWNKDRTQIAICPNNHEVHIYEKSGAKWTKVHELKEHN
C H A P T E R 2 . P R E D I C T I O N A N D C L A S S I F I C AT I O N O F P R O T E I N – P R O T E I N I N T E R A C T I O N 57
68
7450
50
50
50
5088
70
79
40
96
88
91
61
58
73
65
65
65
50
88
5091
88
79
57 57
100
91
96
68
5771
65
69
59
50
50 50
69
52
577172
72
99
50
58
75
61
78
65
68
93
ARP2/3 complex subunit 3
ARP2/3 complex subunit 1A
Clathrin light chain B
WASP-family protein member 3
AP1 sigma 1B
AP1 beta 1
ARF-GAP Git2
Abi-2
WASP-family protein member 1
CYFIP2
Clathrin light chain A
AP1 sigma 1A
AP1 gamma 1
PAK 3
Gamma-synergin
Nck-associated protein 1 (HEM-2)
ARF-1
Clathrin heavy chain
ARF-GEF 2
SLIT-ROBO Rho-GAP 3
ARF-GAP Git1
Arfaptin 2
Cdc42 homolog
ARP2/3 complex subunit 2
Abi-1
Rho-GEF 7 (PAK-interacting exchange factor beta)
ARP2/3 complex subunit 4
p21-Rac1
AP1 mu 1
Figure 2.19 Constructed interaction network for the AP-1 complex. Interactions known by literature or interac-
tion database are depicted in red, predictions based on these are yellow, and blue lines represent predictions based
on 3D structural templates. Numbers indicate the sequence identity in percent that the predicted interaction shares
with the template. The higher this number, the more reliable the prediction. For the sake of clarity, the cut-off is set
at 50% here, except for the discussed example of the AP-1–Clathrin example.
Text mining challenges: Clathrin should be linked to the AP-1 complex subunit beta. General
problems of text mining still affect our approach. If interactions are not extracted in the first place, we
lack this information and hence cannot infer any similar predictions. In our study, this occurs in case of
the AP-1—Clathrin interaction. It has long been known that Clathrin is associated with adaptor proteins
on clathrin-coated vesicles that mediate traffic of between intracellular compartments. The physical in-
teraction between Clathrin and the beta 1 and beta 2 subunits of the AP complexes was first described
1993 by Gallusser and Kirchhausen. However, neither the incorporated interaction databases, nor the
literature-based NetPro database contain this particular interaction. For NetPro, the reason seems obvi-
ous. The relevant sentence in the abstract of Gallusser and Kirchhausen (1993) states: “It was found that,
in the absence of all the other AP subunits, beta 1 and beta 2 interact with clathrin.” The fact that the
interaction partners are just described as “beta1” and “beta2” makes it extremely hard for an algorithm
to reason that these two are actually AP subunits. As we are lacking this interaction, and since no such
interaction could be inferred from structural templates, we cannot connect Clathrin with the AP-1 complex
in the interaction network. There is, however, a homologous interaction our method detects: According to
interaction database DIP (Salwin´ski et al., 2004), yeast beta-adaptin homolog APL2 interacts with yeast
clathrin heavy chain 1 (Yeung et al., 1999). The BLAST search of our method picks up the similarity be-
tween the yeast and mouse orthologues of AP-1 beta subunit (40% identities, 62% positives) and Clathrin
heavy chain (49% identities, 70% positives). On this basis, our approach predicts a potential interaction
between the two murine proteins. In this case, it turns out that the prediction is correct, with the known,
but missing interaction validating our prediction.
Structural template-based approach. Structures are available for a considerable number of the AP1-
related proteins (Table 2.4). The first stage easily detects these templates by sequence identity search via
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Thr3
Ala3
Asn52
Thr52
Trp56
Phe56
p21Rac QAIKCVVV ... IPTVFDNYS ... KPVNLGLWDTAGQEDYDRLRPLSYPQ...
Cdc42 TIKCVVV ... VPTVFDNYA ... EPYTLGLFDTAGQEDYDRLRPLSYPQ...
*                            *   * 
Figure 2.20 Structural modelling of the CDC42–Arfaptin 1 interaction. Left: The known complex structure
p21Rac1 (blue) interacting with Arfaptin 1 (grey) serves as a template. CDC42 (red) and Rac1 (blue) structurally
align reasonably well (RMSD 0.8). Bottom: Residues contributing to the binding site in the complex. Interacting
residues are marked yellow, mismatching interacting residues are marked with a star. Right: Interface mismatches
(Ala/Thr, Asn/Thr, Trp/Phe) after structural superposition of CDC42 and Rac1. Although being different amino acids,
their structural side chain arrangement is similar.
BLAST. If at 40% sequence identity cut-off no domain structures are found, we employ threading to assign
domains. For every protein pair, we check if the SCOPPI database lists any of the assigned domains as
interacting. If so, we mark these two proteins as potentially interacting.
Since crystal structures are available for the AP-1 and the Arp2/3 complex, the structural templates-
based approach connects the subunits according to their contacts (blue lines in Figure 2.19). One inter-
esting candidate is the predicted connection between the Rho GTPase CDC42 and Arfaptin, an effector
of the Arf GTPase.
The small Rho GTPase CDC42 is a potential interactor of Arfaptin 1. The small GTPases Rho, Rac
and CDC42 are regulators of actin structures, cell adhesion and motility. Here, we predict the interaction
between CDC42 and Arfaptin 1. As template, we use the crystal structure of RAC1-GDP in complex
with Arfaptin (PDB ID 1i4l, Tarricone et al., 2001). Figure 2.20 shows the superposition of CDC42 and
Rac1 with an RMSD of 0.8. The interfacial residues of both GTPases, as defined to be within 5 Angstrom
distance to the Arfaptin, are aligned and highlighted in yellow. Closer examination of the three mismatches
(Ala/Thr, Asn/Thr, and Trp/Phe) in the interface reveals that all three residues align reasonably well in the
superposition of CDC42 and Rac1. We therefore have reason to believe that at least from a steric point of
view the interaction is feasible.
Reliability scores and evidence. Our approach generates reliability scores as well as supporting evi-
dence for the protein–protein interactions predicted. For structure-based predictions, we provide a struc-
tural template as well as confidence scores. These are sequence identity percentages and/or threading
p-values. For literature-derived predictions, we provide statements from PubMed articles which explic-
itly document details of the interaction. In addition, joint sequence identity scores are available for every
predicted interaction. These are 100% for known interactions described in the literature and lower for
decreasing degrees of potential homology. An introduction of various cut-off levels could account for the
different interaction nature of proteins, e.g. a stricter level for GTPases, and a more relaxed level for unspe-
cific protein interactions. If the binding site is known, the matches of interfacial residues serve as additional
parameters for the quality of the predicted interaction. The more conserved the interface, the more likely
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the interaction.
2.4 Discussion
2.4.1 SCOPPI
We presented SCOPPI, the Structural Classification of Protein–Protein Interfaces. SCOPPI applies SCOP
domain definitions and a distance criterion to determine inter-domain interfaces. Using a novel method
based on multiple sequence and structural alignments of SCOP families, SCOPPI presents a compre-
hensive geometrical classification of domain interfaces. Various interface characteristics such as number,
type and position of interacting amino acids, conservation, interface size, and permanent or transient na-
ture of the interaction are provided. Proteins in SCOPPI are annotated with Gene Ontology terms, and
the ontology can be used to quickly browse SCOPPI. The usefulness of these features is illustrated by
examples where SCOPPI is found valuable to study various aspects of protein interactions. In particular,
these include similarity, diversity, conservation and orientation of binding sites.
The unique feature of SCOPPI is a classification of domain interfaces according to their geometry.
The classification is based on an algorithm that uses both sequential and structural features. Its accuracy
is evaluated on a hand-curated dataset of interfaces. We classify virtually all domain interfaces of known
structure, which results in nearly 6,000 distinct types of interfaces. In 40% of the cases, the interacting
domain families associate in multiple orientations, suggesting that all the possible binding orientations
need to be explored for modelling multidomain proteins and protein complexes. Our classification provides
a convenient framework to query genuine gene fusion, which conserves binding orientation in both fused
and separate forms. The result suggests that the binding orientations are not conserved in at least one-
third of the gene fusion cases detected by a conventional sequence similarity search. We show that any
evolutionary analysis on interfaces can be skewed by multiple binding orientations and multiple interaction
partners. The taxonomic distribution of interface types suggests that ancient interfaces common to the
three major kingdoms of life are enriched by symmetric homodimers.
Impacts of interface type classification
Considering the limited success of the most sophisticated docking methods available, cataloguing all
the know interfaces is a good basis for an alternative approach for the prediction of protein tertiary and
quaternary structures. The efficiency of docking could be greatly enhanced by sampling, where possible,
candidate interactions from known interfaces, enabling systematic docking for a whole genome using
only a reasonable amount of computation. In terms of computational complexity, the advantage of using
interface classification over combinatorial docking parallels homology modelling over ab initio prediction
of protein folding.
In SCOPPI, 4,068 distinct interface types are collected from 2,118 family-family pairs and investigated
regarding how the geometry of interfaces relates to a network of interacting protein families in terms of
interface diversity, specificity, and conservation. The interfaces are shown to be diverse even between
homologous pairs of proteins, showing 1.2–1.9 different interface types on average (see Table 2.2). The
data suggest that nearly 40% of family pairs of known structure associate in multiple orientations. A careful
consideration of alternative interfaces will be necessary in modelling tertiary or quaternary structures
using known interfaces. In general, a family tends to use distinct surface regions for each partner, when
the family has diverse interaction partners and each face is shown to be highly specific to its partner and
the binding orientation.
Knowledge about domain associations can greatly reduce the search space that needs to be explored
by combinatorial docking. For modelling complexes of 20 subunits, assuming three candidate docking
solutions, 3(20−1)≈ 1.2×109 conformations need to be explored. With the interface classification, only
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3(20−1)×0.4 ≈ 4,200 conformations are to be explored assuming 40% of the family pairs have, on average,
three types of interfaces. Although the known interfaces represent only a small fraction of all interfaces in
nature, interface modelling is expected to play a critical role in combination with other experimental and
computational methods.
2.4.2 Interaction prediction with SCOPPI
SCOPPI and pancreatic cancer
In this case study, we proposed an integrative approach to identify key interactions and pathways from a
set of genes. We apply this approach to a data set of genes deregulated in pancreatic cancer. We propose
a method that predicts interactions among a given set of genes. We apply the method to our data set of
deregulated pancreas cancer genes. As a result, we predict 40 novel interactions that are specific for the
underlying disease. We map these interactions onto a well-known picture of cancer hallmarks and draw a
network of all predicted interactions as well as literature confirmed interactions.
We observe that most of the literature confirmed interactions are located inside the cell, whereas the
predicted interactions are mainly taking place between transmembrane and extracellular proteins. One
reason for this bias could be that transmembrane proteins are more diffucult to study experimentally
than cytosolic proteins. The interactions found may prove valuable to improve our understanding of the
regulatory mechanisms underlying the development of pancreas cancer.
Finally, we examine one example in detail: the predicted interaction between TMPRSS4 and TFPI2.
We believe that TFPI2 naturally inhibits the TMPRSS4 protease. Since we find TFPI2 to be downregulated
in pancreatic cancer, TMPRSS4 might be able to facilitate tissue invasion and metastasis.
A comprehensive method for protein interaction prediction
We propose a fully automated method for the retrieval and prediction of protein–protein interactions. By
merging information from literature abstracts stored in PubMed, interaction databases, and structures in
the Protein Data Bank PDB we obtain a comprehensive picture on documented interactions. On the basis
of this knowledge, we can construct an interaction network for any given data set, and further extend it
predicted interactions at various confidence levels based on sequence or structural similarity to known
interaction templates.
Applied to a data set of proteins that form coat complexes on vesicle membranes, our method iden-
tifies almost all relevant interactions. Further interactions are predicted, among them potential linkers for
the AP1- and the Arp2/3 complex. Therewith, we provide potential interaction candidates for further experi-
mental testing. By incorporating the whole spectrum of text mining interactions described in the biomedical
literature, data stored in interaction databases, and all structurally known domain–domain interactions, our
method ensures a comprehensive network reconstruction that can assist the molecular biologist. Applying
it on a genome-wide scale, we can further scale up this network to a systems biology level that provides
a view on a whole interactome, thus providing a valuable tool for the life sciences.
2.4.3 Limitations of method
Availability of structural data
The most restricting limitation for structure-based interaction prediction is the availability of structural data.
To be able to predict an interaction between two proteins, structural data for both is needed, which aggra-
vates the problem. If we assume that for 40% of the proteins of an organism the structure is known or can
be modelled confidently, then the probability to have structural data for two proteins is only 0.4×0.4 = 0.16.
That is, we can predict interaction only for a fraction of 16% of all interactions.
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Table 2.5 Structural coverage of species according to available protein structures in PDB. E. coli is the best
covered organism, with 39% of its proteins known by structure. In absolute numbers, the most protein structures
are available for human, which is almost 6,000. Note that many model organisms such as fly, worm, and zebrafish
are only poorly covered.
Species Genome
size †
Structures
in PDB
Distinct
structures
in PDB ‡
Percentage
of genome
covered
PROKAROYTES
Escherichia coli 4,290 4,489 1,685 39
Bacillus subtilis 4,779 768 426 9
Mycobacterium tuberculosis 3,959 676 295 7
EUKAROYTES
Homo sapiens 21,370 14,768 5,900 27
Saccharomyces cerevisiae 6,532 1,667 832 13
Mus musculus 22,990 2,647 1,380 6
Rattus norvegicus 17,738 1,418 533 2
Bos taurus 20,118 895 205 1
Drosphila melanogaster 14,141 366 205 1.4
Xenopus laevis 18,023 193 165 0.9
Arabidopsis thaliana 27,498 404 229 0.8
Caenorhabditis elegans 20,176 107 87 0.4
Danio rerio 20,925 s 60 31 0.1
† Number of known protein coding genes, taken from the NCBI Entrez (prokaryotes)
and Ensembl databases (eukaryotes)
‡ Non-redundant set, filtered at 95% sequence identity
How well are model organisms covered in terms of structural data?
Although more than 50,000 protein structures are currently available in the Protein Data Bank, PDB
(Berman et al., 2000), this number is unevenly distributed among different species. Table 2.5 shows the
number of structures per species, and relates this number to the number of protein-coding genes in that
species. In terms of coverage, the best studied organism is E. coli, with almost 40% of its protein known
by structure. In terms of absolute numbers, most structures are known for human, which is almost 6,000.
However, these represent only 27% of protein coding genes, making a pair 0.27×0.27≈ 0.07.
Notably, most of the popular model organisms such as yeast, worm, fly, and zebrafish have a quite
poor coverage. It seems that the prime interest in these organisms is not to model protein surfaces, which
is a basis for drug development, and therefore especially interesting in human. On the other hand, many
genome-wide interaction studies were performed in yeast, as mentioned in the introduction.
As a positive outlook, we observe a supra-linear growth of protein structures (see Figure 2.21, black
line). Along with new structures becoming available, also new domain families (red line) and new interfaces
(green line) are discovered. Although it is difficult to extrapolate this growth, large scale effort such as
the Structural Genomics Consortium (Williamson, 2000) that focus on systematically solving all human
proteins give confidence that a much higher coverage can be expected at least for human in the near
future.
Structure prediction
For the interactions predicted from known complex structures (see Table 2.3), the accuracy of structure
predictions by means of Threading is crucial. Despite the fact that we filter out medium and low confidence
predictions (according to confidence scores provided by the Threading method), the actual structure might
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Figure 2.21 The growth of structural data over time. The total number of protein structures with multiple do-
mains (black), the number of domain families (red), family pairs (blue), and interface types (green) is growing in a
supra-linear fashion.
still differ from the predicted one. For this reason, we compare the putative interface residues of both
predicted interaction partners with the interface residues of the known complex structure used as template.
We argue that a high sequence identity in the interface region favours a similar interface structure. We
do not claim that these interactions are necessarily true, but we are rather confident that they provide
reasonable candidates for experimental testing.
Evaluation
False positives. Our method shares the common limitations of interaction prediction methods. Techni-
cal false positives (i.e. those due to the method) are likely, especially for predictions with low joint sequence
percentage. Biological false positives (i.e. interactions that could be observed in vitro, but have no biolog-
ical relevance, because the two proteins are not expressed in the same tissues or compartments, or not
at the same time) can at least in this study be ruled out due to the experimental setup used to produce
the data set. It ensures that the tested proteins are within close proximity, thus displaying a considerable
potential to form interactions.
Specificity. Another problem is that of the specificity of our predictions. Small GTPases and their ef-
fectors (such as GTPase activating and guanine nucleotide exchanging proteins) are good examples for
forming specific interactions (A Hall, 2000). The problem can be addressed by a rigorous sequence iden-
tity threshold, as suggested above.
Although a considerable number of proteins in our study are known by structure, and although our
method has access to ∼25,000 different domain interaction templates, we are not able to link the AP-1 or
the Arp2/3 complex to any other protein in the data set by merely using structural information. This points
at the problem that there are still comparatively few multi-domain structures available that can serve as
modelling templates for interactions. As a positive outlook, we observe a supra-linear growth of these
templates (see Figure 2.21).
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Experimental validation is crucial. It is difficult to assess predicted interactions by other means than
the biological experiment. The main problem is estimation of a false positive rate. How can one be sure that
two proteins do not interact? Simple absence of the interaction in reliable data sources is not sufficient—
the interaction might just not have been discovered yet. The closed-world assumption, i.e. interactions not
known are also not true, does not hold for biology. Our predicted interactions are currently being tested by
our collaborating group. The result of these experiments will allow for a thorough evaluation of our method.
2.5 Materials and Methods
2.5.1 SCOPPI
Domain–domain interactions. The contents of SCOPPI are results of the followings steps: 17,083 Pro-
tein structures are taken from the Protein Quaternary Structure Server PQS at EBI (http://pqs.ebi.ac.uk)
(Henrick and Thornton, 1998), which offers coordinates for likely quaternary states of structures con-
tained in the Protein Data Bank (PDB) (Berman et al., 2000). These correspond to 14061 structures in
PDB (Berman et al., 2000). Applying SCOP 1.67 domain definitions (Murzin et al., 1995) yields 70,527
domains grouped into 2,209 families. Interacting domain pairs within one PQS file are determined using
PSIMAP (Park et al., 2001; Dafas et al., 2004). PSIMAP considers a pair of domains as interacting if
at least five interacting residue-residue contacts exist within a 5 Å distance. We define the interacting
residues of each domain as face and the corresponding pair of faces as interface. Furthermore, we dis-
tinguish between two interaction modes: Inter interactions occur between two domains that have different
chain identifiers in the PQS entry, whereas intra interactions involve domains on the same chain.
Permanent and transient classification. Following Kottha and Schroeder (2006), each domain–domain
interaction is classified as permanent or transient according to these rules:
1. If the two domains are located on the same chain of the protein, their interaction is labelled as intra,
and neither permanent nor transient is assigned.
2. If the chains of the two domains are homologous, the interface is identified as homo dimer. By
default, all homo dimer are considered permanent. Whenever we come across homomers with
transient interactions in literature, we change their type to transient manually.
3. The interface is classified as permanent interface between hetero-multimers in the following cases:
(a) The chains of the two domains have the same PDB molecule identifier (MOLID in the COMPND
section).
(b) According to the PDB molecule identifiers, the two domains are in different chains of the same
protein. For example, the first molecule might be labelled as hemoglobin alpha chain, and the
second molecule as hemoglobin beta chain.
(c) The domains have the same Swiss-Prot identifier.
(d) The names of the Swiss-Prot entries indicate that the domains are in different chains of the
same protein (see above).
(e) The domains are labelled with the same Enzyme Class (EC), and the EC name is complete
(e.g. 2.5.1.18, but not 2.7.-.-).
Interface clustering. Domain sequences are parsed from PQS files. For each family, a multiple se-
quence alignment is built by MUSCLE (Edgar, 2004). The face residues are mapped onto the aligned
sequences. The clustering of faces is a two-step procedure: First, the aligned sequences are converted
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to an interface tag (IFT) by representing interface residues by 1’s and other residues by 0’s, resulting in
a linear vector such as 0–000101110–-100. The IFTs of each family are clustered into groups with sim-
ilar patterns. The distance between two vectors u,v is measured by the cosine angle distance ignoring
positions containing gaps. DIFT becomes 0 between identical IFT pairs and 1 between IFT pairs without
any common interface residue. Since only faces of highly similar IFT patterns (DIFT < 0.2) are grouped
together, the resulting clusters consist mostly of equivalent surfaces.
In a second step, geometrical features measuring the similarity between two faces are used to further
merge the clusters: Upon structural superposition of two domains with MultiProt (Shatsky et al., 2004), a)
the overlap of faces—i.e. the percentage of atoms that are within 3 Å of the other face—and b) the angle
between two lines connecting the domains’ common center of mass and the centers of mass of the two
faces are calculated. The clustering thresholds for a) and b) where set to 60% and 40°, which proved best
on systematic benchmarking. After this step, the 92,979 domain contacts of SCOPPI are clustered into
8,381 distinct interfaces.
Face overlap and face angle distance. There are two geometric features–face overlap and face angle
to measure the distinctness between two faces. Both features are calculated after the superposition of
two domains in a family with MULTIPROT (Shatsky et al., 2004).
Face overlap distance (DO) is measured as
DO(fA, fB) = 1−max
( |IA|
|fA| ,
|IB|
|fB|
)
|IA|, |IB| are the number of intersection atoms and |fA|, |fB| are the total number of atoms in each face
respectively. The intersection atoms of one face are defined as the atoms within 3Å from the other face
atoms. Accordingly, a face fully subsumed by the other yields the face overlap distance, DO = 0.
Face angle distance (DA) measures the angle between the two centroids of the two faces and the
common centroid of the two domains. The centroid is determined by using the Cα carbons of the face
residues or the domain residues for computational efficiency.
Non-redundant interface sets. A series of non-redundant interface sets are provided at different se-
quence identity levels ranging from 50% to 100%. To this end, representative sequences for each thresh-
old are generated for each family using CD-HIT (Li et al., 2001). Further collating of domain pairs with
same face types leads to non-redundant interface sets. For each interaction, the change in accessible
surface area, ∆ASA is calculated with Naccess (http://wolf.bms.umist.ac.uk/naccess/), which is an imple-
mentation of the Lee and Richards probe method (Lee and Richards, 1971). Conservation coloring: For
each family, the number of occurrences of a particular residue divided by the length of the column is calcu-
lated for each column of the multiple sequence alignment and then assigned to every residues of that type.
If all residues in a column are glycines, every glycine gets a score of 1 therefore, and if 30% were alanines,
glycines would get 0.7 and alanines 0.3. Ten rainbow color shades ranging from bright red (≥ 0.9) to pur-
ple (< 0.1) display the assigned score. Please note that conservation scores are calculated based on the
currently displayed sequences, so they will change with different redundancy levels or∆ASA cut-offs.
Gene ontology annotations. GO annotations for PDB files are made available by the GOA project
(Camon et al., 2004). For each family, we provide a simple GO Annotation overview by counting GO
terms of the PDB files of that family. For the GO categories cellular component (C), molecular function (F)
and biological process (P), the three most frequent GO terms are shown. The Medline link of GOA is used
to link to the GoPubMed server (Doms and Schroeder, 2005), where the relevant literature for a particular
PDB entry can be viewed hierarchically indexed by Gene Ontology terms.
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Implementation of web content. The SCOPPI website was implemented in Python. The underlying
data is stored in a MySQL database.
2.5.2 Pancreas cancer proteome
Data set. The gene expression data used in our work originates from several microarray studies: (Grütz-
mann et al., 2003a; Grützmann et al., 2003b; Grützmann et al., 2004b; Grützmann et al., 2005). These
studies compare expression profiles of pancreatic ductal adenocarcinoma cells to healthy exocrine pan-
creas cells. Our data set consists of 1612 genes, out of which 944 were found up-regulated and 668
down-regulated in PDAC.
Structure-based prediction of protein interactions. We implemented a methodology that utilises
structural data from SCOPPI to predict potential interaction among the PDAC data set deregulated genes.
The resulting potential interactions are further investigated by considering amino acid sequence conser-
vation of ≥ 50% at the interaction interface when compared to the structural template. In the following we
describe the working steps of the method as shown in Figure 2.13:
(i) Structure assignment and Family classification. Most of the data set genes are of unknown structure.
We use the Genomic Threading Database (GTD) as fold recognition method to assign SCOP structural
families to the gene products. Only assignments with certain and high confidence by GTD are considered.
This results in 656 remaining genes. (ii) Interaction prediction. For the assigned SCOP domains, we use
SCOPPI to identify interacting domain pairs. In this step, we consider two proteins as interacting if each
contains a domain where there is structural evidence for such a domain–domain interaction according to
SCOPPI. The evidence interaction then serves as a structural template to model the predicted interaction.
Figure 2.13 sketches the structure assignment and interaction prediction step of the method. (iii) Interface
conservation evaluation. In order to compute the interface conservation, the information about residues
in the interface is taken from the SCOPPI database. We align the original protein sequence against the
SCOPPI template sequence and calculate the sequence identity percentage of the interface residues. The
evaluation criterion is explained as follows: If one protein has a conservation of more than 50 % of residues
at interface against counterpart of the known template structure, we assume that they share the same
interaction partner. Applying this criterion to the whole PDAC data, many interactions are filtered out, and
40 remain. (iv) Interaction confirmation. In order to evaluate our method, we compared our finally predicted
interactions against those confirmed by experimental interaction databases. For this purpose, NetPro
(http://www.molecularconnections.com), BIND (Bader et al., 2003), and HPRD (Mishra et al., 2006) are
used.
Modelling and docking procedures. For the homology modelling we used MODELLER version 8v0
(Martí-Renom et al., 2000). BDOCK (Huang and Schroeder, 2005) was used for docking. We applied
conjugate gradient energy minimization using NAMD (Phillips et al., 2005) with the CHARMM22 force
field. For the simulation on the TMPRSS4–TFPI2 complex, we observed a stabilisation of the complex
after 10,000 steps.
Protein structures. The following structures were used from the Protein Data Bank: Complex of trypsin
interacting with amyloid beta-protein precursor inhibitor domain (PDB ID 1brc) as template for modelling
the TMPRSS4–TFPI2 interaction. Crystal Structure of the Catalytic Domain of Human Complement C1S
Protease (PDB ID 1elv) to model the structure of TMPRSS4. Bovine Pancreatic Trypsin Inhibitor (PDB ID
1bpi) was used to model the structure of TFPI2. The BDVU structure was taken from Crystal Structure of
Thymidine Kinase from Herpes Simplex Virus Type I (PDB ID 1ki8).
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2.5.3 Meiotic microtubule-associated protein interaction network
Isolation and mass spectrometric characterization of the microtubule-binding proteome. The iso-
lation proteins associated with microtubules in meiotic egg extracts followed the protocol described in
Liska et al. (2004) and Gache et al. (2007). Taxol-stabilized microtubules were added to clarified egg
extracts and incubated at 20°C. After several successive centrifugations through a glycerol cushion to
remove unattached proteins, microtubule-bound proteins were eluted, first, by the high concentration of
ATP, and second, by 0.5 M NaCl. The first elution step released all proteins whose association with mi-
crotubules was ATP-sensitive (for example, motor proteins), while the second, salt elution step, removed
the remaining proteins. To establish the specificity of purification of ATP-sensitive proteins, AMP-PNP
was omitted, instead an excess of ATP was added to the extract. This step prevented virtually all of the
proteins otherwise recovered in the ATP-fraction from binding to microtubules, proving the veracity of the
interaction.
Network building. The map of the microtubule proteome was initially compiled using PathwayStudio 4.0
(Ariadne Genomics, Inc.). After compiling the core map with all proteins binding directly to microtubules,
we related all identified known proteins using information available in the Ariadne Genomics ResNet 3.0
database, followed by manual curation. In the resulting network, connections between proteins or protein
complexes were deliberately limited to the following relations: “binding”, “regulation” (positive or negative)
and “phosphorylation” (Nikitin et al., 2003). We created some protein complexes which were absent from
the database (for example: multi t-RNA synthetase complex, RNA-containing Kif5B-transported granules,
HURP-complex and origin recognition complex). When the names of the human and Xenopus proteins
were different, we provide in the Network the name of the Xenopus protein.
In order to provide open access to the network, we re-compiled it in Cytoscape (Shannon et al., 2003),
and further refined it manually. We added relevant “binding” links and specified references where a pro-
tein/microtubules or protein/protein association was established through literature searches. For simplicity,
the relationships of proteins which are in a complex are shown as “binding” this complex. All links were
manually “curated” through links verification and cross-referencing in the NCBI PubMed database.
In order to complement the literature-derived interaction data, experimental interaction evidence was
collected from curated interaction databases. The following databases were downloaded: BIND (Bader
et al., 2003), DIP (Salwin´ski et al., 2004), IntAct (Kerrien et al., 2007)), HPRD (Mishra et al., 2006), and
MINT (Chatr-aryamontri et al., 2007). In addition, we used a literature-derived database, NetPro from
Molecular Connections (http://www.molecularconnections.com).
Orthologue mapping. Human orthologue entry is used for the search in the InParanoid database
(O’Brien et al., 2004b). Interactions were assigned to a protein pair in this study, if these proteins or
orthologues of these proteins were described as interacting in a database. To this end, sequences of all
proteins in the databases were compared with all proteins found in this study by a BLAST search using
a 75% sequence identity cut-off. In rare cases, only low homology human orthologues of Xenopus pro-
teins could be identified using reciprocal BLAST searches (e.g., Xenopus RNF36 and Xnf7 both match
to human protein TRIM69, Acc. No. Q86WT6, with low homology of 42–43%). BLAST hits were checked
manually and only correct orthologue assignments were kept.
2.6 Author contributions and acknowledgements
SCOPPI. The SCOPPI database is the result of a close collaboration with my colleagues Andreas Hen-
schel and Wan Kyu Kim. The work was created in an environment of tight collaboration, on both planning
level and implementation level. Wan Kyu Kim, Andreas Henschel, and Christof Winter conceived and
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designed the SCOPPI clustering algorithm. Wan Kyu Kim and Andreas Henschel implemented the clus-
tering for the interface classification. Wan Kyu Kim pursued the algorithm analysis, i. e. creation of the
benchmark set and evaluation of the performance of different clusterings. Screenshots for interfaces were
provided by Andreas Henschel, as well as the GO browser. Other SCOPPI interface characteristics were
provided by Christof Winter and Wan Kyu Kim. The implementation of the web interface was done by
Christof Winter. The case study on ancient homo-dimers was done by Wan Kyu Kim and Christof Winter.
All use cases were done by Christof Winter.
Pancreatic cancer use case. The structural modelling of pancreatic cancer interactions was done in
close collaboration with Gihan Dawelbait. Anne Tuukkanen performed the energy minimization experi-
ments. Thanks to Andreas Henschel for help with modelling. Parts of Figure 2.14 reprinted from Cell,
Vol. 7, D. Hanahan and R. A. Weinberg, The hallmarks of cancer, 57–70, Copyright (2000), with permis-
sion from Elsevier.
Xenopus use case. The meiotic microtubule-associated protein interaction network (Figure 2.16) is
based on and enriched with manual curations from Vincent Gache and Andrei Popov.

Chapter 3
Prediction of protein–RNA interaction
This chapter presents the development, validation, and application of an algorithm to search for protein
binding sites in RNA sequences. This algorithm was applied to identify potential binding sites for a partic-
ular protein, PTBP1, in a candidate set of messenger RNA sequences. This set originated from proteins
found in a screen for insulin regulators in pancreatic beta cells by a collaboratoring laboratory.
Parts of this chapter were published in:
Süß C, Czupalla C, Winter C, Pursche T, Knoch KP, Schroeder M, Hoflack B, Solimena M (2008). Rapid
changes of mRNA binding protein levels following glucose and IBMX stimulation of insulinoma INS-1 cells.
Mol Cell Proteomics
3.1 Background
In this section, we want to focus on biological and molecular principles of protein-DNA interactions in
general, and on the messenger RNA and its interaction with regulating proteins in particular. Further, we
will give an overview about the state of the art in predicting those interactions.
3.1.1 Principles of protein–RNA interaction
Interactions between proteins and nucleic acids, such as DNA and RNA, are fundamental for cellular life.
Protein–RNA interactions are particularly important in regulation of gene expression, since they control
messenger RNA processing, turnover, transport, localization, and translation (Siomi and Dreyfuss, 1997).
The spliceosome (Staley and Guthrie, 1998) and the ribosome (Ramakrishnan and White, 1998) are two
examples of tight synergistic interactions of RNA and protein. Protein–RNA interactions have also been
shown to play critical roles in cellular defense and developmental regulation (K Hall, 2002). Recently, there
is increasing evidence that especially non-coding RNAs are involved in regulation of a variety of cellular
processes, for example in the regulation of transcription by direct interaction with transcription factors
(Amaral et al., 2008).
Molecular mechanisms of protein–RNA interaction
Interaction between proteins and nucleic acids have been studied extensively on the molecular level.
The works of Nadassy et al. (1999) and Jones et al. (2001) have provided important insights into the
physicochemical and geometrical nature of these interactions.
RNA, like proteins, assumes complex three-dimensional structures to perform specific roles. Unlike
proteins however, RNA forms more locally stable structures, or structural motifs, that are combinatori-
ally linked by tertiary interactions. The number of these identifiable motifs appears to be relatively small
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Figure 3.1 The generic structure of a eukaryotic mRNA. Illustrated are some post-transcriptional regulatory
elements that affect gene expression. From 5’ to 3’: 7-methyl-guanosine cap, hairpin-like secondary structures,
interacting proteins, anti-sense RNA, and polyadenylation. These control translation, sub-cellular localisation, and
stability of the mRNA. UTR, untranslated region (adapted from Mignone et al., 2002).
(Hendrix et al., 2005). Traditionally, RNA structure, like protein structure, is described at the sequence
or primary structure level, the secondary, tertiary and quaternary levels. The Structural Classification of
RNA, SCOR (Tamura et al., 2004), is an attempt to provide a hierarchical classification of RNA structural
elements. Structural RNA motifs comprise hairpin loop motifs, symmetric and asymmetric internal loops,
junction loops, and hook-turn motifs (Leontis and Westhof, 2003). Research for the identification and clas-
sification of RNA structural motifs is ongoing. Ultimately, the goal is to predict these motifs from sequence
and to make use of them as building blocks in RNA engineering (Hendrix et al., 2005).
Proteins tend to interact with portions of RNA that form complex secondary structure elements (Na-
gai, 1996). Compared to protein-DNA interactions, protein-RNA interactions involve more frequently base
edge and ribose atoms than phosphate atoms (Lejeune et al., 2005). The most favoured amino acid-
nucleotide pairings observed lysine-phosphate, tyrosine-uracil, arginine-phosphate, phenylalanine-adenine
and tryptophan-guanine (Ellis et al., 2007).
Many RNA-binding proteins have a modular structure and contain RNA-binding domains of 70–150
amino acids that mediate RNA recognition (Mattaj, 1993; Pérez-Cañadillas and Varani, 2001). Protein do-
mains specifically binding to single-stranded RNA can be separated from those binding to double-stranded
RNA. Single-strand RNA binding protein domains comprise the RNA-binding domain, RBD (also known
as RNA recognition motif, RRM, or ribonucleoprotein domain, RNP), the KH domain, small zinc-binding
domains, and the Pumilio homology domain (K Hall, 2002). Many single-strand-RNA-binding proteins rec-
ognize sequences that are presented in loops (Auweter et al., 2006). The RBD is one of the most abundant
protein domains in eukaryotes, and present in about 2% of all human genes (Maris et al., 2005). RBDs
are typically 90 amino acids long and bind a variable number of nucleotides, which is usually between two
and eight. Despite the known structure of several RBDs, the mode of RNA recognition by RBDs is still not
clear (Cléry et al., 2008).
Regulation of translation via binding of proteins to messenger RNA
Messenger RNAs (mRNAs) are the central conduits in the flow of information from DNA to protein. They
encode the information of one gene in order to serve as template for the synthesis of a protein. In the
sequence of an mRNA, the protein coding region is embedded between the upstream 5’ and downstream
3’ untranslated region (UTR). Many UTRs harbour sequence and structural motifs as regulatory elements
which are used to control the stability, localisation, and translation of the mRNA (Wilkie et al., 2003).
These motifs, recognised by RNA-binding proteins, are often short-sequence elements whose activity can
be influenced by their secondary structure (Mignone et al., 2002). Figure 3.1 illustrates some regulatory
elements of eukaryotic mRNAs.
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Translational regulation by means of mRNA-binding proteins is crucial in numerous biological situa-
tions. In conditions of nutrient starvation, apoptosis, or viral infection, a global response modifies the trans-
lational efficiency of most mRNAs in the cell. In early embryonic development, where there is often little or
no transcription, translation of maternal mRNA is tightly controlled in processes such as cell division, cell-
fate determination, pattern formation, and embryonic axes establishment (Kuersten and Goodwin, 2003).
Overall, mRNA stability is estimated to control the expression of about 5–10% of human genes (Moore,
2005).
There has been a rapid expansion in the identification and characterization of mRNA regulatory el-
ements and their binding proteins. In the majority of cases, however, the mechanism by which transla-
tional regulation is achieved is not well understood (Wilkie et al., 2003). Most often, regulation involves
repression by proteins that bind to the 3’ UTR (Abaza and Gebauer, 2008). Rabani et al. (2008) recently
identified common structural elements in fast-decaying and slow-decaying mRNAs and linked them with
binding preferences of several RNA binding proteins. UTRdb and UTRsite (Mignone et al., 2005) are cu-
rated databases that store 5’ and 3’ untranslated sequences of eukaryotic mRNAs and their regulatory
elements. In general, the importance of UTRs in regulating gene expression is underlined by the finding
that mutations in the UTR can have serious pathological consequences (Conne et al., 2000).
3.1.2 Prediction of protein–RNA interaction
Although progress has been made in the development of predictive methods for protein–protein interac-
tions (compare section 2.1.4), less attention has been paid to the development of predictive methods for
protein–RNA interactions. In general, these methods can be divided into methods that predict whether a
protein binds RNA, and methods that predict whether an RNA binds protein. Whereas the former searches
for RNA-binding sites or RNA-binding domains in proteins, the latter tries to identify sequence motifs or
structural motifs in RNA.
Protein-based prediction methods
Focusing on the protein side of the protein-RNA interaction, Han et al. (2004) used a support vector
machine approach to predict protein–RNA interactions. For mRNA-binding proteins, they were able to
correctly predict if a protein was mRNA-binding with an accuracy of nearly 80%. Terribilini et al. (2006)
trained a Naive Bayes classifier on a non-redundant set of protein-RNA complexes of known structure
to predict which amino acids in a protein sequence of unknown structure are most likely to bind RNA.
In leave-one-out cross-validation experiments, their method identifies interface residues with 85% overall
accuracy. The prediction is available as part of the RNABindR web tool (Terribilini et al., 2007). Tong
et al. (2008) proposed a hybrid RNA-interaction site prediction method which combines support vector
machine learning with evolutionary information of amino acid sequences encoded in position-specific
scoring matrices for prediction of RNA-binding sites. They reported an accuracy of 72% on a dataset
where RNABindR achieved 64% accuracy.
RNA-based prediction methods
Methods focusing on the RNA side of the protein-RNA interaction can be divided into sequence-based and
structure-based approaches. Sequence-based methods usually consider a continuous sequence motif
as binding site. These motifs are either known, or they can be identified by means of motif discovery
algorithms (Bailey, 2007).
The purpose of motif discovery is to discover patterns in nucleotide or protein sequences in order to
better understand the structure and function of the molecules the sequences represent. Sequence motif
discovery algorithms include MEME (Bailey and Elkan, 1994), Consensus (Hertz and Stormo, 1999), Mo-
tifSampler (Thijs et al., 2002), Gibbs Motif Sampler (Thompson et al., 2003), GLAM (Frith et al., 2004),
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PhyME (Sinha et al., 2004), and Gemoda (Jensen et al., 2006a). MEME (Bailey and Elkan, 1994; Bailey
et al., 2006) was one of the first tools developed for motif discovery. Using an expectation maximization
algorithm, MEME analyzes nucleotide or protein sequences for similarities among them and produces
a description (motif) for each pattern it discovers. Some motif discovery algorithms such as Compare-
Prospector (Liu et al., 2004) take advantage of conservation information in multiple alignments of ortholo-
gous sequence regions. This has been shown to improve the detection of transcription factor binding sites
because they tend to be overrepresented in sequence regions of high conservation.
There are a variety of algorithms that address structural motifs of RNA. In most of the known RNA
structures, secondary structure is conserved during evolution, despite substantial sequence variation (Fo-
gel et al., 2002). Pioneering work was the RNAMOT pattern-matching program by Gautheret et al. (1990)
that used descriptors of structural features to align a list of RNA sequences. RNABOB, a fast RNA motif/-
pattern searcher, (Eddy, 1996) is an implementation of RNAMOT. Further programs are Palingol (Billoud
et al., 1996), PatScan (Dsouza et al., 1997), and RNAMotif (Macke et al., 2001; Fogel et al., 2002). The
RNAMotif algorithm discovers RNA structural elements and searches a database for RNA sequences
that match a motif describing secondary structure interactions. A match means that the given sequence
is capable of adopting the given secondary structure, although this is not intended to be predictive. The
specification of the secondary structure is given with a descriptor that contains both the sequence and
the structure pattern. Gautheret and Lambert (2001) compute a secondary structure profile from RNA
sequence alignments and use this profile to match it against a target database. An online version of
their algorithm is available at the ERPIN (Easy RNA Profile IdentificatioN) server (Lambert et al., 2004).
RNAProfile (Pavesi et al., 2004) aims at discovering conserved secondary structure motifs in unaligned
RNA sequences with unknown secondary structure. It is included in the MOtif Discovery Tools web server
(Pavesi et al., 2006). Further programs that search for structure motifs in RNA sequences are PatSearch
(Grillo et al., 2003), RNAProfile (Pavesi et al., 2004), and CMfinder (Yao et al., 2006). CMfinder is an RNA-
motif prediction tool using an expectation maximization algorithm with heuristics for motif search, and a
Bayesian framework for structure prediction combining folding energy and sequence covariation.
Programs that perform RNA sequence-structure alignments for detecting the binding motif comprise
RSEARCH (Klein and Eddy, 2003), the work of Backofen and Will (2004), Liu et al. (2005a), and MARNA
(Siebert and Backofen, 2005).
The idea of using RNA secondary structures to guide sequence motif finding towards single-stranded
region has been put forward by Hiller et al. (2006). Their tool MEMERIS can be used to detect motifs
constrained to single-strand regions (Hiller et al., 2006). MEMERIS precomputes position-specific values
measuring the single-strandedness of all substrings of an RNA sequence. These values are used as prior
knowledge about the motif starts to guide the motif search.
3.1.3 The polypyrimidine tract binding protein PTBP1
PTBP1 binds to pyrimidine-rich regions of messenger RNAs
PTBP1 is an mRNA binding protein that was found to bind to polypyrimidine tracts (García-Blanco et al.,
1989). It was first identified as a component of the pre-mRNA splicing machinery, where it targets the
C/U-rich region of introns (Patton et al., 1991). PTBP1 has nuclear as well as cytoplasmic activities. In the
nucleus, it regulates pre-mRNA splicing (Spellman and Smith, 2006; Sharma et al., 2005; Wagner and
Garcia-Blanco, 2001) and poly(A) site cleavage (Castelo-Branco et al., 2004). In the cytoplasm, it has
been shown to regulate cap-independent translation through an internal ribosomal entry site (Hellen et al.,
1993; Song et al., 2005). It further regulates mRNA localisation (Cote et al., 1999), and mRNA stability for
insulin and other secretory granule proteins (Tillmar et al., 2002; Knoch et al., 2004; Knoch et al., 2006;
Fred and Welsh, 2009).
Alternative splicing of the Ptbp1 transcript generates different isoforms (Gil et al., 1991), the largest
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Figure 3.2 Mechanism of the PTBP1 action on protein translation. PTBP1 specifically binds to untranslated
regions (UTRs) of mRNAs. Binding to the 5’ UTR results in promotion of translation, binding to the 3’ UTR results in
stabilisation of the mRNA. As a results, the mRNA is less degraded and more translated, leading to an immediate
increased protein concentration (image adapted from Suckale and Solimena (2008)).
of which measures 59 kDa and contains four RNA recognition domains (see Figure 3.3). PTBP1 was ob-
served as a monomer in solution (Monie et al., 2005; Song et al., 2005), although formation of homodimers
upon binding of certain RNAs is discussed (Auweter and Allain, 2008).
Oberstrass and co-workers (2005) solved the structure of the four RNA recognition domains bound to
RNA oligonucleotides with the sequence CUCUCU in solution using NMR (Figure 3.3). They concluded
that PTBP1 is a sequence-specific RNA binding protein with a preference for CU tracts. Further, they
proposed a model of how the RNA recognition domains could bring separated pyrimidine tracts in close
proximity.
The sequence specificity for PTBP1 binding was investigated by Tillmar et al. (2002) in different
species. Comparing the mRNA sequences of insulin in different species, they found a CYYYYCYYYYYG
consensus sequence motif for PTBP1 binding (Figure 3.4).
The role of PTBP1 in the pancreatic beta cell
The pancreas is a gland in the upper abdomen of vertebrates. Besides an exocrine part producing diges-
tive juices that are released into the gut lumen, the pancreas has an endocrine part producing hormones
that are released into the blood. One such hormone, insulin, is produced in the beta cells of the endocrine
pancreas. Insulin causes most cells to take up glucose from the blood and, in the case of liver and mus-
cle cells, store it as glycogen. It further increases fatty acid synthesis and uptake of amino acids, and it
decreases lipolysis, proteolysis, and gluconeogenesis. Lack of effect of insulin results in diabetes mellitus,
the most common metabolic disorder in humans.
Within the beta cell, ready-made insulin is stored in secretory granules. Upon stimulation, for example
by glucose, secretory granules are fused with the plasma membrane in order to release insulin. Proper
stimulants are glucose or cAMP-inducing agents such as 3-isobutyl-1-methylxanthine (IBMX). In addition
to insulin secretion, glucose induces the rapid biosynthesis of pre-proinsulin as well as components of
the insulin secretory granule components, including pro-hormone convertases 1/3 (PC1/3) and 2 (PC2),
chromogranin A, and the granule transmembrane protein ICA512 (Guest et al., 1989; Alarcón et al., 1993;
Martin et al., 1994; Ort et al., 2001). This rapid up-regulation of secretory granule components can be
largely attributed to post-transcriptional mechanisms such as increase of mRNA stability and stimulation
of translation (Tillmar et al., 2002; Suckale and Solimena, 2008). In particular, PTBP1 has been shown to
increase stability of the mRNA for insulin and other secretory granule components by binding to mRNA
5’ or 3’ UTRs (Tillmar et al., 2002; Knoch et al., 2004; Knoch et al., 2006; Fred and Welsh, 2009). Upon
glucose stimulation, PTBP1 is believed to shuttle out of the nuclear into the cytoplasmic component of
the beta cell, where it binds to these mRNAs, resulting in increased protein synthesis of insulin and
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Figure 3.3 The PTBP1 protein has four RNA-binding domains (RBD). The structure for each separate domain,
but not for the full protein, is known based on NMR studies (image from Oberstrass et al., 2005). For each RBD,
the overlay of the 20 lowest energy structures (middle) and the most representative structure in complex with a
single-stranded RNA oligonucleotide with sequence CUCUCU (bottom) is shown.
secretory granule components. Thus, PTBP1 serves as important, immediate control for the rate of insulin
biosynthesis (Suckale and Solimena, 2008).
3.1.4 Screen for novel regulators of insulin response in the pancreatic beta cell
The work presented in this chapter was the result of a collaboration with the research group for experimen-
tal diabetology of Michele Solimena at Technische Universität Dresden. The Solimena lab was interested
in finding novel regulators of insulin response in the pancreatic beta cell. To this end, Süss et al. (2009)
performed a screen to examine the proteomic changes occurring shortly after stimulation of an in vitro
beta cell model with glucose or with the cAMP elevating agent 3-isobutyl-1-methylxanthine (IBMX). Pro-
teins were stained with either Cy3 and Cy5, separated by two-dimensional differential gel electrophoresis,
and identified by mass spectrometry.
As a result, 78 proteins were found to be differentially expressed when comparing resting cells without
stimulation to cells stimulated with glucose or IBMX. Out of these 78 proteins, 63 were still differentially ex-
pressed in presence of the transcription inhibitor Actinomycin D. In these cases, changes were expected to
be caused by post-transcriptional regulation. Given the established role of PTBP1 as post-transcriptional
regulator of insulin and related secretory granule components, further targets PTBP1 were expected to
be found among these candidates. Since it was not feasible to test all 63 candidate proteins in detailed
follow-up binding studies, there was a clear need to prioritise by predicting potential PTBP1 binding sites
for each candidate.
3.2 Definition of open problem
Premise
• PTBP1 is known to regulate the biosynthesis of insulin and components of the insulin secretory
machinery. To this end, it binds to the untranslated regions of messenger RNAs. Thus, PTBP1
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PTB consensus binding sequence             CYYYY CYYYY YG
Rat I (J00747)             UCCACCACUCCCCG  CCCAC CCCUC UG  CAA
Rat II (J0O748)            CCACCACUACCCUG  UCCAC CCCUC UG  CAA
Mouse I (NM008386)         CCACCUCGACCCGC  CCCAC CCCUC UG  CAA
Mouse II (NM008387)        CCACCACUACCCAG  CCUAC CCCUC UG  CAA
Rabbit (M61153)                   UGCCCCC  CACCC ACCCC UG  CCCGCGCCCCCC
Guinea pig (K02233)                CCUCCC  ACUCU CCCCU GG  CAA
Syrian hamster (M26328)  CCUCACCACUACCCAG  CCCAC CUUCC UG  CA
Octodon degus (M57671)             CCUGCU  GCUCU GCCCU GG  CA
Pig (AF064555)                       CGCC  UGCUG CUCCC CG  CACCCC
Cow (M54979)                                 GCC UGCCC CG  ACAC
Sheep (U00659)                             CCUGG CCCGC CG  CC
Dog (VOO179)                           CC  UUCGG CUCUC UG  CACCCC
African green monkey (X61092)          CC  CUCCA CCUCC UG  CACC
Owl monkey (J02989)              CCCUGCAC  CCUCC UCACC UG  CAC
Homo sapiens (NM000207)         CCCCCCACC  CGCCG CCUCC UG  CAC
Chicken (X58993)                           CUUAC UCUAU CG  ACCUUC
Butterflyfish (AF199588)       CCUCCCUGCCUU  CUUCC UUUUA AG  U
Anglerfish (V00634)                     UU  UCCCU CGCCU UG  CUU
Common carp (X00989)              CCAAUGA  CUUCU CCACC UG  UU
Chum salmon (X00148)                CUCUU  CUCUU CUCUC UG  CC
Catla catla (AF373021)                 CU  UUCCC CUGUU UG  CA
Nile tilapia (AF038123)             CCCCA  CCUCG CUCCC UC  CUUC
Barfin flounder (AB029318)     CCCCCCUCACGC  CCCGG CCCUU UG  CGUC
Figure 3.4 Comparison of the PTB consensus binding sequence with preproinsulin mRNA pyrimidine-rich
3’-UTR sequences from different species reveals a consensus binding sequence of CYYYYCYYYYYG, where
C denotes cytosine, G denotes guanine, and Y denotes a pyrimidine base. Underlined letters indicate positions
of transitions that differ from the PTB consensus binding sequence. GenBank accession numbers are given in
parentheses (as published in Tillmar et al., 2002).
regulates on the post-transcriptional level, independent of gene transcription.
• It is known that PTBP1 preferentially binds to single-strand RNA regions with the sequence motif
CYYYYCYYYYYG.
• In a recent screen in a collaborating group, a set of 63 proteins in insulin-producing pancreatic beta
cells were identified that changed their concentrations while gene transcription was inactivated.
This set is expected to be highly enriched in proteins that are regulated by either PTBP1 or by other
mRNA-binding proteins.
Open problem
Can we predict mRNA binding partners for PTBP1 based on their nucleotide sequence and the known
binding motif?
3.3 Results
This section presents the sequence motif algorithm, its application to the candidate set of post-transcriptionally
regulated proteins, a benchmark of the algorithm, and experimental validation of algorithm predictions. A
detailed description of data sources and implementation is given in the Materials and Methods section on
page 88.
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3.3.1 The sequence motif algorithm
In order to predict binding sites for PTBP1 on candidate messenger RNAs, the sequence motif algorithm
was developed. The development was guided by the following biological constraints:
• The CYYYYCYYYYYG binding motif as described in Tillmar et al. (2002) was required to be present
in the mRNA sequence. To account for deviations from the binding motif which were observed in sev-
eral confirmed targets, up to two mismatches were allowed (see Figure 3.4, underlined residues).
• The binding motif should be conserved in orthologous sequences in the species of human, mouse,
and rat.
• The binding motif should be located in a region of single-strand RNA, following the structural studies
of Oberstrass et al. (2005) and Auweter et al. (2006).
Algorithm steps
The resulting sequence motif algorithm takes a list of candidate gene or protein identifiers as input, and
produces a list of candidates with putative PTBP1 binding sites ranked by their likelihood as output. The
algorithm steps are as follows:
For each protein, do:
1. Identify orthologues in human, mouse, and rat
2. Retrieve all available mRNA sequences for each orthologue and split sequences into 5’ and 3’ UTR
sequences
For each UTR, do:
3. Create a multiple sequence alignment with sequences from all three species
4. Identify regions conserved in two or three species
5. Search for CYYYYCYYYYYG binding motif hits in conserved regions
6. For each UTR sequence containing binding motif hits, calculate p-value to assess significance of
the hits. Repeat N times:
(a) Create a random permutation of the sequence
(b) Search for binding motif hits
(c) Store number of hits
Calculate p-value as frequency of observing the same number of hits or more in the random se-
quences as in the original sequence, divided by N
7. Perform secondary structure prediction of the conserved mRNA consensus sequence
8. Check whether any found binding motifs are located in single-strand region of mRNA
In the following, the algorithm steps will be described in detail using prohormone convertase 2 (PC2) as an
example—a protein with a known binding site that is part of the benchmark set presented in section 3.3.2.
Steps 1 and 2: Identify orthologues and retrieve mRNA sequence. Orthologues in rat, mouse, and
human were identified by using the InParanoid database (O’Brien et al., 2004b) and by careful manual
assignment in cases of missing database entries. Messenger RNA sequences were obtained from the
Entrez Nucleotide database at NCBI. Sequences were split into 5’ and 3’ UTRs by removing the coding
region as specified in the database entry.
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Figure 3.5 Multiple sequence alignment of available 3’ UTR sequences of prohormone convertase 2 (PC2)
for human, mouse, and rat (result of step 3 of the sequence motif algorithm). Nucleotides are coloured as adenine,
green; cytosine, yellow; guanine, red; thymine, blue. The consensus sequence and its conservation are shown
below. A binding motif hit between residues 25 and 36 of the alignment is marked with a black frame (result of step
5 of the sequence motif algorithm).
Step 3: Create multiple sequence alignment. The multiple sequence alignment was created with
MAFFT (Katoh et al., 2002), which is one of the most accurate programs for that purpose (Wilm et al.,
2006). For the example protein PC2, the result of this step is shown in Figure 3.5. Overall, the sequence
conservation between mouse and rat is higher than between any other two species. Approximately two
thirds of the residues appear fully conserved in all three species. Due to splicing variants, mRNA se-
quences belonging to the same species usually do not share all residues.
Steps 4 and 5: Identify conserved regions and search for binding sites. Regions conserved in ei-
ther two or all three species were searched for the PTBP1 binding motif CYYYYCYYYYYG (C, cytosine; G,
guanine; Y, cytosine or uracil), tolerating 0, 1, or 2 mismatches. The search was implemented by creating
regular expressions. For an exact hit (0 mismatches), the regular expression C[CU][CU][CU][CU]C[CU]-
[CU][CU][CU][CU]G was used. For one mismatch, regular expressions were created systematically by
allowing any character at each position, giving rise to 12 regular expressions. Similarly, 66 regular expres-
sions were created to cover all 2 mismatch cases. Figure 3.5 shows a binding site motif hit in the multiple
sequence alignment of PC2 with one mismatch in the human sequences.
Step 6: Assess significance of sequence motif hits. To assess the significance of hits, we ask the
question of how likely a hit of a CYYYYCYYYYYG motif would occur just by chance. To this end, each
sequence giving rise to binding site hits was shuffled (i.e., randomly permuted) and again searched for hits.
This process was repeated 100,000 times per sequence. Shuffling preserves the nucleotide composition
of the sequence, but is likely to destroy any biological meaningful sequence pattern.
Figure 3.6 shows the resulting distribution of 3’ UTR sequence of prohormone convertase 1/3. In the
original sequence, 5 hits were found when allowing up to 2 mismatches. In 100,000 random permutations
of the original sequence, 5 hits or more were only observed in 90 cases, yielding a relative frequency of
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Figure 3.6 Assessment of significance. Distribution of frequency of binding motif hits in 100,000 random se-
quences for the 3’ UTR of prohormone convertase (result of step 6 of the sequence motif algorithm). The relative
frequency of observing the same number of hits or more as in the original sequence serves as p-value to assess
the significance of the original sequence hits.
0.0009. We treat this frequency as a direct measure of the probability to observe the original hits just by
chance, and assign it as p-value to the number of found binding sites for that particular candidate.
The random sequence approach is also adopted by sequence pattern databases such as PROSITE
(Bairoch, 1992). In order to evaluate their specificity, PROSITE patterns are searched against a random
database. This database is created by local shuffling of the residues in windows of 20 residues.
Steps 7 and 8: Predict secondary structure and identify single-strand region binding sites. Using
RNAfold (Hofacker and Stadler, 2006), a minimum free energy structure was predicted from the UTR
sequences and visualised with RNAplot. Binding sites found in step 5 were located, marked, and checked
for their occurrence within a single-strand region. A binding site was counted as single-stranded if more
than half of its nucleotides were non-paired in the minimum free energy structure.
For prohormone convertase 2, Figure 3.7 shows the resulting secondary structure prediction. The
predicted binding site, marked with triangles, is fully located in a single-strand region. In addition, a low
predicted entropy in this region (red colour) means a high reliability of the predicted structure. Positional
entropy computed from the pair probabilities using the relplot utility which is part of the Vienna RNA
Package (Hofacker, 2004) is encoded in colour. Low entropy regions have little structural flexibility and
the reliability of the predicted structure is high. High entropy implies many structural alternatives, making
structure prediction less reliable.
Final result. The final result of a sequence motif algorithm run is a ranked list of candidates. Sec-
tion 3.3.3 presents the results for experimentally found differentially expressed and post-transcriptionally
regulated proteins of the pancreatic beta cell.
Complexity of the sequence motif algorithm
Three steps of the sequence motif algorithm are computationally expensive: the multiple sequence align-
ment (step 3), the random sequence significance assessment (step 6), and the secondary structure pre-
diction (step 7).
Given N sequences of length L, the time complexity for step 3 is O(N2L2), O(L) for step 6, and O(L3) for
step 7. Note that the last two mentioned steps are independent of N because N sequences are condensed
into one consensus sequence. Since N  L (the average sequence length L is around 600, whereas
average number of sequences N per candidate is around 5), the limiting step is step 7 and O(L3) becomes
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Figure 3.7 Secondary structure prediction of the 3’ UTR of prohormone convertase 2. Minimum free energy
structure as predicted with RNAfold (Hofacker and Stadler, 2006). Colour hue ranges from red for low entropy
(high probability), via yellow and green to blue and violet for regions with very high entropy (low probability). One
occurrence of the motif is marked in a loop region close to the 5’ end.
an upper bound for the time complexity of the whole sequence motif algorithm. Currently, there are no
known algorithms for RNA secondary structure prediction with a complexity better than O(L3) (Wexler
et al., 2007).
3.3.2 Benchmarking the sequence motif algorithm
As proof of concept, the algorithm was tested against a set of benchmark mRNAs with known, experi-
mentally validated PTBP1 binding sites. A study by Knoch et al. (2004) found the mRNAs of preproinsulin,
prohormone convertase 1 (PC1/3), prohormone convertase 2 (PC2), islet cell autoantigen 512 (ICA512),
and chromogranin A to be PTBP1 targets.
The algorithm was run as described in the previous section. For each benchmark mRNA, sequences
were collected for human, mouse, and rat. The consensus sequence was searched for potential binding
sites. The results are listed in Table 3.1. Binding site hits were found in all of the benchmark mRNAs.
Interestingly, hits were confined to the 3’ UTR in each case. Single-strand binding sites were detected in
all cases. Except for chromogranin A, all hits were significant with a p-value< 0.01. Perfect hits with 0 mis-
matches in case of PC2, hits with one mismatch for insulin and PC1/3, but also hits with two mismatches
for PC1/3, ICA512, and chromogranin are observed. Note that the two mismatches hits for PC1/3 and for
ICA512 still have significant p-values.
The benchmark validation demonstrates the ability of the algorithm to detect present PTBP1 binding
sites in mRNA sequences and thus to explain binding of PTBP1 to known targets. The validation also
confirms that binding sites consistently appear in single-strand regions. Further, it justifies to allow a
number of 2 mismatches, since a fewer number cannot explain binding to ICA512 or chromogranin A with
this algorithm.
3.3.3 Application of the sequence motif algorithm to screen for novel PTBP1 targets
The algorithm as described the section 3.3.1 was applied to 63 rat proteins that were found differentially
regulated in pancreatic beta cells. The algorithm was run with requiring either two or three species to be
conserved in step 4. The results are shown in Tables 3.2 and 3.3.
Considering only regions fully conserved in the three species mouse, human, and rat, we find that 11
out of 78 proteins exhibit significant PTB binding sites in their UTRs (Table 3.2). Interestingly, nearly all
binding sites where located in the 3’ UTR. None of the binding sites found had zero mismatches. Syntaxin
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Table 3.1 Proof of concept validation of the sequence motif algorithm. Knoch et al. (2004) experimentally
confirmed binding sites for PTBP1 in the mRNAs of preproinsulin (insulin), prohormone convertase 1 (PC1/3), pro-
hormone convertase 2 (PC2), islet cell autoantigen 512 (ICA512), and chromogranin A. The algorithm was run on
three-species consensus sequences for these mRNA sequences. In all cases, the algorithm found single-strand
binding sites in the 3’ UTR. Except for chromogranin A, all binding sites were significant with a p-value < 0.01.
Benchmark mRNA UTR Number
of mis-
matches a
Predicted
binding
sites
p-value b Predicted bind-
ing sites single-
strand c
Insulin 3’ 1 1 0.0054 1
PC1/3 3’ 1 2 0.0011 1
PC1/3 3’ 2 5 0.0009 1
PC2 3’ 0 1 0.0091 1
ICA512 3’ 2 14 0.0037 5
Chromogranin A 3’ 2 5 0.0157 1
a The allowed number of mismatches can be 0, 1, or 2
b The p-value is the probability of obtaining at least the same number of hits in a random
sequence of same composition
c Secondary structure of RNA was predicted using RNAfold (Hofacker and Stadler, 2006)
Table 3.2 Application of the sequence motif algorithm. Predicted conserved (human, rat and mouse) PTBP1
binding sites in the mRNA UTRs from candidate proteins. Binding site hits are sorted by p-value, p < 0.01. Stmn1
is listed twice in the table due to different number of mismatches detected in the PTBP1 consensus sequence and
consequently different p-values.
Entrez
Gene
Symbol
Protein UTR Mis-
matches a
Binding
sites
p-value b Binding
sites single-
strand c
Aldoa Aldolase A 3’ 2 12 0.0001 4
Dpysl2 Dihydropyrimidinase-related protein 2 3’ 2 35 0.0006 8
Lmna Lamin A 3’ 2 22 0.0013 7
Pkm2 M2 pyruvate kinase 3’ 2 15 0.0017 6
Mapk1 Mitogen activated protein kinase 1 5’ 1 3 0.0026 1
Dnm2 Dynamin 2 3’ 1 5 0.0029 1
Stmn1 Stathmin 1 3’ 1 3 0.003 1
Sgta Small glutamine-rich tetratricopeptide
repeat (TPR)-containing, alpha
3’ 1 7 0.0041 2
Stxbp1 Syntaxin binding protein 1 3’ 2 28 0.0047 15
Stmn1 Stathmin 1 3’ 2 8 0.0063 4
Ndrg1 N-myc downstream regulated 1 3’ 1 4 0.0098 1
Necap1 NECAP endocytosis associated 1 3’ 1 4 0.0099 2
a The allowed number of mismatches can be 0, 1, or 2
b The p-value is the probability of obtaining at least the same number of hits in a random sequence of same composition
c Secondary structure of RNA was predicted using RNAfold (Hofacker and Stadler, 2006)
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Table 3.3 Application of the sequence motif algorithm. Predicted conserved (minimum: two species) PTBP1
binding sites in the mRNA UTRs from candidate proteins. Some candidates are listed several times in the table due
to different number of mismatches detected in the PTBP1 consensus sequence and consequently different p-values.
Predicted PTB binding sites conserved in at least two species, sorted by p-value (p < 0.01)
Entrez
Gene
Symbol
Protein UTR Mis-
matches a
Binding
sites
p-value b Binding
sites single-
strand c
Stau2 Staufen, RNA binding protein, ho-
molog 2
3’ 1 9 0 4
Lmna Lamin A 3’ 2 33 0 12
Dpysl2 Dihydropyrimidinase-related protein 2 3’ 2 42 0 10
Aldoa Aldolase A 3’ 2 12 0.0001 4
Tubb2b Tubulin beta chain 15 3’ 2 13 0.0001 3
Stau2 Staufen, RNA binding protein, ho-
molog 2
3’ 2 21 0.0001 5
Stxbp1 Syntaxin binding protein 1 3’ 2 36 0.0001 21
Pkm2 M2 pyruvate kinase 3’ 2 18 0.0002 6
Stau2 Staufen, RNA binding protein, ho-
molog 2
3’ 0 2 0.0005 1
Sgta Small glutamine-rich tetratricopeptide
repeat (TPR)-containing, alpha
3’ 1 9 0.0006 4
Serbp1 Plasminogen activator inhibitor 1 RNA-
binding protein
5’ 1 3 0.0007 3
Snx3 Sorting nexin 3 3’ 1 5 0.0007 2
Glul Glutamate-ammonia ligase (glutamine
synthase)
3’ 2 19 0.0014 4
Dpysl2 Dihydropyrimidinase-related protein 2 5’ 2 9 0.0018 1
Inexa Alpha-internexin 3’ 2 21 0.0026 6
Stmn1 Stathmin 1 3’ 1 3 0.003 1
Ndrg1 N-myc downstream regulated 1 3’ 2 17 0.003 3
Necap1 NECAP endocytosis associated 1 3’ 1 5 0.0032 1
Atp6v1a ATPase, H+ transporting, lysosomal
V1 subunit A
3’ 2 25 0.0039 6
Pkm2 M2 pyruvate kinase 3’ 1 4 0.0063 1
Stmn1 Stathmin 1 3’ 2 8 0.0063 4
Pcbp2 Poly(rC)-binding protein 2 3’ 2 9 0.0064 3
Dpysl2 Dihydropyrimidinase-related protein 2 3’ 1 7 0.0065 2
Ppp1r8 Protein phosphatase 1, regulatory
(inhibitor) subunit 8
3’ 2 11 0.0065 4
Cmpk Cytidylate kinase 3’ 2 11 0.0094 5
Ppp1cb Protein phosphatase 1, catalytic sub-
unit, beta isoform
3’ 2 16 0.0095 1
Ndrg1 N-myc downstream regulated 1 3’ 1 4 0.0098 1
a The allowed number of mismatches can be 0, 1, or 2.
b The p-value is the probability of obtaining at least the same number of hits in a random sequence of same composition.
c Secondary structure of RNA was predicted using RNAfold (Hofacker and Stadler, 2006).
82 C H A P T E R 3 . P R E D I C T I O N O F P R O T E I N – R N A I N T E R A C T I O N
AGA
G
AA
GA
CGG
CC
CCC
C
UCU
C
U C G G
C
C CG G C C
A U C U U G
U
G
G
G
A
A
G
A
G
CU
G
A
A
G C A
G
G
C
G
C
U
C
U
U
G G C U C G G C G C G
G C
C C
G C U G C
A A
U
CCGUGG
AGG
AACGCGCCGCCGAG
CC
AC
C
A
U C
Serbp1
5' UTR
low entropy high entropy
1
1
1
111 begin of motif hit
end of motif hit
n
n
with n mismatches
5’
3’
Figure 3.8 Minimum free energy structure of the 5’ UTR of messenger RNA for serpine1 mRNA binding protein 1
(Serbp1). Significant occurrences of the PTBP1 binding motif conserved in at least two species (see Table 3.3) are
marked with triangles. The secondary structure was predicted with RNAfold (Hofacker and Stadler, 2006). Colour
hue ranges from red for low entropy (high probability pairs), via yellow and green to blue and violet for regions with
very high entropy (low probability).
binding protein 1 (Stxbp1) exhibits the highest number of single-strand binding sites. It should be also
noted that Stxbp1 has the the highest single-strand over all binding sites fraction (15/28 ≈ 0.54). On
the other hand, Dynamin 2 has seven potential binding sites, but just one out of them is located in a
single-strand region.
Lowering the conservation criterion to include regions conserved in at least two species, we find 20
proteins with significant binding sites (Table 3.3). Again, nearly all binding sites where located in the 3’
UTR, with the exception of the plasminogen activator inhibitor 1 (Serbp1) and dihydropyrimidinase-related
protein 2 (Dpysl2). One candidate, Staufen 2 (Stau2), had exact matches of the binding site motif. A p-
value of 0 was observed in three cases because of the random sequence step resulted in a total of 0
binding motif hits.
The secondary structure predictions for the serpine1 mRNA binding protein 1 (Serpb1) and for Stau-
fen 2 (Stau2) and Stau are depicted in Figures 3.8 and 3.9. For Serbp1, it can be seen that the three motif
hits are part of one single continuous C/U-rich region. The entropy in this region tends to be low, which
indicates that the structure prediction is reliable. Parts of the binding site region are double-stranded,
although eight residues are single-stranded in each motif hit. For Stau2 (Figure 3.9), three distinct binding
regions can be identified that give rise to four binding motif hits. The overall entropy is below average.
These two candidates, together with Poly(rC)-binding protein 2 (Pcbp2), were subjected to experimen-
tal validation, which is presented in section 3.3.4.
3.3.4 Experimental validation of predicted interactions
From results in Table 3.3, three mRNA candidates were selected and experimentally tested for interaction
with PTBP1. The experiments were carried out by our collaborators. The selection was motivated by the
collaborators’ hypothesis that the promising candidate might be an RNA binding protein as well. Hence,
the three RNA binding proteins Staufen 2 (Stau2), Poly(rC)-binding protein 2 (Pcbp2), and Plasminogen
activator inhibitor 1 (Serbp1) were chosen. Briefly, our collaborators analyzed their expression following
Ptbp1 knockdown by RNAi or overexpression of PTBP1. After Ptbp1 knockdown, only the levels of the 52
kDa isoform of Staufen 2 were modestly increased, while they did not change upon PTBP1 overexpression
(Figure 3.10). The levels of the other Staufen 2 isoforms, of SERBP1 and of PCBP2 did not significantly
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Figure 3.9 Minimum free energy structure of the 3’ UTR of messenger RNA for Stau2. Significant occurrences
of the PTBP1 binding motif conserved in at least two species (see Table 3.3) with different number of mismatches are
marked with triangles. The secondary structure was predicted with RNAfold (Hofacker and Stadler, 2006). Colour
hue ranges from red for low entropy (high probability pairs), via yellow and green to blue and violet for regions with
very high entropy (low probability).
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Figure 3.10 Experimental validation of three predicted interactors of PTBP1. The validation experiments were
carried out by our collaborators. (A and B) Quantification of PTBP1 knockdown and of the endogenous and total
PTBP1 levels. The average level of PTBP1 in cells transfected with the control vector was equaled to 100%. (C
and D) Quantification of immunoblots for four different isoforms of Staufen2, PAI-RBP1 (SERBP1), and PCBP2. The
levels of these proteins in control cells were equalled to 100%. Each bar shows the quantification from 3 independent
experiments (* p < 0.05; ** p < 0.01; *** p < 0.001). Error bars represent standard error of the mean. Figure from
Süss et al. (2009).
differ in either condition. In view of these findings, the possibility that SERBP1, Staufen 2, or PCBP2 are
regulated by PTBP1 seems unlikely.
3.4 Discussion
3.4.1 Open problem revisited
This chapter addressed the open problem if we can predict mRNA binding partners for PTBP1 based on
their nucleotide sequence and the known binding motif.
What did we learn from the development of the sequence motif algorithm and its application to known
and putative binding partners of PTBP1? First, searching for the CYYYYCYYYYYG binding motif in single-
stranded regions of messenger RNAs can explain the binding of PTBP1 to the benchmark set of known
targets. In particular, binding sites located in the 3’ UTR were sufficient to explain binding in all these cases.
In this light, 5’ UTR double-stranded binding of PTBP1 observed by Mitchell and colleagues (2005) is
unlikely to play a role for regulation of insulin and related proteins in the beta cell. Second, binding regions
not fully conserved in rodents and human are prone to be false positives. This might explain why some
predictions could not be validated experimentally. In fact, conservation appears to be a strong indicator of
biological relevance and should definitely be considered. Although three mRNA candidates were selected
for experimental validation, only one of them, Stau2, showed a modest increase after knockdown of Ptbp1,
suggesting an inhibitory role of PTBP1 on that particular candidate. Possible reasons are discussed in
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section 3.4.4 below. It remains to be seen how candidates with fully conserved binding regions such as
syntaxin will perform in further experiments.
As with the prediction of protein-protein interactions, a general problem is the missing information
about truly negative examples. For the case of PTBP1 interactions, these negative examples would be
messenger RNAs with experimental proof that they do not interact with PTBP1. Owing to the fact that
even if such data existed, it is hardly published, there is no such set of examples for PTBP1 that could
serve as negative control. Here, we embarked upon the strategy of using random sequences of same
length and nucleotide composition as negative control. The assumption is that any present biologically
meaningful sequence pattern is destroyed after randomising the sequence. Such random models were
used early to assess the statistical significance of molecular sequence features (Karlin and Altschul, 1990).
A slight problem remains, however. For RNA, secondary structure plays an important role as it can for
example hide binding sites for single-strand binding proteins in a double-stranded region (see section 3.1).
A random model should ideally account for that. The naive approach of incorporating secondary structure
prediction into random sequence step, is not feasible. As outlined in section 3.3.1, the time complexity of
RNA folding algorithms is currently at O(L3), with L being the sequence length. A repeated run of 100,000
random sequence simulations would require 100,000 secondary structure predictions. Even with the help
of supercomputing, this would take several months to compute for all proteins investigated here.
3.4.2 Alternative approaches
Employing regular expressions for binding site search as implemented in the sequence motif algorithm
is a straightforward approach. Compared to regular expressions, more expressive methods exist such as
position specific scoring matrices or Hidden Markov Models (Eddy, 2004). In these representations of a
sequence pattern, probabilities can be assigned to each position of a sequence.
The question can be raised whether the sequence motif algorithm benefits from representing the
PTBP1 binding site, currently represented with the regular expression CYYYYCYYYYYG, with a Hidden
Markov Model, and then using this model to search for the binding site in candidate sequences. To address
this, a Hidden Markov Model was created based on the aligned insulin binding sites from Figure 3.4 using
the HMMer software (Eddy, 1998). However, no significant hits could be found for most of the sequences
of the benchmark set of known PTBP1 binding partners. HMMer E-values were often in the order of 1 or
higher. An E-value (expectation value) of 1 means that one hit with the same HMMer score or a better
one is expected to occur just by chance in a random sequence of the same length. It is not entirely
clear why these insignificant E-values occur, despite the fact that the random sequence model in step of
the sequence motif algorithm reports p-values  0.05 (see Table 3.1). One possible reason is that the
Hidden Markov Model was more general rather than more specific, due to capturing some non-informative
noise in the sequences. As a consequence, random sequence hits become more likely, while true hits
remain unaffected. Nevertheless, in most cases the binding sites identified with the HMM approach were
identical to those identified with the regular expression approach. Following the Occam’s Razor principle
of explaining a phenomenon with as few assumptions as possible, we chose regular expressions for the
sequence motif algorithm.
One could argue that there might be a sequence binding motif different from CYYYYCYYYYYG that
is better suited to capture PTBP1 binding sites. To this end, a motif discovery approach was applied
to the benchmark set. The MEME (Bailey and Elkan, 1994) motif finder analyses nucleotide or protein
sequences for similarities using an expectation maximisation algorithm. As output, it produces position-
specific scoring matrices as well as regular expressions. MEMERIS (Hiller et al., 2006) is an extension
of MEME. MEMERIS uses an RNAfold secondary structure prediction to precompute position-specific
values measuring the single-strandedness of all substrings of an RNA sequence. This information is then
used to guide a MEME motif search towards single-stranded regions.
MEMERIS was applied to the benchmark set UTR sequences with motif length settings of 6, 8, 10,
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Table 3.4 Result of a MEMERIS motif discovery with motif lengths of 6, 8, 10, and 12 for the 3’ UTR of prohor-
mone convertase 2. The top 5 ranked motifs discovered are shown. Although MEMERIS (Hiller et al., 2006) restricts
motif discovery to single-strand regions, it fails to identify truly polypyrimidine (C/U)-rich regions that could explain
PTBP1 binding.
Motif length 6 8 10 12
Ranked hits
1 AAUGGA AAUGGAA[AG] ACAAUGGAA[AG] AAAUAUAGCGUU
2 AUAGCG AAAUAUAG AAAUAUAGCG ACAAUGGAAGCA
3 AAUGAU AAUGAUUA AAUGAUUAUU AAUGAUUAUUUU
4 [AU]GGCAG GGCAGGCA [GU]UUCAGGCAG C[AG][GU]UUC[AU]GGCAG
5 AGCAAU AGCAAUUC AGCAAUUCCA UUA[AU]UCUG[AU]AGC
and 12. None of the so discovered motifs were (C/U)-rich and hence could be thought of being PTBP1
binding sites. The results shown in Table 3.4 exemplify this for the 3’ UTR of prohormone convertase 2.
The most conserved single-strand motifs with length 6, such as AAUGGA, appear to be (A/G)-rich rather
than (C/U)-rich. This is the same for longer motifs. Results for the other benchmark proteins looked similar.
The conclusion drawn from this is that other elements – of structural, regulatory, or other nature – are
apparently more conserved than the PTBP1 binding site. Motif discovery approaches therefore fail, even
when being restricted to single-strand regions.
In step 6a of the sequence motif algorithm (see page 76), a random permutation of the mRNA UTR
sequence is created. Altschul and Erickson (1985) describe efficient graph-based algorithms to generate
random sequence permutations that preserve dinucleotide usage, dinucleotide and trinucleotide usage,
or dinucleotide and codon usage, which could be used as an alternative. A test on the benchmark set (Ta-
ble 3.1) showed that p-values obtained from comparison to random dinucleotide-preserving permuations
did not signtificantly differ from those obtained with a completely random permutation.
3.4.3 How conserved is messenger RNA secondary structure between species?
To assess how robust RNA secondary structure prediction is, and how conserved secondary structure is
in orthologous messenger RNAs, we predict the structure of the 3’ mRNA of prohormone convertase 2
for the three species of human, mouse, and rat. The result is shown in Figure 3.11. We find that two loop
regions are conserved in all three mRNAs, one around sequence position 20, and one around position 85.
The PTBP1 binding motif is located in the loop region between position 25 and 36. The three nucleotide
sequences are also visible as part of Figure 3.5 on page 77 in rows 1, 6, and 13. The human and rat
structure look the most similar, although the sequence identity is higher between mouse and rat. The
stem-loop structure between positions 40 and 70 is identical between rat and mouse. We conclude from
this that overall secondary structure is only partly conserved, and that the conserved parts are likely to be
functionally important.
3.4.4 Limitations
The sequence motif algorithm approach exhibits several limitations. First, secondary structure prediction
of messenger RNAs is far from being perfect. The algorithm might therefore falsely predict binding sites
that actually are part of double-strands, or miss binding sites in single-strands that are not detected as
such. Second, the random model used for assessment of significance does not take into account the local
secondary structure of binding motif hits. This could lead to an overestimation of binding sites in random
sequences, and was discussed in section 3.4.1. Third, binding regions might not always align clearly in a
multiple sequence alignment with sequences from different species. As a result, conserved binding sites
can appear less conserved than they actually are.
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Figure 3.11 Comparison of secondary structure prediction of the 3’ UTR of prohormone convertase 2 in
human, rat, and mouse. Secondary structure elements conserved in all three species are highlighted in yellow.
Numbers in red indicate 5’ end, 3’ end, and sequence position.
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For a reliable detection of single-strand binding regions, an accurate mRNA secondary structure pre-
diction is necessary. Although it has been demonstrated that dynamic programming – as employed by
state of the art algorithms such as mfold (Zuker, 2003) or RNAfold (Hofacker and Stadler, 2006) – can
accurately predict a minimum energy structure, the native fold is often in a suboptimal energy state (van
Batenburg et al., 1995). It can hence vary greatly from the predicted one. Wiese and Hendriks (2006) es-
timated an accuracy of current algorithms in the range of 50–90%. A possible improvement, although not
implemented in the sequence motif algorithm, would be to additionally use the entropy for each position
as calculated by the Vienna RNA Package relplot utility (Hofacker, 2004). Low entropy indicates higher
accuracy of the prediction. A restriction to low entropy regions could make the binding site prediction more
specific, but at the expense of being less sensitive.
A further problem is that in some cases PTBP1 binding regions of the same mRNA in different species
do align not at all or only partly in a multiple sequence alignment. This can be caused by the presence of
longer stretches of strongly conserved regions that force the alignment algorithm to align these regions at
the expense of the PTBP1 binding sites. The more species are included, the more often this effect was ob-
served. Examples for such conserved regions can be found in Table 3.4. This limitation is generally hard to
deal with. As a possible solution, we applied a version of the DIALIGN alignment tool (Morgenstern, 2004)
that allows to set user-defined anchor points. Anchored DIALIGN (Morgenstern et al., 2006) implements a
semi-automatic anchored alignment approach where the user can specify an arbitrary number of anchor-
ing points in order to guide the alignment procedure. Anchoring points were defined around the regular
expression matches of the PTBP1 binding motif. However, anchored DIALIGN was still sometimes unable
to correctly align all binding sites when multiple binding sites were present. In the end, the problem was
solved by another limitation, which turned out to be the available UTR sequences in vertebrate species.
For the 78 candidate proteins investigated, we found that reliable sequence information is mainly available
for human, mouse, and rat. For other vertebrate species, either orthology information or annotated UTR
sequences could not be found for the majority of candidate proteins. This is expected to hopefully change
in the future.
Despite the discussed limitations, the sequence motif algorithm was demonstrated to work well on
five known PTBP1 targets, where it identified significant single-strand biding occurrences of the PTBP1
binding motif that can explain PTBP1 binding.
3.4.5 Disease relevance of PTBP1
Diabetes mellitus is the most common metabolic disease in the western world. In Germany, eight million
people are suffering from this disease. Diabetes and diabetes complications create yearly costs in the
order of 25 billion euro, accounting for one fifth of the total health budget in Germany (Hauner et al.,
2007). A better understanding of the molecular mechanisms of insulin control might ultimately lead to new
therapeutics in diabetes.
Recently, He et al. (2007) found PTBP1 to be overexpressed in 38 out of 44 ovarian cancer samples.
This suggests a novel role for PTBP1 in tumorigenesis, and its overexpression might be required for the
development and maintenance of epithelial ovarian tumors. However, Wang et al. (2008a) demonstrated
that overexpression of PTBP1 is not sufficient to induce transformation and conclude that PTBP1 is not
oncogenic by itself, but rather may support malignancy. It remains to be seen whether PTBP1 can serve
as a therapeutic target in the treatment of ovarian cancer. For Diabetes mellitus, the same holds true as
well.
3.5 Materials and Methods
Collection of sequences. Candidate proteins of rat INS-1 cells were mapped to their NCBI Entrez
Gene identifiers. Human and mouse orthologous genes were obtained by use of the InParanoid database
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(O’Brien et al., 2004b). NCBI Entrez Nucleotide was then queried for available mRNA sequences associ-
ated with the rat, mouse, and human genes. 5’ and 3’ untranslated regions (UTR) as defined in Entrez
Nucleotide were separated and the poly(A) tail was removed from the 3’ UTR. In total, 2,105 UTR se-
quences were collected, averaging to seven 5’ UTR and eight 3’ UTR sequences per protein and species.
The average 5’ UTR length was 144, and average 3’ UTR length was 654 nucleotides.
Conservation. To identify conserved regions, a multiple sequences alignment was constructed for each
UTR of a candidate protein using MAFFT L-INS-i (Katoh et al., 2002). A consensus sequence was cal-
culated from residues that were at least 50% conserved. For each conserved position of the alignment,
the number of species showing the conserved amino acid was recorded. Positions conserved in only one
species were excluded from further analyses.
Search for PTB binding sites. Each UTR was screened for the presence of the PTB binding motif
CYYYYCYYYYYG, where C denotes cytosine, G denotes guanine, and Y denotes a pyrimidine base
(following Tillmar et al. (2002)). Hits were counted where the motif matched with zero, with one, or with
two mismatching nucleotides. Overlapping hits were counted separately, allowing a continuous binding
region to give rise to several hits.
Significance of binding sites found. In order to assess the significance of matching hits of the binding
motif CYYYYCYYYYYG, a p-value was calculated for each number of binding sites found in an UTR. To
this end, each UTR sequence was shuffled 100,000 times and subsequently searched for the binding
motif. Shuffling ensured that the nucleotide composition was preserved. The frequency of observing at
least the same number of hits in the random sequences as in the original sequence was counted. The
p-value was calculated by dividing this frequency by 100,000. It resembles the probability that the same
number of hits observed occurs by chance. Hits with a p-value < 0.01 were considered to be significant.
Secondary structure assessment. Since structural studies show that PTB domains bind single-stranded
RNA (Oberstrass et al., 2005), we predicted the secondary structure of consensus UTR sequences using
RNAfold (Hofacker and Stadler, 2006). RNAfold implements a dynamic programming algorithm that calcu-
lates the minimum free energy structure of a given RNA sequence. Binding site hits were mapped onto
the predicted secondary structure. A binding site was considered as single-stranded if more than half of
its nucleotides were non-paired in the minimum free energy structure.
Implementation of the sequence motif algorithm. The sequence motif algorithm was implemented in
Python. For sequence processing, several modules of BioPython were used (Bassi, 2007). Approximately
1,000 lines of code were written. For the repeated random sequence significance analysis, the super-
computing infrastructure of the Center for Information Services and High Performance Computing of the
Technische Universität Dresden was used.
3.6 Conclusion and outlook
The sequence motif algorithm presented in this chapter can reliably detect protein binding sites based
on a sequence motif that is restricted to a particular local secondary structure of an RNA sequence. To
this end, the algorithm combines regular expression pattern search with evolutionary confirmation and
secondary structure prediction. Although the sequence motif algorithm was tailored to detect PTBP1
binding sites with the consensus binding motif CYYYYCYYYYYG in single-strand binding regions, it can
easily be generalized to accept any motif in regions of any particular structure.
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For 13 out of 78 proteins, the algorithm identified potential single-strand PTBP1 binding sites in their
messenger RNA untranslated regions which were conserved in rat, mouse, and human. The predictions
were ranked by their probability. The in silico benchmark test on sequences with known binding sites
revealed a high sensitivity of the sequence motif algorithm. The results of the experimental validation
of three candidates predicted to harbour PTBP1 binding sites did not suggest a regulation by PTBP1,
hinting at the fact that the predictions contain false positives. It should be noted, however, that all three
candidates had only binding sites conserved in two out of three species. The choice of which candidates
were subjected to experimental validation was mainly that of our collaborators. Currently, a candidate
with a binding site fully conserved in all three species, syntaxin binding protein 1, is being experimentally
tested for interaction with PTBP1. Syntaxin binding protein 1 is known to be involved in fusion and release
of vesicles, which is fundamental to secretion.
In terms of biology, the sequence motif algorithm aims at a better understanding of the regulation of
insulin response in the pancreas. According to the World Health Organization, at least 170 million people
worldwide suffer from diabetes, with this number expected to double within the next 20 years. Identifying
targets of PTBP1 and hence regulators of insulin secretion might contribute to the treatment of diabetes
by providing novel protein drug targets or by aiding in the design of novel RNA-binding therapeutics.
Chapter 4
Prediction of cancer patient survival
This chapter presents a computational approach to find genes in human cancer tissue samples whose
expression is predictive for the survival outcome of the cancer patient. The central idea of this approach is
the incorporation of background knowledge information in form of a network, and the use of an algorithm
similar to Google’s PageRank. Applied to pancreas cancer, it identified a set of eight genes that allowed to
predict a poor or good prognosis for a patient, which can have implications for the correct choice of therapy.
Manuscript in preparation containing parts of this chapter:
Winter C, Jahnke B, Kristiansen G, Wente M, Niedergethmann M, Bahra M, Friess H, Knoesel T, Schilling
K, Hentrich V, Aust D, Rümmele P, Saeger HD, Grützmann R, Schroeder M, and Pilarsky C.
A gene signature to predict survival in pancreas cancer.
4.1 Background
4.1.1 Pancreatic cancer
The human pancreas is a cone-shaped gland located in the upper abdomen (see Figure 4.1). It consists
of an exocrine part and an endocrine part. The exocrine part produces digestive juices that are released
into the intestine. The endocrine part, also known as the islets of Langerhans, produces hormones such
as insulin that are released into the blood.
Malignant transformation of pancreatic cells leads to pancreatic cancer. The by far most common form
of pancreatic cancer originates from ductal epithelia of the exocrine part, and is termed pancreatic ductal
adenocarcinoma. It accounts for around 100,000 deaths each year in Europe and the United States. Ac-
cording to epidemiologic studies, about one third of the cases is caused by smoking and chronic alcohol
consumption (Muscat et al., 1997). Pancreatic cancer has an extremely poor prognosis — the 5-year sur-
vival rate is below 2% (Gudjonsson, 2002; Beger et al., 2003). This is due to an early dissemination of
cancer cells via the blood and the lymphatic system, combined with a late occurrence of symptoms. Such
symptoms are upper abdominal pain, back pain, sudden onset of diabetes, jaundice, fatty stools, and un-
explained weight loss. At the time of diagnosis, in more than 90% of the patients the cancer has already
infiltrated neighbouring tissue, and in one third of the patients metastases are present (Beger et al., 2008).
Mostly, it is not the local tumor mass itself which causes the death of patients, but instead the progressive
organ metastases.
Treatment usually consists of surgical removal of the tumor followed by chemotherapy. Chemotherapy
provides a significant survival benefit in patients with resected pancreatic cancer, whereas chemoradio-
therapy has a deleterious effect on survival (Neoptolemos et al., 2004). For more than 95% of the patients,
however, pancreatic cancer is still incurable (Gudjonsson, 2002).
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Figure 4.1 Anatomy of the human pancreas. The pancreas is a gland that lies deep in the upper abdomen
within the curvature of the duodenum, sandwiched between the stomach and the vertebral column.
4.1.2 Gene expression profiling with high-density oligonucleotide arrays
High-density oligonucleotide arrays, also known as DNA microarrays, can simultaneously measure the
expression of thousands of genes in cells of a biological sample. As a result, the researcher obtains a
gene expression profile of such a sample at a particular time, in a single experiment. Comparing gene
expression profiles allows to study, for example, how healthy tissue differs from disease tissue, or how
cells react to particular treatments. Usually, the goal is to identify the set of genes that change their ex-
pression. In case of increased expression a gene is said to be upregulated, whereas in case of decreased
expression it is said to be downregulated.
Since the introduction of microarrays in the mid 1990s (Schena et al., 1995), the number of published
papers per year that use microarray technology is steadily increasing, with around 5,000 publications in
2007. A typical chip for the human genome such as the Affymetrix HG-U133 Plus 2.0 Array contains
about one million of spots that measure the expression of most of the currently known human genes,
which is about 22,000. Each spot harbours millions of copies of a particular 25-nucleotide long single-
strand DNA probe (see Figure 4.2, upper right), resulting in a density of approximately 1 million probes
per 1.3 cm2. The probe is designed to specifically bind to a complementary sequence that occurs in a 3’
UTR messenger RNA of a particular gene. Twenty-two such probes typically make a probe set, and there
can be one to several probe sets per gene.
When performing a microarray experiment, the messenger RNA of a biological sample is extracted,
copied into complementary DNA (cDNA) or complementary RNA (cRNA), and fragmented. Each fragment
is labelled with a tag. During incubation, cDNA or cRNA fragments hybridize to their matching counterpart
probes on the microarray chip. After washing, spots with hybridized fragments can be identified by fluo-
rescence detection. The resulting image is scanned and subjected to image analysis. Signal intensities
for each spot are measured, yielding raw intensity data. Background correction, between-array normal-
ization, and summarization finally result in an expression matrix, where each probe set has an assigned
expression value (Figure 4.2, left).
With respect to the following analysis of the gene expression data, the last three steps of background
correction, normalization and summarization are often described with the term preprocessing. Several
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Figure 4.2 Outline of a typical microarray experiment. See text for details.
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preprocessing methods exist, the most popular being MAS5 (Affymetrix, 2001), dChip (Li and Wong,
2001), RMA (Irizarry et al., 2003), GCRMA (Wu et al., 2004), and vsn (Huber et al., 2002). They differ
in if and how they assess background intensity, how they normalise expression levels across samples,
and how they summarise probes to probe sets. Numerous comparisons have been carried out in order
to find out which method performs best (Fan et al., 2005; Dallas et al., 2005; Irizarry et al., 2006; Jiang
et al., 2008; Owzar et al., 2008). None of the methods, however, turned out to be generally superior to
any other method. Seo and Hoffman (2006) suggested that the choice of the right method is project and
organism specific. MAS5 readily ranked among the methods with the worst performance, and hence is
not recommended by Affymetrix anymore.
4.1.3 Cancer classification with gene expression profiling
Cancer is a disease in which genetic changes drive cells into uncontrolled growth (Weinberg, 2006). With
the advent of microarray technology in medical research, numerous studies were conducted to shed light
on gene expression alterations in cancer cells.
Four different approaches that are based on comparing gene expression levels can be summarized:
• Comparing cancer tissue with healthy tissue:
Identify genes whose changed expressions are the cause of the cancer phenotype
• Comparing cancer cells treated with different reagents in the laboratory:
Identify genes and proteins which are involved in the mode of action of the reagent, or genes that
convey chemoresistance which cells might develop towards the reagent
• Comparing tissue samples of the same type of cancer:
Identify cancer subtypes that exhibit different gene expression patterns
• Comparing gene expression in a patient tissue sample with a clinical parameter:
Identify genes whose expressions are correlated with a clinical parameter of the patient such as
response to therapy, prognostic outcome, or susceptibility to disease
The last two points usually involve identification of a set of genes that are predictive for a subgroup of
cancer patients. This set is termed a gene signature. Ideally, once such a signature is found, the clinician
would order a lab test measuring expression of the signature genes for a patient, and use this information
for his decision on how to proceed with a therapy.
Table 4.1 lists major studies of the past decade that focused on finding predictive signatures. Many
of these studies, however, seem to have been over-optimistic in assessing the predictive power of their
signatures. When subjected to more rigorous evaluation approaches, several of the studies exhibited flaws
in the statistical analysis of data, showed much worse accuracy, or could not be re-produced at all (see
notes at table bottom).
4.1.4 Finding a predictive gene expression signature
A great challenge, which is also faced in this chapter, is the process of finding a gene signature that is
indicative for a certain observed response variable such as patient survival. A signature generally consists
of a rather small number of genes, in the order of tens to hundreds. With much larger signatures, there
is rarely a considerable benefit found from the additional genes, but an increased risk of overfitting of
the prediction rule, as will be discussed below. In contrast, the number of measured genes where the
signature genes can be chosen from is in the order of ten thousands. Past studies used signature sizes
ranging from 6 to ∼450 genes, with a median size of 70 genes (see Table 4.1). Starting from gene
expression measurements of given samples and a response variable, this process can be outlined as
follows:
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Table 4.1 Microarray-based cancer classification studies on finding predictive signatures published in
high-impact journals. The studies were published in Science, Nature, Nature Medicine, PNAS, PLoS Medicine,
Cancer Cell, Lancet, or New England Journal of Medicine. Some studies exhibit considerable flaws in methodology,
as pointed out in the notes at the table bottom.
Study Disease Number
of patient
samples
Number of
genes in
signature
Clinical
parameter
Golub et al. (1999) Acute myeloid leukemia vs.
acute lymphoblastic leukemia
72 50 Disease classifica-
tion
Alon et al. (1999) Colon cancer 62 Not reported Tumor vs. healthy
tissue
Alizadeh et al. (2000) Diffuse large-B-cell lymphoma 40 Not reported Disease subclassifi-
cation
Khan et al. (2001) a, b Small round blue cell tumors 88 96 Disease classifica-
tion
Sørlie et al. (2001) Breast cancer 85 456, 264 Tumor subclasses,
Survival
West et al. (2001) Breast cancer 49 100 Outcome
Shipp et al. (2002) Diffuse large B-cell lymphoma 77, 58 30, 13 Subclassification,
Outcome
Rosenwald et al.
(2002) c, d
Diffuse large B-cell lymphoma 240 17 Survival
Yeoh et al. (2002) Acute lymphoblastic leukemia 327 7–20 Subclassification
and outcome
Pomeroy et al. (2002) e Medulloblastoma 60 8 Survival
Beer et al. (2002) Lung adenocarcinoma 86 50 Survival
van ’t Veer et al.
(2002) c, f
Breast cancer 117 70 5-year metastasis-
free survival
van de Vijver et al.
(2002)
Breast cancer 295 70 Prognosis
Iizuka et al. (2003) c Hepatocellular carcinoma 60 12 1-year recurrence-
free survival
Huang et al. (2003) g Breast cancer 89 Metagenes Nodal metastatic
states and relapse
Dave et al. (2004) h Follicular lymphoma 191 67 Survival
Lossos et al. (2004) Diffuse large B-cell lymphoma 66 6 Survival
Bullinger et al. (2004) Acute myeloid leukemia 116 133 Survival
Wang et al. (2005) Breast cancer 286 76 Distant metastasis
Dave et al. (2006) Burkitt’s lymphoma vs. diffuse
large-B-cell lymphoma
303 217 Disease classifica-
tion
Zhao et al. (2006) Renal cell carcinoma 177 259 Survival
Shedden et al. (2008) Lung adenocarcinoma 442 Various Survival
Lenz et al. (2008) Diffuse large-B-cell lymphoma 414 39, 283, 71 Survival after treat-
ment
Boutros et al. (2009) Non-small-cell lung cancer 147 6 Survival
a Tibshirani and Efron (2002) found that the complex neural network model used by the authors is essen-
tially extracting linear principal components, and thus is unnecessarily complicated for this problem
b Lai et al. (2006) pointed out an information leak biasing the results caused by the authors’ use of the com-
plete dataset (including the validation set) for gene subset selection
c Michiels et al. (2005) found that the published misclassification rates were below the lower 95% confi-
dence limit obtained by random validation
d Segal (2006) pointed out an information leak because test set data was used for an initial clustering
e Michiels et al. (2005) used a multiple random validation strategy on the same data, and found that the
original study did not classify patients better than chance
f Tibshirani and Efron (2002) tried but were unable to exactly reproduce the analysis, even with help of the
authors. Ein-Dor et al. (2005) found that the list of 70 genes found by the authors was highly unstable.
g Ruschhaupt et al. (2004) found only 75% accuracy instead of the 90% reported by the authors
h Tibshirani (2005) re-analyzed the data and found that the authors’ results were extremely fragile—in par-
ticular, when their equal-sized training and test sets were swapped, the authors’ finding disappeared and
virtually nothing was significant
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1. Reduce gene feature space by filtering
2. Identify informative genes
3. Select a subset of informative genes that define a signature
4. Build a prediction rule with the signature, often by means of machine learning
5. Evaluate the performance or accuracy of the prediction rule
The last three steps are often performed iteratively in order to improve the prediction rule.
Reduce gene feature space by filtering
A gene expression microarray chip produces an intensity signal which is converted into a numerical value
for each gene. The set of measured genes constitutes the gene feature space. The initial step is to
reduce this feature space. Recent studies which employed deep sequencing of the human transcriptome
revealed that only half of the human genes are expressed in a tissue at a particular time (Sultan et al.,
2008). It is therefore advisable to filter out at least the lower half of genes, since these are are likely not
to be expressed at all, and their expression values are likely to represent noise rather than biologically
meaningful signal. Unfortunately, there is no consensus in the literature on how to decide whether an
expression value is indicating if a gene is expressed or not. Some authors prefer thresholds for flooring,
others make use of present/absent calls which are calculated by the Affymetrix MAS5 software (Affymetrix,
2001). For our dataset, we chose to apply a cutoff for mean and standard deviation of expression levels.
After excluding genes that are not expressed, the remaining genes are usually filtered according to
their variance. Genes that do not vary between samples provide no information for distinguishing between
the samples and hence should be excluded. Popular filtering measures are the standard deviation or
variance of the gene expression over all samples, a (max−min) absolute variation, or a max/min fold
variation threshold. Note that no information concerning the response variable is used in the filtering step.
Identify informative genes
A central step in the analysis of a microarray experiment is to find those genes whose expression signi-
ficantly differs between distinct groups of samples. These genes are said to be differentially expressed,
and they provide information that allows to distinguish between the groups. Various methods have been
proposed to identify differentially expressed genes. They can roughly be divided into ordinary methods
using fold change or t-statistics, and modifications of the t-statistic, often using likelihood or Bayesian
model approaches. For handling continuous response variables such as survival time, special techniques
such as Cox regression exist. These methods will be presented in the following.
Fold change. The simplest method for deciding whether a gene is differentially expressed is to evaluate
the log ratio of its expression between two groups of samples. Genes that differ by more than an arbitrary
threshold are then considered to be differentially expressed. When repeated samples per gene are avail-
able, common practice is to compute the ratio of averaged intensities. This fold change method was used
in the early analyses (Schena et al., 1996; DeRisi et al., 1997), and is still popular with thresholds at 2- or
3-fold.
Despite its simplicity, the fold change methods exhibits several drawbacks. First, only mean values
are considered, ignoring the variability or variance. Genes with large variances are more likely to pass the
cutoff just because of noise. Second, there is no associated value that indicates the level of confidence if
the gene is differentially expressed or not. Any chosen cutoff therefore remains somewhat arbitrary, and
biologically relevant changes in expression might be happening below this cutoff, leading to false negative
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results. Allison et al. (2006) hence conclude that using fold change alone as a differential expression test is
not valid. Opgen-Rhein and Strimmer (2007) found that using fold change is only a good idea if variances
are similar.
t-test. Since a simple fold change criterion does not take into account variability, it soon became popular
to use traditional statistical tests such as the t-test or its non-parametrical counterpart, the Wilcoxon
test. These calculate a t-statistic to which a p-value can be assigned from the t-distribution. The p-value
represents the probability of obtaining a t at least that extreme by chance. One problem is that variation
in gene expression is poorly estimated with small numbers of replicates, so genes with low variance may
be selected even if they are not truly differentially expressed. A large t might for example arise simply
because of a small denominator (see also page 136 for the t-test formula). So, the t-test was found to
give high false discovery rates in small samples, and to be only weakly related to fold change. It hence
works best with larger data sets than one usually has. Opgen-Rhein and Strimmer (2007) found that the
ordinary t-statistic shows average though never optimal performance regardless of the variance structure
across genes.
It should be pointed out that p-values convey nothing about the sizes of the differences between
groups. Small differences of no real interest can be statistically significant with large sample sizes, whereas
important effects can be statistically non-significant only because the number of subjects studied was
small.
Moderated t-tests. To remedy the above-mentioned problems, various modifications of the ordinary t-
statistic have been presented. Their common idea is to employ modified estimators of variance that borrow
information between genes. Golub et al. (1999) proposed a t-like signal-to-noise statistic. The SAM t-test
(Tusher et al., 2001) adds a small constant to the gene-specific variance estimate in order to stabilize
the small variances. SAM also employs sample-label permutations to evaluate statistical significance. As
opposed to these frequentist approach methods, further developments were influenced by the Bayesian
approach. The regularized t-test proposed by Baldi and Long (2001) replaces the usual variance estimate
with a Bayesian estimator based on a hierarchical prior distribution. Lönnstedt and Speed (2002) pro-
posed an empirical Bayes approach that combines information across genes. Other information sharing
methods have also been developed using similar strategies (Newton et al., 2001; Wright and Simon, 2003;
Kendziorski et al., 2003).The empirical Bayes test (Smyth, 2004) is based on a moderated t-statistic with
a Bayesian adjusted denominator similar to that proposed by Tusher et al. (2001). Ideker et al. (2000) put
forward the use of the maximum likelihood method, where they apply a generalized likelihood ratio test for
each gene to determine whether, under a given model, gene expressions are significantly different.
Since even these modified statistical tests permit genes with arbitrarily small fold changes to be con-
sidered statistically significant, it has become increasingly common to require that differentially expressed
genes satisfy both p-value and fold change criteria simultaneously. Patterson et al. (2006) required genes
to pass a modest level of statistical significance (p < 0.01 or p < 0.05) and then ranked significant genes
by fold change with a cutoff of 1.5, 2, or 4. They found that this combination ranking gave much better
agreement between different microarray platforms than p-value alone. Other studies have applied a fold
change cutoff first, and then ranked by p-value (Peart et al., 2005; Raouf et al., 2008; Huggins et al., 2008).
Grützmann et al. (2004b) used a SAM analysis followed by a fold change cutoff filtering. Because these
combination approaches remain ad hoc, McCarthy and Smyth (2009) recently proposed a new method
termed t-tests relative to a threshold, TREAT, for assessing differential expression in microarray experi-
ments. Their method is an extension of the empirical Bayes moderated t-statistic (Smyth, 2004), and can
be used to test whether the true differential expression is greater than a given threshold value. Opgen-
Rhein and Strimmer (2007) introduced the "shrinkage t" statistic and compared it to moderated t statistics
as well as ordinary t-statistic and fold change. They reported that the shrinkage t and the moderated
98 C H A P T E R 4 . P R E D I C T I O N O F C A N C E R PAT I E N T S U R V I VA L
t-statistics are the only two methods that perform optimally in all of their simulation settings.
Handling of survival data. If the aim is to identify genes that are associated with survival, there are
principally two ways to treat the survival variable. The traditional approach is to apply the Cox proportional
hazard model (Cox, 1972) with survival as a continuous variable. The Cox model defines a hazard function
that represents risk of dying at a particular time. The hazard function depends on a baseline hazard
that is modified multiplicatively by independent variables of interest (for example, patient age, or tumor
size). These variables are weighted by parameters, and the parameters are estimated by partial likelihood
maximization. The estimated parameters, or regression coefficients, indicate the effect and significance
of each variable on survival. Finally, the model can be used to estimate the probability of surviving to a
particular time. Traditionally, the Cox proportional hazard model is applied in situations where the number
of samples greatly exceeds the number of the independent or predictor variables (n p). In microarray
analysis, however, one deals with the opposite situation of p n. Often, the Cox model is then applied in
a univariate fashion, and a Cox score statistic is determined as a measure of the univariate association
between each gene and the survival time.
An alternative approach is to treat survival as a categorical variable. The distinction between the
groups can be based on clinical knowledge or on structure proposed by the data. In many previously pub-
lished studies, two groups of short-term and long-term survivors, or poor-prognosis and good-prognosis
patients were defined. Shipp et al. (2002) reduce survival times to two groups of cured versus refractory
disease patients. Bullinger et al. (2004) used k-means clustering of genes correlating with survival to
identify two subgroups of samples, and by means of a Kaplan-Meier survival analysis then assigned a
good-outcome and poor-outcome label to each subgroup. Other authors employed a time threshold of
one year or five year survival to define two groups (van ’t Veer et al., 2002; van de Vijver et al., 2002;
Iizuka et al., 2003).
Multiple hypothesis testing issues. A basic difference between microarray data analysis and tradi-
tional biomedical research is the dimensionality of the data. Whereas a clinical study might collect ten to
a hundred data points for thousands of patients, a microarray study will obtain many thousands of data
points for ten to a hundred samples. When testing thousands of genes whether they significantly differ
between groups, one must account for multiple comparisons. Even if the statistical p-value assigned to
a gene indicates that it is extremely unlikely that differential expression of this gene was due to random
rather than treatment effects, the very high number of genes on an array makes occurrence of false pos-
itives quite likely. For example, testing 10,000 genes with a t-test for differential expression with a simple
p < 0.05 threshold will lead to 500 genes in the result list as false positives, being significant by chance
alone.
A simple method to control for the occurrence of these false positives is the Bonferroni correction. To
correct for n comparisons, the statistical significance level is simply divided by n. For 10,000 genes, this
could mean to test for p < 0.05/10,000. One would then expect at least one false positive in the result list
with a probability of 0.05. This chance of having at least one false positive, i. e. of committing at least one
type I error, is also called the family-wise error rate (Westfall and Young, 1993).
For microarray analyses, the Bonferroni method is often too conservative. In many cases, a biologist
would tolerate a certain number of false positives genes in the result set, as long as this number can be
controlled. This led to the proposal of the false discovery rate, FDR (Benjamini and Hochberg, 1995). It
is defined as the expected proportion of false positive genes among those declared as differentially ex-
pressed. If the FDR is set to 0.05, 5% of genes considered statistically significant (that pass the restriction
after correction) will be identified by chance (false positives). Unlike a significance level, which is deter-
mined before looking at the data, FDR is a post-data measure of confidence. It uses information available
in the data to estimate the proportion of false positive results that have occurred. In a list of differentially
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expressed genes that satisfies an FDR criterion, one can expect that a known proportion of these will rep-
resent false positive results. FDR criteria allow a higher rate of false positive results and thus can achieve
more power than family-wise error rate procedures.
The advent of computerized resampling methods, such as bootstrapping and Monte Carlo simulations,
has given rise to techniques for estimating the false positive rate (Efron and Tibshirani, 1993). In many
situations, the distribution of the test statistics is unknown. Bootstrap or permutation resampling can be
used to estimate raw and adjusted p-values while avoiding parametric assumptions about the distribution
of the test statistics.
Another way of dealing with the problem of multiple testing is to simply ignore it and do ranking of
genes instead of testing. In gene discovery experiments for which microarrays are used, the primary aim
is to rank the genes in order of evidence against a null hypothesis rather than assign absolute p-values.
This is because only a limited number of genes may be followed up for further study regardless of the
number which are significant (Smyth, 2004). Especially when searching for predictive genes, one would
like to rank genes in order of predictive power, and use the top-ranked genes for building a predictive
model. In the analysis that is presented in this chapter, we will follow this line of thinking and focus on
ranking rather than testing.
Select a subset of differentially expressed genes to define a signature
Once the genes that differ with respect to the outcome variable are identified, the aim is to use these
genes to build a model that allows to predict the outcome variable based on the genes’ expression levels
in future samples. The selection methods described above yield a list of potentially informative genes
that can be used for building a predictive model. Depending on data, method, and cutoffs, this list can
still contain hundreds or thousands of genes, so that a further step of selection of a feature subset is
necessary.
Subset selection by ranking. The most common approach is to rank the differentially expressed genes
by the statistic that was employed to find them, and then to select a number of top-ranked genes. Since
the ranking of features is independent of the learning machine that does the actual classification, it is
considered a filter method (Blum and Langley, 1997). Opposed to this, the learning machine itself can
be used for feature selection. Such techniques are considered wrapper methods and try to identify the
features that are important for the generalisation capability of the machine.
One can further distinguish univariate from multivariate selection approaches. Whereas the former
evaluate the informativeness of each gene individually, the latter evaluate the informativeness of a group
of genes, involving combinatorial searches through the complete space of possible feature subsets. Fre-
quently the claim is made that because genes are often co-regulated due to pathway dependencies,
multivariate selection approaches are more desirable than univariate approaches (Lai et al., 2006).
Multivariate feature selection methods. One could imagine to find a signature with greater predictive
power by considering combinations of genes that are not all top-ranked. It is easy to see that if, for example,
the top two genes are highly correlated, there is not much increase in predictive power when adding the
second gene to the first for creating a two-gene signature. Instead, combining the first gene with a lower-
ranked one is likely to give better prediction results. This resembles a multivariate search strategy. It is
also clear that it is not always feasible to test all possible combinations — for a dataset of 8,000 genes, for
example, there exist 4×1026 different 8-gene signatures.
Several multivariate search strategies have been put forward in the literature, all involving combina-
torial searches through the space of possible feature subsets. Guyon et al. (2002) propose an iterative,
multivariate backward search called Recursive Feature Elimination. It employs a classifier — typically a
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support vector machine, SVM — to attach a weight to every gene in the starting set. Based on the assump-
tion that the genes with the smallest weights are the least informative in the set, a predefined number of
these genes are removed during each iteration, until no genes are left. The performance of the SVM deter-
mines the informativeness of the evaluated gene set. Bø and Jonassen (2002) introduced a multivariate
search approach that performs a greedy forward search by adding genes judged to be informative when
evaluated as a pair. Geman et al. (2004) introduced the top-scoring pair method, which aims at identifying
a single pair of predictive genes.
Problems of multivariate methods. The problem with multivariate strategies, however, is that few
datasets are large enough to support multivariate gene selection without overfitting. Overfitting results in
a good prediction of the training samples, but in poor prediction for independent samples. This is caused
by the usually large number of candidate genes, providing a large number of ways of combining these
genes, and the usually few samples. When evaluating different selection methods, Lai et al. (2006) found
that simple gene selection strategies worked as well or much better than complex multivariate strategies.
They adopted several univariate and multivariate selection approaches in seven different dataset scenar-
ios. The univariate methods were signal-to-noise-ratio (introduced by Golub et al., 1999) and t-test, the
multivariate methods were the base-pair selection and forward selection proposed by Bø and Jonassen
(2002), recursive feature elimination, and the top-scoring pair method. In five of the seven datasets univari-
ate selection approaches gave consistently better results than multivariate approaches. The top scoring
method, the simplest multivariate selection approach, achieved the best results on the remaining two
datasets. Lai et al. (2006) conclude that the correlation structures, if present, are difficult to extract due
to the small number of samples. Consequently, overly-complex gene selection algorithms that attempt to
extract these structures are prone to overtraining. In this light, we decided not to embark on a multivariate
strategy in order to avoid these problems.
Build a prediction model with the signature
In the past decade, several high-profile studies used microarray gene expression data of tumors to predict
clinical variables of patients (see Table 4.1). In the following, their approaches are presented. Table 4.2
summarises the methods used therein.
Pioneering work was done by Golub et al. (1999) using a weighted voting classifier for distinguishing
acute myeloid leukemia (AML) from acute lymphoblastic leukemia (ALL). They introduced the signal-to-
noise statistic defined as (µ0− µ1)/(σ0 +σ1), with µi and σi being the mean and standard deviation of
expression for each class. Similar results were obtained using a standard t-statistic as the metric, defined
as (µ0−µ1)/
√
σ20/N0 +σ21/N1, where Ni represents the number of samples in each class. All genes were
ranked by their signal-to-noise statistic as measure of correlation with the class to be predicted. The top
50 genes were selected to form a signature. To predict the class of a given sample, each of the 50 genes
in the signature casts a weighted vote for either AML or ALL, dependent on whether its expression level in
the sample is closer to the mean expression levels of AML or ALL in the set of training samples. Summing
of votes determined the winning class. Applied to an independent collection of 34 leukemia samples,
the predictor correctly predicted 29 of the 34 samples, and indicated uncertainty about the remaining
five samples without classifying them. Using a self-organizing maps approach described by Tamayo et
al. (1999), Golub et al. could further show that the AML–ALL distinction could have been automatically
discovered by clustering of the data, without biological knowledge.
Pomeroy et al. (2002) used the same signal-to-noise statistic introduced by Golub et al. (1999) to
find marker genes for outcome prediction of central nervous system tumors. The outcome was a binary
variable of success or failure of treatment in a dataset of 60 children with medulloblastoma. The marker
genes were used to build several models, among them k-nearest neighbors, weighted voting, and support
vector machines. The authors tested these models with variable numbers of genes between 1 and 200,
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Table 4.2 Methods used for building a signature-based prediction model. Most studies divide patients into a
poor and a good prognosis group.
Study Method Definition of two
groups (poor/good)
Pomeroy et al. (2002) Signal-to-noise ratio and weighted voting Success or failure of
treatment
Khan et al. (2001) Artificial neural networks after principal component
analysis filtering
Four distinct diagnostic
categories
van ’t Veer et al. (2002) Pearson correlation coefficient of gene expression
ratio with prognosis
Metastasis within 5
years
Huang et al. (2003) Principal component within a cluster after k-means
correlation-based clustering
Recurrence of tumor
Rosenwald et al. (2002) Linear combination of genes found in hierarchical
clustering after Cox proportional hazards filtering
Median of survival time
Beer et al. (2002) Linear combination of genes found by univariate Cox
proportional-hazard regression
Expression percentile
cutoff
Lu et al. (2006) Risk score based on partial Cox regression Survival < 2 and > 5
years
Boutros et al. (2009) Nonlinear semisupervised method based on feature
selection by greedy forward selection with unsuper-
vised pattern recognition
Unsupervised pattern
recognition (clustering)
Iizuka et al. (2003) Linear combination of genes ranked by fisher crite-
rion, support vector machine
Recurrence of tumor
within one year
Bullinger et al. (2004) Nearest shrunken centroids K-means cluster analy-
sis of SAM genes
Zhao et al. (2006) Supervised principal components based on Cox
proportional-hazard scores
Survival time as quantita-
tive variable
selected according to their training set correlation with outcome. The final chosen model was the one that
minimized the total error in a leave-one-out cross-validation procedure. An 8-gene k-nearest neighbor
outcome prediction model yielded the lowest error rate.
Artificial neural networks were employed by Khan et al. (2001) to classify small round blue-cell tu-
mors — named so because of their similar histological appearance — into four distinct diagnostic cate-
gories of neuroblastoma, rhabdomyosarcoma, non-Hodgkin lymphoma, and Ewing sarcoma. Part of their
feature reduction was a principal component analysis after filtering for a minimal level of expression. The
authors found that using the 10 dominant principal components per sample as inputs produced well-
calibrated neural network models.
Several studies tried to predict the outcome of breast cancer patients. Van ’t Veer et al. (2002) inves-
tigated breast cancer samples from 78 patients divided into a bad prognosis group of 34 patients who
had developed distant metastases within 5 years, and a good prognosis group of 44 patients who had not.
Genes with greater two-fold difference and a p-value < 0.01 in more than five tumors were considered
significantly regulated across the groups and were selected, resulting in some 5,000 genes. Hierarchical
clustering of these genes allowed to some extent already to distinguish between good prognosis and
poor prognosis tumors, which was surprising. To specifically identify genes associated with prognosis, the
authors calculated Pearson correlation coefficients of the gene expression ratio of each significant gene
with the prognosis group. Genes with an absolute value of the correlation coefficient > 0.3 were selected,
which resulted in 213 genes. A permutation test revealed that on average 36 genes would have been
selected by chance. Finally, the authors selected a 70 gene signature that was subject of controversy in
the literature. Van de Vijver et al. (2002) validated this signature in 295 patients, of which 61 were also
used to develop the signature. Patients with a good prognosis had better overall survival (95% vs. 55% at
10 years) than patients with a poor prognosis. Multivariable analysis further revealed that prognosis group,
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tumor size, and adjuvant chemotherapy were the strongest predictors of distant metastases.
Similarly, Huang et al. (2003) investigated 89 tumor samples from breast cancer patients. They fol-
lowed the example of van ’t Veer et al. (2002) and used recurrence of the tumor as a binary outcome
variable. They introduced the concept of metagenes: A metagene is the principal component within a
cluster, derived from k-means correlation-based clustering. Nearly 500 such metagenes were identified.
In a predictive statistical tree model, the metagenes were shown to have a prediction accuracy of ∼90%.
Ma et al. (2004) devised a test for breast cancer recurrence with only two genes, the so-called H/I test,
where high expression of one gene, HOXB13, predicts recurrence, and high expression of a second gene,
IL17BR, predicts non-recurrence.
Rosenwald et al. (2002) found a 17 gene signature for predicting survival after chemotherapy for
diffuse large B-cell lymphoma. First, genes were identified that were significantly associated with good or
a bad outcome under the Cox proportional hazards model. These were then assigned to groups of genes
found by means of hierarchical clustering in a previous study (Shaffer et al., 2001). The authors then
selected 16 genes from four groups comprising 3 germinal-center B-cell genes, 4 MHC class II genes, 6
lymph-node genes, and 3 proliferation genes. A linear combination of the average values of these groups
(with coefficients derived from the Cox model) was indicative for the outcome, with a high score indicating
a poor outcome.
To predict survival of patients with lung adenocarcinoma with gene expression profiles, Beer et al.
(2002) devised a risk index. They used various gene expression percentile cutoffs to categorize patients
into high or low groups. The risk index was defined as a linear combination of the gene-expression values
for the 50 top genes identified by univariate Cox proportional-hazard regression modeling, weighted by
their estimated regression coefficients. Kaplan-Meier survival plots and log-rank tests were then used to
assess whether the risk-index assignment to high/low categories was validated in the test set.
Lu et al. (2006) conducted a meta-analysis of datasets from seven different microarray studies on
non-small cell lung cancer for differentially expressed genes related to survival time, with a total number
of 324 patients. Using partial Cox regression (Li and Gui, 2004), they identified a gene expression signa-
ture consisting of 64 genes that was highly predictive for which stage I lung cancer patients may benefit
from more aggressive therapy. Boutros et al. (2009) pointed out that the majority of signatures developed
for non-small cell lung cancer used linear or risk-score methods to classify patients (Beer et al., 2002; Lu
et al., 2006), which are unable to capture nonlinear interactions among genes. Because regulatory rela-
tionships which are based on a “or” logic cannot generally be captured by linear methods, they developed
a nonlinear semisupervised method by coupling unsupervised pattern recognition to gradient descent op-
timization, resulting in an algorithm called modified Steepest Descent. This iterative algorithm adds genes
to an existing classifier based on their ability to maximize the significance of a log-rank test on patient
groups identified by k-medians clustering. Applied to a training dataset of 147 non-small cell lung cancer
patients, the algorithm generated a prognostic signature comprising 6 genes.
Iizuka et al. (2003) aimed at the prediction of early recurrence of liver cancer. They defined two groups
of patients, such with and without recurrence of the tumor within one year. They first identified all genes
that had a mean average difference greater than two-fold between the two groups. They then used the
fisher criterion, defined as (µ0− µ1)2/(σ20 ·N0/(N0 + N1) + σ21 ·N1/(N0 + N1)), to select the top 50 genes.
Finally, the authors did an exhaustive search to assess the effectiveness of all possible subsets of these
50 genes. In the end, they came up with a 12-gene scoring system as the optimum, which used a linear
combination of the genes’ expression levels. Iizuka et al. also investigated the predictive performance
of a support vector machine-based system by increasing the number of genes from the top ten to the
top 300 identified, following the gene selection procedure of Furey et al. (2000). The SVM-based system
performed best when the number of genes was 50. Still, their own 12-gene scoring system showed a
better performance.
Bullinger et al. (2004) built an outcome-class predictor for the survival of acute myeloid leukemia
patients with the use of PAM method (Tibshirani et al., 2002) based on nearest shrunken centroids. The
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nearest shrunken centroid method uses denoised versions of the centroids as prototypes for each class.
Centroids are location estimates of the distribution of predictors within each class. The predicted class of
a new sample is the one whose centroid is closest to it. To define good and poor outcome groups, genes
were first filtered for correlated with survival by the SAM method (Tusher et al., 2001), which involves a
modified Cox proportional-hazards maximum-likelihood score. K-means clustering was used to divide the
remaining genes into two groups, and Kaplan–Meier survival analysis was used to assign good and poor
outcome labels to the groups.
Zhao et al. (2006) use survival time as quantitative variable for renal cell carcinoma. To this end, they
employed the supervised principal components approach proposed by Bair and Tibshirani (2004). The
basic idea is to first identify univariate Cox proportional-hazard scores for each gene and to keep only
genes that exceed a certain threshold (estimated by cross-validation). Then the first or first few principal
components of the reduced data matrix are computed, and these principal components are used in a
regression model to predict the outcome. The resulting gene expression predictor comprised 259 genes
and was reported to accurately predict survival.
Evaluation of the performance or accuracy of the prediction model
The gold standard for the evaluation of a predictor is to validate its performance on independent data.
When dealing with patient samples, such independent data is often scarce, and thus most of the published
studies split their available samples into two sets, a training and a test set. The performance of a class
prediction rule is assessed by applying the rule created on the training set to the test set. To get an
unbiased estimate of the performance, it is crucial that information of the test set is only used once for
assessing the performance. If this is violated, the occurring information leak will result in optimistically
biased performances. Several examples for such biases in the literature will be mentioned in the following.
Dupuy and Simon (2007) emphasize that the test set should be used only once and only for testing the
samples with the fully specified classifier developed from the training set, and that the test set must not
be used to choose the best classifier.
An exemplary, blinded validation was applied in the study of Shedden et al. (2008). To characterize
the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas,
a strict protocol for analysis was followed, with data for two independent validation sets held by a third-
party ‘honest broker’ during analysis of the training data. After the participating institutions had submitted
a description of their classifiers, the validation sets were released.
Cross-validation. Because the number of available clinical samples is often limited, withholding a sub-
stantial proportion of the samples from the training set for creating a validation set might considerably
reduce the performance of the prediction rule. Cross-validation procedures use the data more efficiently.
In cross-validation, a small number of samples are withheld, and most of the samples are used to build a
predictor. The predictor is then used to predict class membership for the withheld samples. This process
is iterated, leaving out a new set of samples at each step, until all samples have been classified. In a
leave-one-out cross-validation, for example, each sample is excluded from the training set once at a time
and then classified on the basis of the predictor built from the data for all of the other samples.
The leave-one-out cross-validation procedure provides a nearly unbiased estimate of the true error
rate of the classification procedure. It is important to note that the estimated error rate applies to the
procedure used to build the classifier rather than to the specific prediction model based on all the data,
because there is a different classifier for each leave-one-out training set. The leave-one-out method is
frequently employed, especially most of the studies listed in Table 4.1 do so.
Two limitations are worth mentioning. First, although cross-validated error estimates are nearly un-
biased, they have a large variance for small sample sizes (Simon et al., 2003). For example, a cross-
validated error rate of 0.10 derived from a set of 20 samples may have a large associated standard error
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and does not guarantee a true error rate of 0.10 for the predictor. The standard error can be reduced to
some extent by using more complex versions of cross-validation (Efron and Tibshirani, 1997). Second, the
samples used to build the predictor in the original study may not accurately reflect all characteristics of the
underlying populations of interest — the predictor may ignore important properties of the larger population
or heavily weight peculiarities of the training set.
Three steps of class prediction methods were listed above: identification of informative genes, selec-
tion of a subset of informative genes, and creation of a prediction rule. It is important that all three steps
undergo the cross-validation procedure. Failure to cross-validate all steps may lead to substantial bias in
the estimated error rate (Simon, 2005).
Monte Carlo methods for evaluation. Monte Carlo methods are a class of computational algorithms
that rely on repeated random sampling to compute their results. The motivation for them in the light of
building of a classifier is the following: Especially with smaller sizes one runs into the problem that the
classifier itself might be biased because the training samples were not representative, and the evaluation
might be biased because the test samples were not representative. Michiels et al. (2005) showed that
the molecular signature strongly depends on the selection of patients in the training set: they noted that
different training sets of patients led to a different list of genes in the signature. To remedy this problem,
Michiels et al. proposed a Monte Carlo strategy which they call multiple random validation. The idea is to
repeatedly split the full data set into training and test sets. Stratified sampling is employed to ensure an
even distribution of two classes in the training and test data. The size of the training set is varied, allowing
to study its influence on the results. Michiels and colleagues applied this strategy to the datasets of several
previously published high-impact studies, among them Rosenwald et al. (2002), van ’t Veer et al. (2002),
Beer et al. (2002), Pomeroy et al. (2002), and Iizuka et al. (2003). Under their rigorous evaluation, the
classifying accuracy as compared to the one reported by the original authors was often less or even not
better than chance.
Flaws in evaluation methodologies. Several authors pointed out that the results of some past studies
were over-optimistic. This is often due to improper cross-validation procedures, which lead to a biased
estimation of the prediction accuracy. Such flaws in methodologies will be discussed in detail on page 132.
4.1.5 Gene signature-based tests in clinical use
Despite these shortcomings in evaluation, two diagnostic signature-based tests are already in clinical use
for breast cancer patients: the MammaPrint test, and the Oncotype DX test.
MammaPrint. MammaPrint is a microarray-based test which uses the van’t Veer 70-gene signature
to assess the risk of metastasis. The test was developed in 2002 at the Netherlands Cancer Institute,
and its development is described in Glas et al. (2006). Patients are classified by calculating the correlation
coefficient between a patient’s expression levels of the 70 genes and an average low risk (good prognosis)
expression profile. If the correlation coefficient exceeds 0.4, the patient is classified as having a low risk,
if less, they are classified as having a high risk.
Two independent validation studies were conducted to assess the 70-gene signature. The validation
by van de Vijver et al. (2002) with 151 patients showed a 10 year survival of 95% for low-risk, and of 55%
for high-risk patients. In the Transbig independent European validation with 302 patients (Buyse et al.,
2006), the metastasis-free survival by profile at 10 years was 88% for low-risk, and 71% for high risk
patients. Although being far from perfect, the FDA approved the MammaPrint test in 2007 for use in the
United States.
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Oncotype DX. Oncotype DX is a diagnostic test that quantifies the likelihood of disease recurrence in
women with early-stage breast cancer and assesses the likely benefit from certain types of chemotherapy.
Oncotype DX uses a RT-PCR to determine the expression levels of 21 genes within a tumor to determine
a recurrence score. The recurrence score is a number between 0 and 100 that corresponds to a specific
likelihood of breast cancer recurrence within 10 years of the initial diagnosis. Five of the 21 genes are used
as controls to verify that the test has not been contaminated or run improperly. The remaining 16 genes are
associated with cell proliferation, cellular invasion, HER2 and estrogen activity. Unlike the MammaPrint,
which requires fresh tissue, Oncotype DX works on formalin-fixed, paraffin-embedded tissue samples that
are frequently used in pathology. The MammaPrint and the Oncotype DX test have only one gene in
common.
4.2 Definition of open problem
Motivation
Pancreas cancer has an extremely poor prognosis, with a median patient survival time of 1 ½ years.
In some patients, however, much longer survival times are observed. A plausible explanation could be
that these patients have less aggressive types of pancreas cancer which, although histologically similar,
show different gene expression profiles. Predicting survival time based on gene expression profiles could
identify patients who would benefit from extensive therapy such as surgery and chemotherapy as opposed
to patients who would not. For the latter, less aggressive or different treatment could result in better life
quality.
Open problem
Can we identify genes whose expression in pancreas cancer tissue samples correlates with the survival
time of pancreas cancer patients? Can these genes be used as a molecular signature to reliably predict
the survival time of patients diagnosed with pancreas cancer?
4.3 Results
4.3.1 The pancreas cancer survival dataset
Patients. The dataset used for this analysis consists of gene expression profiles from 30 patients with
pancreatic ductal adenocarcinoma that underwent surgery in German hospitals between 1996 and 2007.
Microarray chip experiments were performed by the collaborating group of Christian Pilarsky at Dresden
university hospital. For each patient, the clinical parameters age, sex, cancer staging according to the
tumor-node-metastasis (TNM) classification, and survival time after operation were recorded. None of the
patients received adjuvant chemotherapy. Table 4.3 shows an overview of the patient characteristics.
Definition of prognosis groups. We use the median survival time of 17.5 months to divide patients into
a poor and a good prognosis group. Figure 4.4 (left) shows a histogram of patient survival times, with poor
prognosis patients in red, and good prognosis patients in blue. Figure 4.4 (right) shows the Kaplan-Meier
survival curves for the two groups. Kaplan-Meier survival estimators (Kaplan and Meier, 1958) measure
the fraction of patients living for a certain amount of time after treatment, which can also be interpreted as
a probability of survival. As can be seen, this probability is by definition 0 in the poor prognosis group for
any time above the median survival time t˜, and 1 in the good prognosis below t˜.
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Table 4.3 Clinical characteristics of patients used in this study. The dataset comprises 30 patients that re-
ceived surgical removal of a pancreatic adenocarcinoma without adjuvant chemotherapy. Most patients had mod-
erately differentiated (G2) or poorly differentiated tumors (G3) which had spread into surrounding tissues near the
pancreas (T3), into regional lymph nodes (N1), but not into distant lymph nodes or distant organs (M0).
Parameter n %
Median age: 66 years (range 40–82 years)
Sex
Male 11 0.37
Female 19 0.63
Tumor stage
T2 2 0.07
T3 26 0.87
T4 2 0.07
Regional lymph node metastasis
N0 12 0.40
N1 18 0.60
Distant metastasis
M0 29 0.97
M1 1 0.03
Tumor grade
G1 1 0.03
G2 11 0.37
G3 17 0.57
G4 1 0.03
Median survival: 17.5 months (range 5–53 months)
Gene expression profiles from microarray experiments. For each patient, one Affymetrix CEL file
containing the signal intensity data was obtained from the collaborators. Most of the analyses were carried
out using the Bioconductor framework (Gentleman et al., 2004) and the R programming language for
statistical computing (Ihaka and Gentleman, 1996).
Initial quality assessment procedures revealed that three samples had strikingly higher signal inten-
sities. Further analysis identified ring artifacts on the chip surface as the source of the higher intensities
(see Figure 4.3). Repetition microarray experiments for these samples corrected this problem. CEL files
were then preprocessed into gene expression profile matrices using RMA (Irizarry et al., 2003). The result-
ing dataset contained the numerical measurements of 55,000 gene expression variables from 30 patients,
arranged in a 55,000 × 30 matrix.
4.3.2 Finding a predictive gene expression signature
As outlined in the introduction (see page 94), we will follow these five steps to develop a pancreas cancer
survival signature:
1. Reduce gene feature space by filtering
2. Identify informative genes
3. Select a subset of informative genes that define a signature
4. Build a prediction rule with the signature, often by means of machine learning
5. Evaluate the performance or accuracy of the prediction rule
C H A P T E R 4 . P R E D I C T I O N O F C A N C E R PAT I E N T S U R V I VA L 107
Figure 4.3 Quality assessment of raw microarray data. Pseudo images of three samples showing the probe
signal intensities arranged according to their physical layout on the microarray chip. In all three cases, a ring arti-
fact is clearly visible. Its source is unknown. Microarray chip experiments were repeated for these samples, which
corrected the problem.
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Figure 4.4 Survival times of pancreas cancer patients in the dataset. Left: In order to divide the patients into
two groups of equal size, the median survival time t˜ was calulated. Patients with a survival time less or equal to
the median were defined to have a poor prognosis, those with a survival time greater than median survival a good
prognosis. Right: Kaplan-Meier plots estimating the probability of survival for both defined groups. Obviously, this
probability is 0 in the poor prognosis group at any time > t˜, and 1 in the good prognosis group for at any time < t˜.
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Feature space reduction by filtering (step 1)
The first step after preprocessing was to reduce the feature space of the initial ∼55,000 expression vari-
ables, in the following referred to as probe sets, for each patient tumor sample. This reduction serves
several objectives:
1. to remove noise from genes with low expression. It is assumed that out of the 20–22,000 protein-
coding genes, only a fraction is expressed at one time in a particular tissue. The non-expressed
genes play roles that are specific for other tissues or for development of the organism and are inac-
tivated. Since the microarray chip gives a positive signal for each probe set (with lowest intensities
typically around 3 on the log2 scale), one wants to remove those genes that are not expressed.
2. to remove genes whose expression changes only little between patients. These genes are simply
not informative as they cannot discriminate between any patient groups. Note that this filtering can
be done without using information about the group one wants to predict.
3. to reduce the problem complexity for further analysis. This turned out to be important for the com-
putationally expensive cross-validation procedure that was performed later. In addition, it reduces
the number of hypotheses to be tested.
The following steps were taken to this end:
1. Remove noise: Probe sets with a mean expression below 6 on the log2 scale were filtered out from
the dataset. Out of ∼55,000 probe sets, ∼30,000 remained after this filtering.
2. Remove uninformative variables: Probe sets with a standard deviation below 0.5 on the log2 scale
were filtered out further. This reduced the number of probe sets to ∼15,000.
3. Reduce problem size: On average, there are 2.4 probe sets measuring the expression level of one
gene on the Affymetrix chip used. With respect to the planned validation procedure, where we are
interested in detecting levels of proteins that are expressed from the signature genes, it is desirable
to have only one expression value per gene. We therefore keep only one probe set per gene by
removing for a gene all but the probe set with the highest mean expression over all patients. As
illustrated in Figure 4.5 for five examplary genes, there is in general a high correlation between
probe sets reporting for the same gene. Keeping only the one probe set with the highest mean
expression for each gene reduces the number of probe sets to 7,871. This is the size of the dataset
that was used for all following analyses.
Figure 4.6 visualises the dataset before and after filtering. It shows a scatter plot of mean against
standard deviation of all probe set expression values, where points are binned into hexagons. The color
code of each hexagon represents the number of data point that it contains. Genes with consistently low
intensity values and low variance across samples can be found in the lower left of the plot. Most probe sets
before filtering fall into this category. We can imagine housekeeping genes placed in the lower right part,
and candidates for signatures genes in the upper parts of the plot. After applying the abovementioned
three steps, we observe that the mean expression comes closer to a normal distribution than before
filtering.
4.3.3 Supervised learning of patient prognosis
The next step after filtering out genes that are likely to be uninformative is to identify the most informative
genes, and to use a subset of them as signature. The signature consists of those genes that allow best to
predict survival outcome of pancreas cancer patients. The identification of this signature is our main aim.
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Figure 4.5 Different probe sets that report for the same gene show a high correlation. The figure shows
a comparison of probe set expression levels for five selected genes for which two or three probe sets exist on
the chip. Patients are ordered according to the expression of the probe sets depicted in blue. For examples such
as MUC5AC, there is an almost perfect agreement between the probe sets’ expression levels. In the other cases,
usually one probe set shows a lower expression level, but still is highly correlated with the other probe sets. This
can be explained with a lower binding affinity of that probe set, which results in a weaker signal. Overall, it can be
concluded that different probe set expressions for the same gene are well correlated.
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Figure 4.6 Dataset gene expression levels before and after filtering. Top: Bivariate histogram plot using
hexagon binning of mean against standard deviation of gene expression levels for all patients. Top left, before
filtering: The majority of genes has both a low mean expression and a low standard deviation over all patients.
Since the expression of these genes hardly varies between patients, they are uninformative for the prediction of any
clinical outcome, and are hence excluded (top right, after filtering). Bottom: Histograms of all expression values in
the dataset before and after filtering. Note that the distribution of expression values in the unfiltered dataset (left)
is skewed, as the data is dominated by low values. After filtering, the remaining probe set expression values follow
closely a normal distribution with empirical mean and standard deviation of the data (overlayed curve, bottom right).
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This means that we are not so much interested in deciding which machine learning technique will give
us the best performance, but rather which genes perform best in a standard machine learning environment.
The next questions are first, how to identify informative genes, and second, how many genes should be
included.
Identifcation of informative genes (step 2)
Traditionally in microarray analysis, features are selected that show the highest differential expression
between two sample groups. Genes that are differentially expressed between two sample groups are
usually identified by fold change, t-test, or a combination of both. The two sample groups in our study are
the poor and the good prognosis group, and the aim is to select those genes as features that differ most
between these two groups.
As mentioned in the introduction, we will use ranking instead of choosing a certain cutoff such as two-
fold change or a multiple testing corrected p-value. We will start with the following basic feature selection
methods:
• Fold change
of expression between poor and good prognosis group
• t-statistic
of expression between poor and good prognosis group
• Correlation coefficient
between expression and survival time
These feature selection methods are described in detail in the Materials and Methods section on
page 135. Whereas the fold change and t-test methods are applied to two groups of patients, the correla-
tion coefficient measures how well the expression of a gene in a tumor sample corresponds to the survival
time of the patient from which this sample was obtained.
Select a subset of informative genes that define a signature (step 3)
Feature selection — also known as feature reduction, variable selection, or variable subset selection — is
the technique of selecting a subset of relevant features for building robust learning models in machine
learning. By removing most irrelevant and redundant features from the data, feature selection generally
improves the performance of learning models.
Applied to our open problem, feature selection will result in a list of genes which allow to predict the
outcome of pancreas cancer patient. Here, these genes are called the signature genes. One immediate
question is how many signature genes are needed? We can address this question from two points of view.
From the machine learning point of view, we are dealing with a classification problem, where the
expression values of the signature genes are the input variables and the prognosis class of the patient is
the output variable. The number of signature genes is the signature size. The bigger the signature size,
the higher the risk of overfitting. Generally, a learning algorithm is said to overfit if it is more accurate in
fitting known data but less accurate in predicting new data. Overfitting results from adjusting to random
features of the training data that have no causal relation to the response variable. If the number of features
greatly exceeds the number of samples, there is a high risk that the classifier memorizes the individual
samples rather than extracts general patterns from the data. Hence, the signature size should not exceed
the number of samples available, which is 30 in our case.
From the biological point of view, the question is how many genes are needed to induce a change in
tumor gene expression that is able to alter the prognosis of the patient. One could imagine that changes
in few genes such as transcription factors that control a higher number of other genes can considerably
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change cellular behaviour. The changes could, for example, lead to accelerated growth and spread of the
cancer, which in turn gives rise to a poorer prognosis. Although this higher number of probably 100 or
more genes would change their expression, it might be sufficient to look only at the probably 5–10 genes
that are the cause for the change.
Considering both machine learning and biological aspects, we aim at a signature size in the range of
5–20. There is another benefit from keeping the signature size small. A few number of genes can be easily
tested and validated by means of other methods such as immunohistochemistry which detect a particular
protein with an antibody. Immunohistochemistry is already broadly used in clinical diagnostic pathology
for tumor classification.
Supervised learning of patient prognosis using selected features (step 4)
The selected features, i. e. the signature genes, are used to train a machine learning algorithm to model
the relationship between signature gene expression and patient outcome. Since outcome can be either
poor or good, the algorithm is a binary classifier. Based on the expression levels of the signature genes,
the classifier has to be trained in order to learn the class, here the prognosis group. Since the classifier is
given the class when trained, this is a case of supervised learning.
In the problem of supervised learning we are given a sample of input-output pairs (also called the
training sample), and the task is to find a deterministic function that maps any input to an output such
that disagreement with future input-output observations is minimized. The difficulty is in generalizing to
new objects not present in the training sample. It should be noted that in our case feature selection turns
out to be more crucial than the choice of the machine learning technique. The reason is that we require,
as motivated above, a rather small number of features, the signature genes, which are selected before
feeding them into the learning algorithm. It is obvious that with uninformative features, the best machine
learning algorithm is limited in its prediction accuracy. The aim is to build a model that predicts the outcome
based on selected features. Since the outcome is either poor or good, we need a binary classifier. To this
end, support vector machines (Boser et al., 1992; Vapnik, 1998; Schölkopf and Smola, 2002) are an
excellent choice.
Support vector machines. A support vector machine (SVM) is a supervised machine learning algo-
rithm for classification problems. The simplest form of a prediction problem is binary classification: trying
to discriminate between objects that belong to one of two categories. The basic concept of a SVM is
treating the objects to be classified as points in a high-dimensional space and finding a line that separates
them. Strictly speaking, the separating line is only a line in two dimensions. In three dimensions, a plane
is needed to divide the space, and in a higher-dimensional space it is a hyperplane. By separating the
space into two, the SVM is a binary classifier.
Often the data is not linearly separable. In this case, the so-called kernel trick is applied, which relies
on a kernel function. In general, a kernel function maps data from a low-dimensional space to a space
of higher dimension. In particular, the kernel function provides a nonlinear mapping from the input space
into the feature space, in which linear separation can be achieved. It is possible to prove that for any given
data set there exists a kernel function that will allow the data to be linearly separated.
The most obvious drawback to the SVM algorithm is that it only handles binary classification problems.
In order to recognize several classes, the simplest approach is to train multiple, one-versus-all classifiers.
This simple approach has been demonstrated to actually work well for cancer classification (Ramaswamy
et al., 2001).
SVMs have been successfully applied to an increasingly wide variety of biological applications (Ben-
Hur et al., 2008) due to their high accuracy, their ability to deal with high-dimensional and large datasets,
and their flexibility in modeling diverse sources of data. A common biomedical application of support
vector machines is the automatic classification of microarray gene expression profiles. SVMs have been
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shown to work well for high dimensional microarray data sets. Furey et al. (2000) demonstrated that using
all 6,817 gene expression measurements, an SVM can achieve near-perfect classification accuracy on
the ALL/AML data set (Golub et al., 1999), although some authors have raised concerns about overfitting.
In a recent comprehensive study, Statnikov et al. (2008) compared random forests and support vector
machines for microarray-based cancer classification on 22 diagnostic and prognostic datasets (11 of
which can also be found in Table 4.1). They found that both on average and in the majority of microarray
datasets, random forests are outperformed by support vector machines both in the settings when no
gene selection is performed and when several popular gene selection methods are used. Other biological
applications involve classifying objects as diverse as protein and DNA sequences, microarray expression
profiles, mass spectra (Noble, 2004), or protein–protein interactions (Ben-Hur and Noble, 2005).
We will use a support vector machine to classify pancreas tumors samples into poor or good prognosis,
based on the expression levels of selected genes.
4.3.4 Evaluation of supervised learning accuracy (step 5)
The usual machine-learning approach is to divide the observations into a training set and into a test
set. The training set will be used to train the classifier. The performance of the classifier can then be
evaluated by applying it to the test set. To avoid overoptimistic results, it is of fundamental importance
that no information from the test set leaks into the process of building the classifier. If we applied this
split into training and test set once, we could evaluate the accuracy of the classifier once on the test set.
With hundreds of samples in each set this might be a reasonable approach. With smaller sizes, however,
one runs into the problem that the classifier itself might be biased because the training samples were not
representative, and the evaluation might be biased because the test samples were not representative.
The performance of the classifier on the test set (i. e., the estimated classification error) can vary
considerably depending on which samples are used in the test set. This is especially true for a small
sample number. One would like to obtain an average error over different test sets, which is achieved
by the multiple random validation strategy (Michiels et al., 2005). Here, the data is repeatedly randomly
divided into training and test set, and each time a new classifier is trained on the training set and its
performance is evaluated on the test set. With a sufficient number of repetitions, say 1000, the average
error can be a good estimate of the true classification error.
To get a robust estimate on the classification error rate, we adopt the multiple random validation
strategy described by Michiels et al. (2005), which will be described in the following.
Monte-carlo cross-validation workflow
In order to assess the ability of different signatures to select genes that allow to predict the patient prog-
nosis group, an evaluation framework was designed. To get a robust estimate on the classification error
rate, we adopt the multiple random validation strategy described by Michiels et al. (2005).
Given: Gene expression matrix with features (genes) and samples (patients) as rows and columns , a
signature size n is set. Outcome as response variable, its workflow is outlined here:
Given a fixed signature size x, training set size y, and certain feature selection method, The following
steps were repeated 1,000 times:
1. Starting point is the dataset after feature space reduction, consisting of a gene expression matrix
with 7,871 features (rows) and 30 patient samples (columns)
2. The data is randomly split into training and test set. Splitting is balanced such that the number of
poor and good samples in the test set are either equal or differ by at most one. This is to ensure
that there is no over-representation of one group in the training set, and of the other group in the
test set.
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3. Using the training set data only, features are ranked according to a feature selection method.
4. The top-ranked n features are selected. These features become the signature.
5. The signature from the training set is used to train a classifier on the sample outcome, using the
training set expression values of the signature genes as input.
6. The classifier is used to predict the outcome of the unseen test set patients.
7. The predicted outcome is compared with the true outcome. The fraction of correctly predicted pa-
tients defines the accuracy.
The overall classification accuracy is the average of all repeated workflow accuracies. In order to
ensure maximally comparable results, the random splits into training and test sets were carried out once
and the sets were recorded. Thus, exactly the same training and test sets were used for each method.
4.3.5 Results from supervised learning
Figure 4.8 shows the prediction accuracy of different feature selection methods with different training set
sizes. The chosen signature size was 7. Prediction accuracy is defined as number of correctly predicted
cases in the test set divided by test set size. Note that the test set size is always 30 minus the training
set size. As a general trend, one can observe that a bigger training set leads to higher accuracy. For the
random feature selection (gray line), where features are selected randomly, independent of any expression
levels, this effect is less pronounced. Still, the accuracy is above 0.5, which is the expected accuracy of
random guessing instead of learning. This means that even in randomly selected features there is some
information that allows to slightly distinguish the poor from the good prognosis group.
A quite puzzling finding in Figure 4.8 is the performance of the fold change feature selection method.
It seems that this method selects features that behave quite the opposite in training and test set. As a
result, the prediction accuracy after machine learning with these features is below 0.5. This effect is more
pronounced the bigger the training set is. One possible explanation for this will be discussed below.
Correlation methods outperform group-based methods
The correlation measures show the best prediction accuracy and outperform other feature selection meth-
ods. Interestingly, except for the random selection of features, the different performance of the methods
(Figure 4.8) reflects quite well the amount of information that a method makes use of. As can be seen
in Figure 4.8, ranking by a correlation measure (either Pearson or Spearman rank correlation coefficient)
outperforms ranking by a t-test. The correlation coefficient is calculated by correlating a gene’s expression
to the individual survival times of the patients, whereas for the t-test only the prognosis group as a poor/-
good binary variable is used instead of individual survival times. The t-test hence uses less information.
In Figure 4.4, left, the spectrum of survival times and the corresponding binary prognosis group variable
are depicted. Choosing features randomly independent of any rank score uses the least information. It
should hence yield the least accuracy. Unexpectedly, feature selection by magnitude of fold change yields
the least accuracy. In the following, a possible explanation is given.
Fold change is an unsuitable feature selection method
As depicted in Figure 4.8, using the fold change criterion for ranking and selecting genes results in a
classification accuracy that is worse than simple guessing. In addition, a bigger training set size seems
to worsen accuracy. Why is that the case? Manual inspection of the misclassified cases revealed that in
many cases genes with a large variance were selected that behaved quite differently in training and test
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Figure 4.7 Workflow to evaluate the accuracy of the prediction of patient outcome. The full dataset is a gene
expression matrix with ∼8,000 features (the genes) as rows and 30 samples (the patients) as columns. For each
patient, the outcome (poor or good) is given (1). The dataset is randomly divided into a training and a test set (2).
Within the training set, genes are ranked by how different they are between patients with poor and good outcome (3).
The most different genes are selected (4). They are used to train a machine learning classifier on the training set
(5). After training, the classifier is asked to predict the outcome of the test set patients (6). The predicted outcome
is compared with the true outcome and the number of correctly classified patients is noted (7).
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Figure 4.8 The effect of different feature selection methods and training set sizes on classification accu-
racy. Monte-carlo cross-validation with different feature selection methods in predicting patient outcome. The plot
shows the mean accuracy of selecting the best seven features with different feature selection methods based on
1,000 randomly selected training sets of increasing size. Classification accuracy is measured in the fraction of cor-
rectly predicted cases in the test set. In general, the bigger the training set, the better the classification accuracy. The
GeneRank-based feature selection outperforms all other methods. Surprisingly, the fold change method performs
worse than random selection of features or simple guessing. Note that the y-axis is trimmed to better highlight the
method differences.
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Figure 4.9 An explanation for the bad performance of the fold change selection method. The plots show the
expression of CRISP3, a gene that was top-ranked according to fold change. Each point represents the expression
level of the gene in one patient. Patients are arranged in the training set, test set, and their union, the complete
set of patients. The ranking that caused selection of this gene is based on the training set only (left), where a
considerable up-regulation of the gene in the poor prognosis group can be assumed. However, the complete data
set (right) reveals that there is no strong difference in expression between the groups. Even worse, the expression in
the test set, on which the accuracy is evaluated, shows quite the opposite distribution compared to the training set.
Note that the training set was selected randomly from the complete set. Note further that CRISP3 shows a bimodal
distribution of expression with one peak around 5 and another peak around 11.
set. Figure 4.9 exemplifies this problem. Based on the training set of 26 patients depicted on the left, the
gene CRISP3 was selected as the gene with the third highest fold change. The fold change was 2.6 on
the log2 scale which corresponds to a 6.2-fold change of expression on the normal scale. From the mere
numbers, one would assume that CRISP3 is clearly upregulated in the poor prognosis group. In the test
set, however, on which the classification accuracy is evaluated, the gene shows a clear downregulation. It
is evident that any attempt to predict prognosis of the test set patients (middle) using a classifier trained
with the data of the training set (left) must fail.
When looking at the complete set of patients, from which the training set was randomly selected,
one first notices that the upregulation in the poor prognosis group is much smaller (1.5 on the log2 scale
compared to 2.6 in the training set). Second, from the distribution of patient expression levels (black points
in the Figure), one would not even postulate an upregulation in the poor prognosis group. The gene rather
shows a bimodal distribution with two expression peaks, one around 5 and another around 11. There
seems to be no preference between the prognosis groups for a lower of higher expression. Yet the biased
training set caused the fold change feature selection method to include this gene in the signature. A test
for unimodality revealed that, in the present data set, ranking by fold change strongly enriches for genes
with a bimodal distribution (Hartigan’s dip test, Hartigan and Hartigan (1985)). Such bimodally distributed
genes have a higher risk of being misclassified in test sets of small size.
To summarise, the bad performance of the fold change feature selection method is likely to be caused
by selection of genes that are more likely to behave differently in training in test sets. This is often the
case for genes with a bimodal distribution. Not only can test sets be sampled in a way quite different from
the training set, but also training sets can be sampled in a way that they create stronger differences than
there are in the full data set. Other feature selection methods such as correlation or t-test do not favour
bimodally distributed genes, but rather yield moderate rankings due less correlation or due to a greater
variance of these genes. They hence tend to select genes that give a better accuracy when evaluated on
the test set. It can be concluded that for the data used in this study, selecting features with the highest fold
change between prognosis groups cannot be recommended.
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4.3.6 Alternative approaches
Extreme sample selection does not improve accuracy
We were interested to find out how the definition of the prognosis group affected the results. We therefore
used thresholds other than the median survival time to define two groups. We defined the lower third of
patients as poor, and the upper two thirds as good prognosis patients. This did, however, not result in
an improved prediction accuracy in our cross-validation workflow. Setting the threshold at the upper two
thirds of the survival time did not result in an improvement as well. We finally adopted the idea of extreme
sample selection described by Liu et al. (2005a). To learn a classifier to predict patient survival, Liu et al.
used those who survived the longest and those who died immediately as training samples, and ignored
all the rest. They found that this strategy often enhanced prediction performance as it brought out the
sharpness contrast in the differences between the two classes of samples. In our case, unfortunately, this
did not help.
Discretization of gene expression values does not improve prediction accuracy
Discretization transforms continuous values of a variable into discrete ones. A simple form of discretization
is binning, where a designated number of intervals of equal width are chosen, and all values within one
interval or bin are assigned the same value. Discretization is used as a data pre-processing technique to
reduce the effects of minor observation errors. Lustgarten et al. (2008) report that the use of discretiza-
tion was able to improve classification of genomic cancer datasets. In their study, they investigated the
performance of support vector machines, random forests, and naïve Bayes classifiers on 24 datasets, 10
of which are also present in Table 4.1. Although support vector machines showed no improvement in per-
formance, there was a significant performance gain for random forests and naïve Bayes classifiers. The
authors’ results suggested that the improvement in classification performance from discretization emerged
to a large extent from variable selection and to a smaller extent from the transformation of the variable from
continuous to discrete. Lustgarten et al. concluded that discretization can be useful for machine learning
algorithms that directly handle continuous variables.
We also asked whether discretizing the gene expression values into bins of various number can
improve the prediction accuracy. To this end, we used two setups with discretization levels (numbers of
bins) between two and ten. In one setup, bins represented intervals of equal size, in the other setup, bins
were quantiles, such that all bins contained an equal number of genes. Binning of expression values was
done on the full dataset without regarding any patient survival time or prognosis group. The results were
disappointing. Although some discretization levels gave a slight improvement, most other levels did not
improve or even drastically worsen the accuracy. Moreover, levels that led to good results in one setup
(such as for example a level of six in the quantile binning), had often poor results in the other setup. Our
conclusion from this was that discretizing is not helpful for our dataset. Moreover, any slight improvements
were probably due to overfitting by selecting a particular discretization level that would probably perform
differently on a different dataset.
4.3.7 The GeneRank algorithm
So far, ranking by Pearson correlation with survival seems to be the best choice with respect to prediction
accuracy (see Figure 4.8). The question is if and how this accuracy can be further improved.
As mentioned before, there seems to be a correlation of amount of information used for feature selec-
tion and accuracy of the classifier. This motivates the use of even further information, such as further clin-
ical parameters of the patient, or biomedical background knowledge. Clinical parameters that are usually
given are patient age, sex, tumor size or tumor differentiation grade. Regarding biomedical background
knowledge, one could for example favour genes that are already known to be associated with survival,
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or one could incorporate pathway information. Clinical parameters, which are listed in Table 4.3, are a
reasonable choice to test first. It turns out, however, that adding clinical parameters as input variables
to the classifier (in addition to the signature genes) do not improve prediction accuracy. Can additional
background knowledge help?
The GeneRank algorithm
The GeneRank algorithm was described by David Gilbert and co-workers (Morrison et al., 2005) and is
derived from the Google PageRank algorithm (Page et al., 1998). The basic idea behind PageRank is that
a document should be important if it is highly cited by other documents. Moreover, citations from important
documents should have more weight than citations from unimportant documents. As employed by the
Google Internet search engine, the PageRank algorithm uses hyperlink information between documents
in the world wide web to assign a numerical weighting (termed the PageRank) to each document with
the purpose of measuring its relative importance within the set of all web documents. The PageRank
algorithm further introduces a constant representing the probability of randomly jumping to a document
instead of following a hyperlink pointing to it.
Just as PageRank assigns a score to a document that is based on scores of documents linking
to it, GeneRank assigns a score to a gene that is based on scores of genes linked to it. This linkage
can be defined in several ways. In the original GeneRank paper, Morrison et al. (2005) use annotation
networks and gene expression correlation networks to this end. Annotation networks are based on the
Gene Ontology (Ashburner et al., 2000), with genes being connected if they share an annotation allocated
by the Gene Ontology Consortium. The authors further propose the use of regulatory networks, protein
interaction data, or previous experimental results.
The basic idea behind GeneRank is what is called the vote of confidence principle. Just as the Page-
Rank of a web page will be high if it is linked to other highly ranked pages, the relative ranking of a gene
should be increased if it is linked to other highly differentially expressed genes. For a detailed description
of the GeneRank algorithm, see the Materials and Methods section on page 135.
Adaptation of the GeneRank algorithm to microarray-based survival prediction
Here, we adapt the GeneRank algorithm to the problem of ranking genes according to their power to
predict patient survival. The algorithm was implemented in R (see Appendix, page 145). Input for the
algorithm is a connectivity matrix W which holds the network information, a vector of node weights ex,
and a parameter d which sets the probability of following a network link instead of jumping randomly
between nodes. Following Morrison et al. (2005), W is symmetric, representing an undirected graph.
Figure 4.10 illustrates how the GeneRank algorithm works on an example network of 10 nodes. The
nodes represent genes, and each node is labeled with its node weight. Assume that the node weight
represents the importance of a gene, for example its correlation with survival. Node weights are also
represented by the node color, ranging between light yellow and dark red for a node weight between 0
and 1. The initial node weights are depicted in the first graph on the upper left. The other graphs show
the result of applying GeneRank (this is actually also true for the first graph, since d = 0 simply does not
change the initial node weights, as can be easily seen from equation 4.5 on page 138).
Moving from top left to bottom right in the figure, the parameter d is changed from 0 to 0.2, 0.4, 0.6,
0.8, and 1. Note that setting the parameter d = 0 is equivalent to ranking by node weight only, ignoring
any network information, and setting d = 1 is equivalent to ranking by network connectivity only, ignoring
any node weights. Naturally, one aims at having a value of d in between. While Google uses a d = 0.85
(Page et al., 1998), different values might be optimal for different datasets.
In order to determine the optimal parameter d for our dataset, an additional cross-validation step is
necessary in the evaluation workflow. Instead of one test set, two validation sets are used, an inner and
120 C H A P T E R 4 . P R E D I C T I O N O F C A N C E R PAT I E N T S U R V I VA L
Figure 4.10 GeneRank example on a network of ten nodes. Node weights, depicted as node labels as well as
node color, define the ranking of the nodes. The initial network is shown in the upper right, where d = 0. Applying
GeneRank with different values of d results in other networks shown. As d increases, weights of the initial network
are more influenced by node connectivity. For d = 1, node weights and hence ranking is solely based on node
connectivity, and is independent of the weights in the initial network.
an outer one. The outer validation set is set aside in the beginning. The remaining samples are repeatedly
split into the training and the inner validation set. The training set is used to train on different values of
the parameter d , and the accuracy is estimated on the inner validation set. Now, the parameter d with the
highest accuracy is selected. The training and validation sets are combined and again used for training,
and the accuracy is estimated on the outer validation set. This procedure ensures that the final accuracy
measure is not biased, since the outer validation set is just used once. If we omitted the use of an outer
validation set, we would estimate the accuracy on the maximum of the inner validation set accuracies.
Clearly, there is an information leak since data set aside for testing would become part of the training
process. As a result, the accuracy estimate would be overoptimistic.
For our dataset, the sizes used are 20, 6, and 4 for the training, inner validation, and outer validation
set.
Rank information used
For assigning initial ranks to the genes in the network, Morrison et al. (2005) propose gene expression
changes, i. e. a measure of differential expression. Consequently, we use the Pearson correlation coef-
ficient of a gene’s expression with the survival time as initial rank. Note that Pearson correlation gave
the highest accuracy of the feature selection methods tested so far. Since the GeneRank adds network
information to that, any increase in prediction accuracy can directly be traced to the network information.
Networks used
We use three different networks for the GeneRank procedure. First, we use a regulatory network defined
by transcription factors and its targets. A transcription factor controls the expression of usually several
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target genes. This means that any change in the activity of a transcription factor — which for example
can be caused by the up- or downregulation of the transcription factor’s gene — affects the expression of
several other genes. An edge in the network connects a transcription factor and its target. Two genes in
the network are connected if one gene encodes for a transcription that controls the other gene.
We further use a protein–protein interaction network, where two genes are connected if their encoded
proteins interact according to reliable experimental evidence. To this end, we use data available in the
Human Protein Reference Database, HPRD (Mishra et al., 2006). HPRD is manually curated and contains
some 35,000 high-quality protein interactions. In addition, we use a coexpression network, where two
genes are connected if their gene expression profiles correlate. Their encoded proteins interact according
to reliable experimental evidence. The coexpression information is taken from the COXPRESdb (Obayashi
et al., 2008), which calculates coexpression from a wide number of publicly available microarray datasets
for human.
4.3.8 Results of feature selection with GeneRank
We test the GeneRank algorithm with the intial rank information of gene expression correlation with sur-
vival combined with different networks. 1,000 loops of outer validation, each containing 1,000 inner valida-
tion loops were done. In the inner validation loop, the parameter d was varied between 0 and 1 in steps of
0.1. The whole workflow was repeated for the three different networks, using the same splits into training
and validation sets. The top-ranked features were selected and used for the machine learning step in the
same manner as described in section 4.3.4 (page 113).
GeneRank outperforms other feature selection methods
GeneRank with the transcription factor network outperformed both the protein–protein and the coexpres-
sion network. Additionally, it outperformed all feature selection methods studied previously. Figure 4.11
shows the result. For all training set sizes, section features with GeneRank has a higher accuracy than
with any other method. We reach a maximum accuracy of 72% with a training set size of 28. Note that
GeneRank is especially beneficial for small training set sizes, where there is a considerable improvement
compared to the Pearson correlation method. For the parameter d , the optimal value was found to be 0.4.
Transcription factor networks are more informative than protein–protein interaction or coexpres-
sion networks
When comparing the different networks used with GeneRank, Figure 4.12 (left) shows that using transcrip-
tion factor networks (TRANSFAC) is clearly superior to using protein–protein interaction networks (HPRD).
Also, combining both networks does not improve the TRANSFAC-based accuracy, but lowers it towards
that of the HPRD-based ranking. Similarly, coexpression-network based GeneRanking performed slightly
better than guessing, and was clearly worse than TRANSFAC-based GeneRanking (not shown). We can
conclude from this that the information about co-expession or protein interactions does not help to identify
genes that are predictive for survival in pancreatic cancer. This is in contrast to recent work of the group
of Trey Ideker (Chuang et al., 2007), where a benefit from using protein–protein interaction networks was
demonstrated in predicting survival in breast cancer patients. We will see in section 4.3.9 why this is the
case.
Are transcription factors and their targets merely better predictors?
One could assume that the good performance of GeneRanking with transcription factor networks is due
to the fact that this method select signatures that are enriched in transcription factors and their targets.
These could turn out to be better predictors by themselves, independent of any network information. To
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Figure 4.11 GeneRank transcription factor-based feature selection outperforms standard feature selection
methods. Accuracy of different feature selection methods in predicting patient outcome. Signature size is seven.
The plot shows the same data as in Figure 4.8, with the GeneRank feature selection using a transcription factor
network in addition (shown in red). Especially for smaller training set sizes, the GeneRank method is clearly superior
to all other feature selection methods.Mont −Carlo cross−vali ation
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Figure 4.12 Left: GeneRank with transcription factor networks yields higher prediction accuracy than Gen-
eRank with protein–protein interaction networks. Depicted are the transcription factor network TRANSFAC (red),
the protein–protein interaction network HPRD (blue), and a combination of both (orange). Right: GeneRank with
transcription factor networks yields higher prediction accuracy than transcription factors or their targets
alone. This suggests that not transcription factors or their targets per se ar good predictors, but that ranking accord-
ing to the transcription factor–target network (TRANSFAC, red) is important.
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test whether network information contributes to the better accuracy, we compare it to two alternative
methods. We define two subsets of features, transcription factors and transcription factor targets. We
then perform a standard Pearson correlation feature selection on these subsets. As a result, we obtain a
signature consisting of transcription factors or transcription factor targets only whose expression correlates
best with survival. We do the same for the union of transcription factors and targets. Figure 4.12 (right)
shows the result. It turns out that there is hardly any information in the transcription factor targets alone.
When these targets are used exclusively in the signature, the accuracy drops to almost 0.5, which is in the
range of guessing. Transcription factors are slightly better, but still far worse than the GeneRank method,
which makes use of the whole network information.
We can conclude that restricting ourselves to transcription factors or their targets in the signature does
not find as good signature genes as GeneRank. In particular, GeneRanking with the transcription factor
network information does seem to better reduce the noise in the gene expression data. This emphasises
the importance of the GeneRank approach.
The thirty genes with the highest GeneRank
The first 30 genes as result from the GeneRank procedure are given in Table 4.4. Several transcription
factors are present among the first 10 genes, namely SP1, FOS, CEBPA, JUN, SP3, STAT3, USF1, and
CDX2. Some well-known cancer-related genes, particularly BRCA1 (a tumor suppressor which was found
mutated in breast cancers), CDX2 (which is often deregulated in gastrointestinal tumors), and CDKN1A (a
cell cycle regulator) are present as well. Surprisingly, the hemoglobin alpha and beta subunits (HBA1 and
HBB) are found in the list. Hemoglobin is the main component of red blood cells, and is hence primarily
expressed in reticulocytes, which are the precursors of red blood cells.
To find out whether any of these genes are known to be associated with pancreatic or any other cancer,
we systematically searched the biomedical literature abstracts for the occurrence of each of the 30 genes.
To this end, we used GoGene (Plake et al., 2009). GoGene finds gene names, Medical Subject Headings
(MeSH) terms, and Gene Ontology (GO) terms in PubMed abstracts. It thus allows to associate genes with
diseases, which are part of MeSH, and biological processes, which are part of GO. We divided the genes
into three distinct groups: known to be related to pancreas cancer, known to be related to neoplasms,
and not related to any of these. The groups are shown as three columns in Table 4.4. Out of the 30
genes, 5 were associated with pancreatic neoplasm as MeSH term, namely JUN, STAT3, BRCA1 IL6,
and CXCL12. Twenty genes had neoplasm as associated MeSH term. Five genes were not yet reported
to be associated with any neoplasm, namely KIAA1576, ECSM2, FOXC1, LUC7L, and CFH.
FOXC1 belongs to the Forkhead box (Fox) proteins, which are a superfamily of evolutionarily con-
served transcriptional regulators. There is evidence that the deregulation of Fox family transcription fac-
tors has a crucial role in the development and progression of cancer, and an emerging role of Fox proteins
as targets for therapeutic intervention as well as biomarkers for predicting and monitoring treatment re-
sponses was recently pointed out by Myatt and Lam (2007).
KIAA1576 and ECSM2 are only poorly annotated. Sequence similarity search with BLAST against
all human protein sequences revealed that KIAA1576 has a 50 % sequence similarity (30 % sequence
identity) to TP53I3, which surprisingly happens to be in the list of 30 genes as well. The similarity is mainly
because both proteins are oxidoreductases. Among the BLAST hits are further ADH1C, which is found
with alcohol-related cancer, and ten more neoplasms-related genes. A BLAST search with the protein
sequence of ECSM2 finds MUC4, MUC5AC, MUC12, und MUC17 as hits. MUC5AC is well-known to be
related to pancreatic neoplasms. It is a secretory protein expressed by mucous cells of the human stom-
ach and in the bronchial tract. MUC5AC is absent from normal pancreas, but de novo expression of this
mucin occurs in early-stage pancreatic intraepithelial neoplasias and in the invasive ductal adenocarci-
noma of the pancreas (Kato et al., 2006). Moreover, the transcription factors SP1 and AP-1 (a dimer of
JUN and FOS) are both involved in the transcription of the MUC5AC gene.
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Lynch et al. (2005) found that mutations in BRCA1 constitute a genetic predisposition for pancreatic
cancer. 5–10% of pancreatic cancer cases are familial. Beger et al. (2004) studied BRCA1 with quan-
titative PCR and immunohistochemical analyses in normal pancreatic tissues, chronic pancreatitis, and
pancreatic cancer samples. They found that BRCA1 expression was down-regulated in chronic alcoholic
pancreatitis, and suppressed in pancreatic cancer, both on RNA and protein levels. In our results, BRCA1
is positively correlated with survival, which may indicate that its tumor suppressing function is also relevant
in pancreatic cancer.
Activation of the STAT3 signaling pathway plays an important role in the progression of pancreatic
cancer (Qiu et al., 2007). STAT3 directly regulates angiogenesis, growth, and metastasis of human pan-
creatic cancer via VEGF expression (Wei et al., 2003; Gray et al., 2005). Wang and Ma (2007) state
that CXCL12/CXCR4 signaling, one of the most important chemokine receptor-ligand complexes, is con-
sidered to play a critical role in pancreatic cancer organ-specific metastasis. According to Burger and
Kipps (2006), CXCL12 can stimulate survival and growth of neoplastic cells and can promote tumor an-
giogenesis by attracting endothelial cells to the tumor microenvironment. Okutomi et al. (2003) found that
c-Jun fails to act as a negative regulator for the cell survival of pancreatic cancer cells. IL-6 represents a
prominent cachexia-associated factor in pancreatic cancer (Martignoni et al., 2005).
The remaining 20 genes are associated with a variety of different neoplasms, among them cancers
of lung, liver, esophagus, stomach, colon, breast, ovaries, uterus, prostate, and thyroid gland, as well as
vascular neoplasms, leukemia, lymphoma, and glioblastoma.
GeneRanking enriches for known survival genes
To test whether the GeneRank list of genes is enriched for genes that are already known for their associ-
ation with survival or prognosis in pancreas cancer, a literature search was conducted. GoGene (Plake et
al., 2009) was searched with the queries “pancreas cancer prognosis” and “pancreas cancer survival” in
order to identify genes described in the literature in association with survival in pancreas cancer patients.
This returns a list of Entrez Gene IDs that were found in the abstracts of papers found in PubMed with
that query. Entrez Gene IDs were filtered for human and used as the literature survival genes list. This
resulted in 777 genes. Universe size was 20,111 genes. p-values were determined using the hypergeo-
metric distribution (function phyper in R).
Table 4.5 shows the result of the enrichment analysis. The 10 top genes after ranking with GeneRank
are almost 8-fold enriched for literature survival genes. For this enrichment, a p-value calculated from
the hypergeometric distribution of 6.8×10−5 indicates the likelihood of observing such an enrichment in
a randomly drawn sample of size 10. For the top 20 genes, enrichment is even higher, and the p-value
increases (8.8-fold enriched, p = 1.2× 10−8). Comparing this to ranking just by absolute correlation of
gene expression with survival time, the enrichment is less pronounced and less significant (2-fold enriched,
p = 0.09 for the top 10 genes). For 100 genes, there is no significant enrichment at all (p = 0.14).
One can conclude several points from this:
1. GeneRank results are highly enriched for biologically meaningful data. This is explainable, since
biological information in the form of transcription factor–target relations is integrated and used for
re-ranking.
2. Correlation of expression levels and survival time alone, i.e. using the data without additional back-
ground knowledge, is able to enrich for literature survival genes. This means that there exists a
dependence of patient survival and gene expression. If the gene expressions were completely inde-
pendent of survival time, one would not expect any enrichment.
3. There is a clear and significant improvement from incorporating knowledge about transcription net-
works over not doing so.
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Table 4.4 The top 30 genes after applying GeneRank based on the correlation of gene expression with
survival and regulatory information from a transcription factor network. A literature search revealed that 25 of
these genes are already known to be related to neoplasm in particular, of which 5 are already known to be related
to pancreatic neoplasms, and 5 genes are as indicated in the three rightmost columns.
Rank Gene
symbol
Entrez
Gene ID
Gene name Corre-
lation
Known
pan-
creatic
neo-
plasm
Known
non-
pancrea-
tic neo-
plasm
Not
re-
lated
1 SP1 6667 Sp1 transcription factor 0.3 ×
2 FOS 2353 v-fos FBJ murine osteosarcoma
viral oncogene homolog
−0.3 ×
3 CEBPA 1050 CCAAT/enhancer binding protein
(C/EBP), alpha
0.4 ×
4 JUN 3725 jun oncogene −0.1 ×
5 SP3 6670 Sp3 transcription factor 0.2 ×
6 STAT3 6774 signal transducer and activator of
transcription 3
0.2 ×
7 BRCA1 672 breast cancer 1, early onset 0.3 ×
8 SRD5A1 6715 steroid-5-alpha-reductase, alpha
polypeptide 1
0.6 ×
9 USF1 7391 upstream transcription factor 1 0.2 ×
10 CDX2 1045 caudal type homeobox 2 0.3 ×
11 KIAA1576 57687 KIAA1576 protein −0.7 ×
12 MED25 81857 mediator complex subunit 25 0.5 ×
13 TFAP2A 7020 transcription factor AP-2 alpha −0.3 ×
14 UCHL1 7345 ubiquitin carboxyl-terminal es-
terase L1
−0.4 ×
15 STAT1 6772 signal transducer and activator of
transcription 1, 91kDa
0.0 ×
16 HBB 3043 hemoglobin, beta −0.5 ×
17 TP53I3 9540 tumor protein p53 inducible protein
3
−0.3 ×
18 ECSM2 641700 endothelial cell-specific molecule 2 −0.5 ×
19 HBA1 3039 hemoglobin, alpha 1 −0.5 ×
20 BTN2A1 11120 butyrophilin, subfamily 2, member
A1
−0.4 ×
21 CDKN1A 1026 cyclin-dependent kinase inhibitor
1A (p21, Cip1)
−0.4 ×
22 PFDN5 5204 prefoldin subunit 5 −0.4 ×
23 IL6 3569 interleukin 6 (interferon, beta 2) −0.4 ×
24 VWF 7450 von Willebrand factor −0.3 ×
25 ENG 2022 endoglin (Osler-Rendu-Weber
syndrome 1)
−0.3 ×
26 CCL2 6347 chemokine (C-C motif) ligand 2 −0.4 ×
27 FOXC1 2296 forkhead box C1 −0.7 ×
28 LUC7L 55692 LUC7-like (S. cerevisiae) −0.5 ×
29 CFH 3075 complement factor H −0.4 ×
30 CXCL12 6387 chemokine (C-X-C motif) ligand 12 −0.5 ×
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Table 4.5 GeneRank enriches for genes described in the literature as relevant for survival in pancreas
cancer. The top-ranked 10, 20, and 100 genes by GeneRank are between 3-fold and 9-fold enriched for these
literature genes, whereas genes ranked by correlation with survival only show moderate enrichment in comparison.
p-values were calculated using the hypergeometric distribution.
GeneRank Correlation
Top n Enrichment p-value Enrichment p-value
10 7.9 6.8×10−5 2.0 0.09
20 8.8 1.2×10−8 2.0 0.08
100 3.3 2.4×10−6 1.4 0.14
4.3.9 A core signature
Transcription factor network around core signature
Figure 4.13A shows the TRANSFAC network around the eight top-ranked genes. The network is repre-
sented as a power graph (Royer et al., 2008). Power graphs are an alternative visualisation for networks
that can reduce the amount edges drawn. The reduction is achieved by grouping together nodes with a
similar neighbourhood. Such groups are shown enclosed in big circles in the Figure. Nodes connected
to the circle are connected to all nodes within that circle. For example, BRCA1 (bottom of Figure 4.13A,
marked red and yellow) is connected to RPA1, RPA2, RPA3, and CTCF, but also to JUN.
The eight core signature genes are highlighted in yellow in the network, and transcription factors are
marked with a black dot. Connections in the network represent relations between transcription factors and
their targets, as obtained from TRANSFAC. The absolute correlation of a gene’s expression level with
the survival time is shown in red. Further, we display the literature survival genes found with GoGene as
described in the previous section as larger nodes.
The biggest circle in Figure 4.13A encloses all genes that are regulated by SP1. Some of these are
regulated by other signature genes in addition, giving rise to smaller circles within the SP1-regulated
genes. Hence, the power graph visualisation allows for a nice representation of regulatory modules: Each
circle represents genes that are regulated by the same combination of transcription factors, forming a
regulatory module.
One such module is depicted in Figure 4.13B. It contains many literature survival genes as well as
some genes highly correlated with survival in our data such as HBA1, F3, CCL2, IL2, and GJA1. This
module is created by the power graph algorithm (Royer et al., 2008) because its genes are connected to
SP1 and FOS, but not to SP3. A subset of this module is defined by genes that are regulated by JUN in
addition. This subset contains the genes IL2, TGFB1, MT2A, and GJA1, which are all well correlated with
survival. We can expect that the measurements of these genes are quite reliable, and that the regulatory
information that we used to define this module leads to an effective noise reduction.
A further interesting finding arises from the physical protein interactions between signature genes
obtained from HPRD (Figure 4.13C). It is well known that transcription factors often function with other
proteins in a complex, and that this complex promotes or blocks the recruitment of RNA polymerase to
specific genes (Brivanlou and Darnell, 2002). The picture obtained from protein interaction experiments
however, as shown in Figure 4.13C, is static. From this network, we learn nothing about combinations
of transcription factors that give rise to distinct regulatory modules. For example, the proteins JUN and
FOS can interact, but according to Figure 4.13B, they not always do so to regulate certain genes. Genes
such as HBA1 or CCL2 are regulated by FOS being present, but not JUN. BRCA1 is regulated by the
presence of JUN, but not FOS. IL2 is regulated by FOS and JUN being present at the same time, probably
interacting. We believe that this is an important reason why regulatory networks work much better for
denoising gene expression data that protein interaction networks.
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Figure 4.13 Transcription factor based network around core signature. (A) All TRANSFAC network connec-
tions for the core signature, which is the eight top-ranked genes, are shown. The core signature genes are marked
yellow. Transcription factors are marked with a dot. Genes reported in the literature associated with pancreas cancer
survival according to GoGene are represented with bigger circles. The absolute correlation coefficient of a gene’s
expression with survival in our dataset is shown in red. (B) Excerpt of the network showing genes that are regulated
by FOS and SP1, but not by SP3. It contains many literature-associated and highly correlated genes. (C) Protein–
protein interactions among all signature genes, representing physical interactions between the transcription factors
SP1, STAT3, JUN, FOS and the transcription coactivator BRCA1.
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How many transcription factors exist for human? How complete is TRANSFAC?
A defining feature of transcription factors is that they contain one or more DNA binding domains which
recognise specific sequences of DNA to which they bind (Ptashne and Gann, 1997; Mitchell and Tjian,
1989). There are approximately 2,600 proteins in the human genome that contain DNA-binding domains
and many of these are presumed to function as transcription factors (Babu et al., 2004). If we assume
that there are ∼2,000 human transcription factors, then the ∼200 transcription factors in TRANSFAC
represent a 10% coverage. Since TRANSFAC contains experimentally validated, high quality data, this
sparseness is not surprising. It would be interesting to see whether predicted regulatory networks are
useful to denoise gene expression microarray data in a similar manner.
The core signature leads to a good prognosis separation of Kaplan-Meier survival curves
Figure 4.14 shows Kaplan-Meier survival curves for patients predicted to have a poor or good prognosis.
Each of the signature genes SP1, FOS, CEBPA, JUN, SP3, STAT3, BRCA1, and SRD5A1 was used to
train a support vector machine classifier individually, and one classifier was trained with all eight signature
genes. A logrank test was performed to assess whether the survival distributions of the two predicted
groups differ significantly. Some genes such as SP1, SP3, and JUN only poorly separate the groups
when used alone for classification. The full eight gene signature, however, results in a clear and significant
separation into poor and good prognosis patients.
Experimental validation of the core signature
Although the core signature can predict well the difference in survival in our data, it is not clear whether
this also holds for new data. It is therefore important to evaluate the signature on an independent set of
patients. At the time of writing, our collaborators are conducting experiments to validate the predictive
accuracy of the core signature on a larger set of patients. Pancreatic cancer tissue microarrays from 500
patients are tested using immunohistochemistry with antibodies against each signature protein. Tissue
microarrays consist of paraffin blocks in which hundreds of separate tissue cores are assembled in array
fashion to allow multiplex histological analysis. This will quantify how much of each signature protein is
present in the patients’ tissues. A predicted outcome based on these quantities will be then compared
with the actual patient outcome.
4.4 Discussion
In this chapter, we showed that the technique of GeneRanking based on regulatory transcription networks
is able to find genes that allow to discriminate between poor and good prognosis patients with pancreas
cancer. The identification of discriminant genes is of fundamental and practical interest. Research in biol-
ogy and medicine benefits from the examination of these genes to confirm recent discoveries in cancer
research or to suggest new ways to be explored. Clinical application benefits from diagnostic tests that
help to select the right therapies. To our knowledge, no gene signature derived from genome-wide expres-
sion profiling that is predictive for survival of pancreas cancer has been described so far.
4.4.1 Comparison with other methods
Our results show comparable accuracy to other cancer survival studies
Using a training set of maximal size, our method has a 72% mean accuracy in correctly predicting the
prognosis group of a patient. That is, given the gene expression levels of eight core signature genes of
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Figure 4.14 Kaplan-Meier survival curves for core signature genes. Each plot shows the survival times of
patients predicted to have a poor (red) or good (blue) prognosis based on the signature shown above the plot. The
logrank p-value indicates the significance of a difference between the survival times of the two predicted groups.
Although some signature genes such as SP1, SP3, and JUN alone result in insignificant p-values, their combination
in the eight gene core signature results in a good, significant separation of predicted patient groups (bottom right
plot).
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a patient’s tumor, the trained support vector machine classifier will assign the correct prognosis to the
patient in roughly 7 out of 10 cases.
Lai et al. (2006) report a mean classification error of 30% for the brain cancer dataset of Pomeroy et
al. (2002). Michiels et al. (2005) used their multiple random validation approach and estimated the mean
classification error of the van ’t Veer et al. (2002) study at 30–40%. A robust estimate on the Huang et al.
(2003) dataset for breast cancer survival by the study of Ruschhaupt et al. (2004) found 75% accuracy.
Most survival studies that claimed to have found signatures with higher prediction accuracy turned out later
to have been over-optimistic, as will be further discussed in section 4.4.4. Overall, our results are well in
line with results reported for other cancers such as breast cancer, lung cancer, or lymphatic malignancies.
It seems that predicting survial from gene expression data remains a hard problem. In contrast, dis-
tinguishing disease tissue from healthy tissue based on measuring gene expression is a relatively easy
problem. When we apply our workflow to a meta dataset derived from pancreas cancer and healthy tis-
sue (Grützmann et al., 2005), we achieve perfect classification using five selected genes. This is possible
because some genes exist whose alteration almost invariably indicates the presence of tumorous tis-
sue. Such molecular hallmarks for pancreas cancer are for example overexpression of the MUC5AC gene
(Kato et al., 2006), or epigenetic inactivation of TFPI2 gene leading to strong suppression of its expression
(Sato et al., 2005). Although markedly different between tumor and normal tissue, our experiments show
that such genes are poor predictors to distinguish short term surviving poor prognosis from long term sur-
viving good prognosis patients. This might indicate that genes involved in tumorigenesis, i. e. initial events
that lead to transformation of normal into malignant cells, are quite different from genes responsible for
aggressive growth, infiltration of neighbouring tissue, and metastatic spread of the tumor, which eventually
is decisive for the prognosis.
Non-microarray-based approaches for pancreas cancer survival prediction
Although to our knowledge no pancreas cancer signature based on genome-wide microarray measure-
ments has been described so far, several approaches based on clinical data as well as few marker genes
exist. Overexpression of cyclin D1, which is involved in cell cycle regulation, is long known to be asso-
ciated with poor prognosis in human pancreatic cancer (Gansauge et al., 1997; Kornmann et al., 1998).
Brennan et al. (2004) report the development of a pancreas nomogram. It is designed to assist physi-
cians in predicting a patient’s probability and length of survival. The nomogram uses a combination of
factors to define and predict treatment outcome. Among these factors are patient characteristics such as
age and sex, anatomical parameters such as margin of resection, location of lesion, number of positive
nodes, histological parameters such as degree of differentiation or T-stage, and symptoms such as back
pain or weight loss. The nomogram was created from a pancreatic adenocarcinoma database with 555
patients and later validated by an external patient cohort of 424 patients (Ferrone et al., 2005). Based
on tissue microarray analysis of 223 surgically resected pancreatic ductal adenocarcinomas, Cao et al.
(2007) pointed out the prognostic significance of maspin, a serine proteinase inhibitor also known as SER-
PINB5. Pancreatic ductal adenocarcinoma acquires maspin expression through hypomethylation of the
maspin promoter. Almost all carcinomas showed maspin expression by immunohistochemical staining,
while no expression was observed in normal ductal epithelium. Overexpression of maspin in pancreatic
ductal adenocarcinoma was found to be associated with poor postoperative survival especially in patients
whose tumors exhibit diffuse expression of maspin.
Similarly, Kristiansen et al. (2006) found the expression a PPARγ to be a significant prognostic factor
for survival, and Grützmann et al. (2004a) found high expression of ADAM9 to be correlated with poor
tumor differentiation and with shorter overall survival in pancreatic cancer.
Stocken et al. (2008) attempted to model prognostic factors in advanced pancreatic cancer based
on the blood samples of 653 patients. Their study confirmed the previously reported prognostic factors
albumin, CA 19-9, alkaline phosphatase and LDH, and identified levels of white blood cells, aspartate
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transaminase, and blood urea nitrogen as additional factors not previously reported. Rückert et al. (2008)
report that co-expression of the kallikreins KLK6 and KLK10 indicates an unfavourable prognosis for
survival in pancreatic ductal adenocarcinoma.
4.4.2 Finding biologically relevant correlations by adding background knowledge
The benefits of adding background knowledge
Key to our approach is to add biomedical background knowledge to experimental data. A similar approach
was proposed by Chuang et al. (2007). They combined the van de Vijver et al. (2002) and Wang et al.
(2005) breast cancer datasets with protein–protein interaction information. The idea behind their approach
was to identify markers not as individual genes but as subnetworks extracted from protein interaction
data. Chuang et al. found that the subnetwork markers were more reproducible than individual marker
genes selected without network information, and that they achieved higher accuracy in the classification
of metastatic versus non-metastatic tumors.
It is of course desirable to find a good balance between experimental data and external background
knowledge. Putting too much emphasis on external knowledge would render the experimental data unnec-
essary. Moreover, it would not generate any new biological insight. Balancing between data and external
knowledge is exactly what the parameter d in the GeneRank algorithm does. On experimental data with
a strong signal one might want to choose a d closer to zero, thus minimising the influence of background
knowledge, on data with weaker signal, as we are dealing with here, one wants to choose a higher d . This
makes the GeneRank algorithm a flexible tool that can adapt to any combination of experimental data and
background information, provided that it is subjected to proper cross-validation.
Background knowledge helps to overcome the curse of dimensionality
The curse of dimensionality complicates machine learning problems that involve learning a state of nature
from a low number of data samples in a high-dimensional feature space. In traditional small-scale biomed-
ical experiments, where only a handful of genes or proteins are studied, it is possible to detect whether
there is a significant correlation between the gene or protein level and some response variable. With ten
thousands of studied genes simultaneously, however, it can become impossible to distinguish genes that
just correlate by coincidence from those that correlate because of an underlying causal relation that is
biologically relevant. Adding background knowledge, for example in the form of pathway information, can
help here. If a gene is correlated by mere coincidence to some clinical variable, one would not necessarily
expect this correlation to hold for genes in the same pathway. If it does, this indicates that a whole pathway
is associated with the clinical variable, which reduces the dimensionality of the problem from the order of
number of genes in a cell to the order of number of pathways, which is considerably less.
Another important contribution of background knowledge is its ability to detect correlations that may
arise from noisy measurements. If several genes that are linked, for example in a regulatory or interacting
manner, show similar correlation to a parameter of interest, it becomes quite unlikely that the correlation
was based on noise, but instead likely that there is a true causal relationship.
4.4.3 Limitations of our study
The basis for our study is a snapshot of gene expression levels in a tissue sample that was obtained
by surgical removal of a patient’s tumor. We further use the time in days that this patient survived after
operation. It would be naive to assume that the survival time is only determined by the gene activities of
the tumor cells. External factors such as age of the patient, other diseases present, complications from
the operation, or the patient’s physical constitution and emotional state are well expected to influence
survival. Epidemiological studies indicate that stress, chronic depression, and lack of social support might
132 C H A P T E R 4 . P R E D I C T I O N O F C A N C E R PAT I E N T S U R V I VA L
serve as risk factors for cancer development and progression (Antoni et al., 2006). In a mouse model of
ovarian carcinoma it was shown that chronic stress promotes tumor growth and angiogenesis (Thaker
et al., 2006).
First, our approach is hence limited to the contributions that the transcriptional state of a tumor tissue
has on the patient survival prognosis. Second, the predictive power of the gene signature found in this
study is limited by the number of patients samples available. As can be seen in Figure 4.11, the curves do
not level off with maximal training set sizes, suggesting that there could be an increased accuracy if more
samples were available. Third, the quality of the underlying microarray measurements might influence
our results. The question about the reliability of microarray expression data is subject to controversial
discussion in the literature. This issue will be elaborated on in section 4.4.5.
4.4.4 Flaws in methodologies of previous microarray studies
In a recent review, Dupuy and Simon (2007) investigated 90 studies in which microarray-based expression
profiles were analyzed for their relation to a clinical cancer outcome. Of 42 studies analyzed in detail, 21
contained at least one basic methodological flaw. As basic flaws were considered:
i) unstated, unclear, or inadequate control for multiple testing,
ii) a spurious claim of correlation between clusters and clinical outcome, made after clustering sam-
ples using a selection of outcome-related differentially expressed genes, and
iii) a biased estimation of the prediction accuracy through an incorrect cross-validation procedure.
Based on their analysis, Dupuy and Simon proposed a checklist of “Do’s and Don’ts,” to serve as
guidelines for statistical analysis and reporting for clinical microarray studies. Several authors, often re-
analyzing the datasets of individual studies, found similar problems, which often resulted in overestimation
of prediction accuracy, and lack of reproducibility and instability of signature genes.
Overestimation of prediction accuracy
Incomplete cross-validation. Especially the last point of Dupuy and Simon was made by many authors.
Ambroise and Mclachlan (2002) reported a selection bias of several studies caused by gene selection on
the whole dataset instead of the training set alone, and emphasised the importance of external cross-
validation. Although this bias is a well known phenomenon, a fairly large number of publications still
carry this bias in their results. In a study (Zhang et al., 2001) where decision trees were built from gene
expression data to classify samples as normal colon or colon cancer, the authors cross-validated only
the steps that occurred after selection of the informative genes, but used the full dataset to identify the
informative genes.
Simon (2005) performed a simulation to examine the bias in estimated error rates for a class prediction
study with various levels of cross-validation. They considered two types of leave-one-out cross-validation:
one with removal of the left-out sample before selection of differentially expressed genes and one with
removal of the left-out sample after gene selection but before computation of gene weights and application
of the prediction rule. The simulation results underscored the importance of cross-validating all steps of
predictor construction in estimating a true error rate.
The study of van ’t Veer et al. (2002) also illustrates this point. As described in the previous section, the
investigators predicted clinical outcome of patients with breast cancer (metastatic disease within 5 years
versus disease-free at 5 years) from gene expression profiles. For assessing the classification accuracy,
they used both an incomplete cross-validation method and a fully cross-validated method, where the
incomplete method did not include reselection of the differentially expressed genes. The difference in
estimated error rates illustrates the importance of proper cross-validating: the incomplete cross-validation
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resulted in an estimated error rate of 27% (12 of 44), whereas the full cross-validation had 41% (18 of 44).
Thus, the incomplete method results in a seriously biased underestimate of the error rate, probably largely
from overfitting the predictor to the specific dataset. Although van ’t Veer et al. report both the partially
and fully cross-validated estimates of the error rate, it is the smaller and invalid partially cross-validated
estimate that has received more attention.
Ruschhaupt et al. (2004) also emphasize that the exclusion of preprocessing steps from the cross-
validation is a common error. They propose a robust approach which they term complete classification
procedure. It combines preprocessing strategies and the classification algorithm in two nested cross-
validation loops. One inner cross-validation loop is used to select the optimal parameters for a given
complete classification procedure, and one outer cross-validation loop is used to estimate the misclassifi-
cation rate. When applying their robust method to the data of Huang et al. (2003) — who introduced the
concept of metagenes for predicting the tumor recurrence of breast cancer patients — Ruschhaupt et al.
found only 75% accuracy, showing that the originally reported 90% accuracy were clearly over-optimistic.
Overestimation due to overfitting. Overfitting of the predictor can be a major limitation in supervised
learning. Overfitting means that the number of parameters of the model is too large relative to the number
of available samples. Because the model parameters are optimized for the data, the model will fit the
sample data, but may predict poorly independent data. This happens because the model picks up random
variations within the sample data that do not represent true relationships that are also present in indepen-
dent data. The mentioned cases of incomplete cross-validation are also examples for an overfitting on the
training data.
A striking example of overfitting was described by Tibshirani (2005). He re-analyzed the data of Dave
et al. (2004), who had developed a classifier for the prediction of survival in follicular lymphoma patients.
To this end, they had split the data into a training set of 95 samples and a test set of 96 samples. Tibshirani
repeated the steps of the original study, but with swapped training and test sets. As a result, the findings of
the original study disappeared and virtually nothing was significant. Also, small changes in boundaries for
the involved clustering procedure led to disappearance of these findings, demonstrating that the results
of the original study were extremely fragile.
Overestimation revealed by Monte-Carlo evaluation strategies. As mentioned before, Michiels et
al. (2005) re-analyzed the data of Rosenwald et al. (2002), van ’t Veer et al. (2002), Beer et al. (2002),
Pomeroy et al. (2002), and Iizuka et al. (2003) to assess their predictive power in a rigorous fashion. Key
to their analysis was a multiple random validation strategy, where repeatedly 500 training sets were cho-
sen randomly from the pool of patients. For each training set, Michiels et al. defined a molecular signature
with the 50 genes for which expression was most highly correlated with prognosis by Pearson’s correlation
coefficient. Prognosis was defined as binary clinical outcome, either following the original papers, or using
the binary status of patients being dead or alive at last follow-up in the case of the Rosenwald and Beer
data. Two average profiles, favourable and unfavourable, were defined as vectors of the average expres-
sion values of the 50 signature genes in patients with favourable and unfavourable prognoses. Michiels
et al. classified each patient in the corresponding validation set according to the correlation between ex-
pression of his or her signature genes and the two average profiles. The predicted category was that with
the highest correlation. This method is commonly known as the nearest-centroid prediction rule (Simon,
2003).
The results were quite unexpected. Only for the van’t Veer data, the upper boundary of the 95%
confidence interval for the classification error fell below 50%, suggesting a significantly better predictive
ability of the molecular signature than expected by chance. For all other studies, this was not the case.
Still, the published misclassification rates in the Beer et al. (2002) and the fully cross-validated rate of van
’t Veer et al. (2002) were close to Michiels’ average rate. For the Iizuka et al. (2003) study, two different
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classification methods were tested: the original estimate from the support vector machine was very similar
to the mean classification rate obtained with the multiple random validation strategy, whereas their more
data-driven score system led to an estimate below the lower 95% confidence limit.
Michiels et al. concluded that studies with larger sample sizes are needed and advocated the use of
validation by repeated random sampling.
Lack of reproducibility and Instability of signature genes
Several problems in reproducing published gene signatures were reported. Tibshirani and Efron (2002)
tried but were unable to exactly reproduce the analysis of van ’t Veer et al. (2002), even with help of the
authors. Michiels et al. (2005) noted that different training sets of patients led to a different list of genes in
the signature. Using a training set of the same size as in the van’t Veer study, only 14 of 70 genes from
the published signature were included in more than half of Michiels’ 500 signatures. In addition, ten genes
not included in the published signature were selected in more than 250 of Michiels’ signatures.
Technical aspects also contribute to the problem of reproducibility. Huang et al. (2003) reported that
on their Affymetrix chip they could find only 17 of 70 van’t Veer genes, which were derived from an Agilent
chip. Furthermore, none of these 17 genes appeared in the key metagenes in their recurrence study. Ein-
Dor et al. (2005) tried to reproduce the results of van ’t Veer et al. (2002) as well and found that the list
of 70 genes was highly unstable. Indeed, many sets of 70 genes can be used to predict survival equally
well, rendering the 70 van’t Veer genes less special than they were thought to be. The breast cancer
signature of Wang et al. (2005), derived from 286 patients, had only three genes in common with the van
’t Veer signature. One possible explanation for the different marker sets is that changes in expression of
the relatively few genes responsible for the metastatic potential may be subtle compared to those of the
downstream effectors, which may vary considerably from patient to patient (Symmans et al., 1995; Tomlins
et al., 2005). In a further study, Ein-Dor et al. (2006) demonstrated that in order to achieve a typical overlap
of 50% between two predictive lists of genes, breast cancer studies would need the expression profiles of
several thousand patients, contrary to the hundreds of patients that are typically the basis for such studies.
In the case of diffuse large B-cell lymphomas, Shipp et al. (2002) failed to reproduce the association
between cell-of-origin subtypes and survival outcome reported by Alizadeh et al. (2000). Lossos et al.
(2004) found that no overlap at all existed among the genes included in the prediction models derived by
Shipp et al. (2002) and Rosenwald et al. (2002).
4.4.5 How reliable are microarray measurements?
There is some controversy regarding the quality of data obtained with microarray technology. Praised as
array of hope by Lander, others considered the microarray chip as an array of problems (Frantz, 2005).
The latter view was mainly driven by the study of Michiels et al. (2005), who found that five out of seven of
the largest cancer microarray studies published on cancer prognosis were no better at predicting patient
subgroups than tossing a coin.
Often, it is the low reproducibility of the differentially expressed genes lists for a disease that raises
doubts about the reliability of microarrays (Miklos and Maleszka, 2004; Ein-Dor et al., 2005). Even techni-
cal replicated samples for intra- or inter-platform comparisons were reported to show very low reproducibil-
ity (Tan et al., 2003). Guo et al. (2006) found that gene lists generated by fold-change ranking were more
reproducible than those obtained by t-test p-values or the Significance Analysis of Microarrays method
(Tusher et al., 2001). This is interesting since for our dataset, fold change is completely unable to find
informative genes (compare page 114). It was widely believed that a high level of technical noise in mi-
croarray data is the most critical deterrent to the successful use of this technology in studies of normal and
abnormal biological processes. In particular, the notorious lack of reproducibility of lists of detected genes
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across platforms and laboratories, as well as validation problems associated with prognostic signatures,
was frequently attributed to this flaw of microarray technology (Marshall, 2004).
On the other hand, Dobbin et al. (2005) observed that the biological variation between tumors exceeds
the technical variation introduced by microarray analysis. A long overdue study, led by FDA scientists
(Shi et al., 2006), provided valuable information for the technological noise assessment, although still
far from being comprehensive. The study involved 137 participants from 51 institutions to systematically
address the technical reproducibility of microarray measurements within and between laboratories as well
as across different microarray platforms. Contrary to popular belief, the analysis strongly suggests that
random fluctuations of gene expression signals caused by technical noise are quite low and the effect of
such fluctuations on the results of statistical inference from microarray data is negligibly small. It further
showed that the microarray measurements are highly reproducible within and across different microarray
platforms, and that microarray technologies are sufficiently reliable to be used for clinical and regulatory
purposes.
Based on this study, Klebanov and Yakovlev (2007) also tried to estimate the level of technical noise
in microarray data. They point out that noise is not low in some absolute sense but rather that it is low
compared to a typical, biologically relevant signal. However, it also has to be acknowledged that, for many
situations, where subtle differences are involved, the level of technical noise can be a real problem.
Zhang et al. (2008) also investigated the problem of the apparently low reproducibility of true differen-
tial expression discoveries in microarray studies. They found, however, that even in some ideal situations
like technical replicate tests with small technical variations, these lists of differentially expressed genes
can be very inconsistent. However, the actual false discovery rate for each list tended to be low. They con-
clude from this that the apparently low reproducibility of such lists from current technical replicate tests
does not indicate low quality of microarray technology. This could be explained with the intrinsic noise
present in gene expression, as analyzed by Pedraza and van Oudenaarden (2005). With such intrinsic
noise, low reproducibility and high quality of microarray measurements are two compatible views, and not
necessarily mutually exclusive.
In the light of our microarray dataset, we can conclude that one should take into account the effect
size, i. e. the difference between two sample groups that one is trying to find, when judging the microarray
quality. Naturally, there are considerable differences between the expression levels of different tissues
or between normal tissue and its cancerous counterpart. Such differences are reliably captured by most
methods. Subtle differences such as between tumor tissues that give rise to different survival times in
their patients are much harder to capture. It is not clear whether these differences are partly covered
by the amount of noise present in microarray measurements. Our hypothesis is that adding background
knowledge can identify signal in even noisy measurements, as shown by the superior performance of the
transcription-network based GeneRank algorithm.
4.5 Materials and Methods
4.5.1 Pancreatic cancer gene expression dataset
Patients samples. Tissue samples were obtained from patients with pancreatic ductal adenocarcinoma
who underwent surgery at Dresden university hospital or at collaborating hospitals in Berlin, Heidelberg,
Mannheim, München, and Regensburg. Messenger RNA was extracted with the Agilent RNA 6000 Pico
Kit. Gene expression was determined using Affymetrix HG-U133 Plus 2.0 GeneChips arrays (Affymetrix
Inc., Santa Clara, California, USA). All these experiments were performed by our collaborators.
Preprocessing of microarray raw data. Affymetrix raw probe level CEL files were background-corrected,
normalised and summarized using RMA (Irizarry et al., 2003) for 30 patients.
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Definition of patient prognosis. Median survival time t˜ was used to define a poor prognosis group of
patients with a survival time less or equal than t˜, and a good prognosis group of patients with a survival
time greater than t˜.
4.5.2 Network datasets
For human transcription factor–target pairs the TRANSFAC Suite 2008 was used (Matys et al., 2006).
For human protein–protein interaction pairs, the Human Protein Reference Database, HPRD, was used
(Mishra et al., 2006). The COXPRESdb database (Obayashi et al., 2008) was used to define a network of
co-expressed human genes. It contains a coexpression value for all pairs of 19,777 genes.
4.5.3 Feature selection methods
In the following, the feature selection methods of fold change, the t-statistic, and correlation which are
used are defined. Aij and Bij denote the expression levels of gene i in sample j in groups A and B.
Fold change. The fold change is defined as the ratio of the gene’s mean expression in one group over
the other group:
FCi =
Ai·
Bi·
If the data is log2-transformed, an equivalent definition is the difference of means
FCi = Ai·−Bi·
The disadvantage of selecting genes by fold change is that only mean values are considered, and not
variability. Genes with large variances are more likely to pass a given cutoff just because of noise.
The t-statistic. The t-statistic is defined as
ti =
Ai·−Bi·
si ·
√
1
n1
+ 1n2
where si is the pooled standard deviation for gene i over all samples and n1, n2 are the group sizes.
When the t-statistic is calculated as part of a t-test, a p-value is obtained from the t-distribution which
indicates how likely an observed difference would occur if there is no difference between the groups.
The advantage of the t-statistic is that it takes into account the distribution of the data. One disadvan-
tage is that genes with small variances are more likely to pass a given cutoff, even if there is only a small
difference in means in the numerator.
Correlation. Correlation measures the linear relationship between two variables A and B, giving a value
between −1 and +1 (the correlation coefficient).
The Pearson correlation coefficient is obtained by dividing the covariance of the two variables by the
product of their standard deviations. It is defined as
ri =
1
n−1
n
∑
j=1
(
Aij −Ai·
sA
)(
Bij −Bi·
sB
)
The Spearman’s rank correlation coefficient ρ is defined as
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ρ = 1− 6∑d
2
i
n(n2−1)
where di = rg(Ai·)− rg(Bi·) is the difference between the ranks of corresponding values Ai· and Bi·, and
n is the number of values in each data set. Spearman’s rank correlation is a non-parametric measure of
correlation. It assesses how well an arbitrary monotonic function could describe the relationship between
two variables.
4.5.4 The PageRank algorithm
The PageRank algorithm, developed by Larry Page and Sergey Brin at Stanford University, assigns a
measure of relevance or importance to each web page. It is designed to be robust to methods that aim at
artificially boosting the PageRank of a page by altering the local link structure. Robustness follows from
the recursive nature of the algorithm, where a page is highly ranked if it is linked to by other highly ranked
pages. A link from page i to page j is regarded as a vote of confidence for page j from page i .
The algorithm views the web as a directed graph G(V ,E), where the N nodes V are the web pages
and the edges E represent the links between pages. This information can be stored in an adjacency matrix,
W ∈ RN×N , where wij = 1 if there is a link from page i to page j , and wij = 0 otherwise. Let degi = ∑Nj=1 wij
be the degree (more precisely, the out-degree) of the i th page.
Suppose we have assigned an initial ranking r0 ∈ RN . The PageRank algorithm proceeds iteratively,
updating the ranking for the j th page from to according to the formula
rnj = 1−d + d
N
∑
i=1
wij r
n−1
i
degi
1≤ j ≤ N (4.1)
Here rnj denotes the ranking of page j at the nth iteration and d ∈ (0,1) is a fixed parameter. The value
d = 0.85 appears to be used by Google (Page et al., 1998). We see from (4.1) that the rank of a page
depends on the rank of all pages that link to it. Scaling by 1/degi in the summation ensures that each
page has equal influence in the voting procedure. Each page gets a rank of 1−d automatically and also
gets d times the votes given by other pages.
Iterating to convergence in (4.1) is equivalent to solving for r ∈ RN in the linear system
(I−dW T D−1)r = (1−d)e (4.2)
where I is the identity matrix, W T is the transpose of W , D = diag(degi ), and e ∈ RN has all ei = 1.
Applying PageRank is equivalent to applying the Jacobi method to (4.2), and convergence to a unique
solution r is guaranteed under the condition
ρ(dW T D−1)< 1 (4.3)
where ρ(·) denotes the spectral radius. The convergence condition (4.3) holds for any 0< d < 1.
4.5.5 The GeneRank algorithm
Following the notation in Morrison et al. (2005):
rnj = (1−d)exj + d
N
∑
i=1
wij r
n−1
i
degi
1≤ j ≤ N (4.4)
Here W ∈ RN×N is a symmetric adjacency matrix for the gene network, so wij = wji = 1 if genes i and
j are connected, and wij = wji = 0 otherwise.
The iteration to convergence in (4.4) corresponds to solving the system
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(I−dW T D−1)r = (1−d)ex (4.5)
where I is the identity matrix, W T is the transpose of W , D = diag(degi ), and d ∈ (0,1).
It is trivial to check that with the choice of d = 0 the system (4.5) has the solution r = ex .
For d = 1, (4.4) becomes
rnj =
N
∑
i=1
wij r
n−1
i
degi
(4.6)
and the system (4.5) becomes
(I−W T D−1)r = 0 (4.7)
All calculations were done in R (http://www.R-project.org). For the implementation of the GeneRank
algorithm in R used, please see the Appendix, page 145.
4.5.6 Support vector machine-based learning
A support vector machine (SVM) is a supervised machine learning algorithm for classification problems
(Boser et al., 1992; Vapnik, 1998; Schölkopf and Smola, 2002). We used a support vector machine to
classify pancreatic tumors samples into poor or good prognosis groups based on the expression levels of
selected genes. Here, we used the LIBSVM implementation as provided in the R package e1071 (version
1.5-18, obtained July 2008 from http://cran.r-project.org/web/packages/e1071/).
Chapter 5
Conclusion and outlook
5.1 Contributions of this thesis
5.1.1 Open problem 1 revisited
Open problem: How can structural knowledge about protein inter-
actions and their interfaces help to reliably predict protein–protein
interactions? How can it be combined and completed by exploiting
sequence-based sources of protein interaction that are commonly
available?
To first gain knowledge on protein interactions on the structural level, we developed SCOPPI, the
Structural Classification of Protein–Protein Interactions. SCOPPI is a comprehensive database that clas-
sifies and annotates domain interactions derived from all known protein structures. SCOPPI applies SCOP
domain definitions and a distance criterion to determine inter-domain interfaces. Using a novel method
based on multiple sequence and structural alignments of SCOP families, we classify virtually all domain
interfaces found in proteins of known structures, resulting in nearly 6,000 distinct interface types.
The SCOPPI database is available online, with a web interface providing various views on the data
and query options. Interface characteristics such as number, type and position of interacting amino acids,
conservation, interface size, and permanent or transient nature of the interaction are further provided.
Proteins in SCOPPI are annotated with Gene Ontology terms, and the ontology can be used to quickly
browse SCOPPI. Screenshots are available for every interface and its participating domains. SCOPPI
allows to systematically study binding site similarity, binding site diversity, binding site conservation, and
binding site orientation. From this, we learn about viral mimicry of human interface binding sites, promis-
cuous domain interactions such as the cytokine–fibronectin example, conservation of the trypsin pocket,
and gene fusion events which preserve orientation of the association in the fusion protein in two out of
three cases. Further, we learn that ancient interfaces are dominated by symmetric homodimers. SCOPPI
is available at http://www.scoppi.org.
Next, to address the open problem of interaction prediction, we present a novel algorithm for structure-
based protein–protein interaction prediction. Two proteins are predicted to potentially interact if they con-
tain domains that are known to interact structurally according to the SCOPPI, and if the binding site
residues, as identified by SCOPPI, in these proteins are sufficiently conserved. To assign these domains
to a given protein sequence, we employ both sequence similarity via BLAST and structure prediction
via Threading. Applied to proteins found in microarray experiments comparing pancreas cancer tissue to
normal tissue, the algorithm predicts 29 high-confidence interactions with structural evidence and good
conservation of the binding site.
One particularly interesting example in this set is the interaction predicted between the up-regulated
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transmembrane protease serine 4 (TMPRSS4) and the down-regulated tissue factor pathway inhibitor
2 (TFPI2). Since the structural template-based algorithm reveals that TFPI2 binds to the active site of
the protease TMPRSS4, we postulate an inhibition of TMPRSS4 by TFPI2. In pancreas cancer cells,
TMPRSS4 is involved in the process of metastasis formation and tumor invasion, and its expression
is correlated with the metastatic potential. TFPI2 is an extracellular protein of the small Kunitz inhibitor
family that is often down-regulated by hypermethylation of the promoter region. We conclude from this
that the up-regulation of TMPRSS4 combined with the down-regulation of its predicted inhibitor TFPI2
plays an important role in metastasis of pancreas cancer. A patent has already been granted that claims
an anticancer agent containing a TMPRSS4 inhibitor as an effective ingredient.
The algorithm is further applied to proteins bound to microtubules during meiosis as well as to a
microarray data set of genes up-regulated during the differentiation of the bone-resorbing osteoclast. Here,
we can infer an interaction network of proteins that are likely to build up and maintain the machinery to
carry out the osteoclast’s specific function. A deeper insight into the key players of this network may
lead to the identification of possible targets for a specific drug therapy of osteoporosis. It also turns out
that especially for the experiment on microtubule-bound proteins, which was done in the clawed frog
Xenopus laevis, the structural coverage for the proteins under experimentation is quite sparse. Hence, we
extend the algorithm by adding experimental interaction data obtained from curated databases as well
as literature data obtained from curated text-mining. We treat these interactions in a manner similar to
the SCOPPI structural templates and use them to map them to similar proteins to predict new interaction.
This approach can infer interactions known in one species to its orthologous proteins in another species,
which are known as interologs. Similarity is measured via BLAST, which for the text-mined interactions
basically allows to run a BLAST search against the literature.
In general our method allows for a comprehensive network reconstruction that can assist the molecular
biologist. Predicted interactions are backed up by structural or experimental evidence and can be inferred
at varying levels of confidence. Structural data allow to pinpoint key amino acids of the binding site, and
check for their presence to improve prediction confidence.
Key contributions
• First comprehensive structural classification of protein interaction binding sites (in close collabora-
tion with my colleagues Andreas Henschel and Wan Kyu Kim)
• Creation of the SCOPPI database and implementation of a web interface to make it available to the
community over the internet
• A novel algorithm to predict protein–protein interactions using structural templates, giving insight
into osteoclast differentiation, which is relevant for osteoporosis, the microtubule-associated net-
work in meiosis, and deregulated protein interactions in pancreatic cancer
• Identification and modelling of a putative interaction between TMPRSS4 and TFPI2, which is likely
to be highly relevant for metastasis and invasion in pancreatic cancer (in close collaboration with
my colleague Gihan Dawelbait)
5.1.2 Open problem 2 revisited
Open problem: Can we predict mRNA binding partners for the
polypyrimidine tract binding protein PTBP1 based on their nu-
cleotide sequence and the known PTBP1 mRNA binding motif? AAA
PTBP1
The sequence motif algorithm presented in chapter 3 addresses this problem. It can reliably detect
protein binding sites based on a sequence motif that is restricted to a particular local secondary struc-
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ture of an RNA sequence. To this end, the algorithm combines regular expression pattern search with
evolutionary confirmation and secondary structure prediction. Although the sequence motif algorithm was
tailored to detect PTBP1 binding sites with the consensus binding motif CYYYYCYYYYYG in single-strand
binding regions, it can easily be generalised to accept any motif in regions of any particular structure.
The in silico benchmark test on sequences with known binding sites revealed a high sensitivity of the
sequence motif algorithm. For 13 out of 78 proteins found in a screen for regulation of insulin secretion,
the algorithm identified potential single-strand PTBP1 binding sites in their messenger RNA untranslated
regions which were conserved in rat, mouse, and human. The predictions were ranked by their probability.
The results of the experimental validation of three candidates predicted to harbour PTBP1 binding sites
did not suggest a regulation by PTBP1, hinting at the fact that the predictions contain false positives. It
should be noted, however, that all three candidates had only binding sites conserved in two out of three
species. The choice of which candidates were subjected to experimental validation was mainly that of
our collaborators. Currently, a candidate with a binding site fully conserved in all three species, syntaxin
binding protein 1, is being experimentally tested for interaction with PTBP1. Syntaxin binding protein 1 is
known to be involved in fusion and release of vesicles, which is fundamental to secretion.
In terms of biology, the sequence motif algorithm aims at a better understanding of the regulation
of insulin response in the pancreas. Insulin deficiency causes diabetes mellitus, a disease that affects
at least 170 million people worldwide and that generates costs accounting for one fifth of the western
national health budgets. According to the World Health Organization, this number is expected to double
within the next 20 years. Identifying targets of PTBP1 and hence regulators of insulin secretion might
contribute to the treatment of diabetes by providing novel protein drug targets or by aiding in the design
of novel RNA-binding therapeutics.
Key contributions
• A novel algorithm that combines RNA structure prediction with sequence motif scanning and evolu-
tionary conservation to identify binding sites on messenger RNAs for post-transcriptional regulation
• Identification of potential regulators of insulin secretion that might contribute to a better understand-
ing and treatment of diabetes
5.1.3 Open problem 3 revisited
Open problem: Can we identify genes whose expression in pancreas
cancer tissue samples correlates with the survival time of pancreas
cancer patients? Can these genes be used as a molecular signature
to reliably predict the survival time of patients diagnosed with pancreas
cancer?
GFAP
CCL2
F3
RBP4
NPY
ALDOA
JUN
IFNG
IVL
SPRR1B
HBA1
MT2A
MYC TGFB1
IL2
SERPINB2
GJA1
FOS
Pancreas cancer is characterised by a poor prognosis with a 5-year survival rate of less than 2%, and
accounts for 100,000 deaths in the United States and Europe each year. Although chemotherapy prolongs
survival, pancreatic cancer is incurable.
In chapter 4, we set out to find a gene expression signature that allows to predict survival time in
patients with pancreas cancer. To this end, we devised a computational approach to find genes in human
cancer tissue samples whose expression is predictive for the survival outcome of the cancer patient.
Basis were microarray-based genome-wide expression profiles obtained from microdissected tissue of
pancreatic cancer patients. From this dataset, we derived an eight-gene signature that allowed to predict
whether the patient carrying a tumor had a poor or a good survival prognosis.
Past studies often presented over-optimistic results because of a flawed evaluation procedure. Here,
we employ a rigorous, supercomputer-supported evaluation which is based on multiple random sampling
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of different training sets, minimising the bias of any particular splits into training and test sets. We also
ensure that no information leak occurs.
Molecular signatures to predict survival have previously been identified for several malignancies such
as breast cancer, lung cancer, liver cancer, kidney cancer, lymphomas, and leukemia. However, no study
investigating survival in pancreas cancer based on genome-wide gene expression has been conducted
so far. Our signature showed a prediction accuracy that is comparable to published signatures for other
cancers.
Furthermore, this thesis contributes a new approach to deal with noisy microarray measurements.
Our hypothesis is that adding background knowledge can identify signals in even noisy measurements,
as shown by the superior performance of the transcription-network based GeneRank algorithm. Selecting
genes predictive for survival solely based on gene expression data seems insufficient. In particular, there
is no guarantee that these genes represent a true and biologically relevant cause that influences survival.
When these genes are tested for predictiveness with multiple random validation where many different
training and test sets are generated, the classification accuracy drops below the guessing threshold of
0.5. One likely explanation is that irrelevant and noisy genes are selected from the training set, which
might explain the differences in the training set, but do not explain the differences in the test set. Hence,
they are a result of overfitting on the training set. Using background knowledge, on the other hand, in
form of genes described in the literature as being relevant for survival, or in form of genes that belong
to pathways that are known to be relevant, allows for a correct prediction of the survival prognosis of
around 70%. While this is still far from perfect, data from other studies shows similar correct classification
rates between 51% and 69% (Michiels et al., 2005). Experimental validation of the signature on a large
independent set of 150 patients using tissue microarrays is currently ongoing.
Key contributions
• An eight gene signature that allows to predict survival in pancreas cancer patients
• A rigorous evaluation framework based on supercomputer-supported multiple random validation
• A new approach to deal with noisy microarray measurements inspired by Google PageRank algo-
rithm which shows that regulatory networks considerably improve prediction accuracy
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5.2 Outlook
Growth of protein structural space
The number and complexity of structures in the Protein Data Bank has grown impressively over the past
decades. These structures have fuelled many scientific discoveries and have led to a better understanding
of structure-function relationships. Structural genomics efforts aim at completing the structure space of
the proteome. Combined with advances in structure prediction, we can expect a reasonable structural
coverage of human proteins in the not too distant future. If we extrapolate the current growth of the Protein
Data Bank, this will be reached in 15 to 20 years.
As more structures become available, prediction of protein interactions as presented in this thesis will
improve in accuracy, and interaction prediction and modelling of complexes will be possible on a larger
scale. Further, increasing computing power will make molecular dynamics simulations of such interactions
and complexes a feasible task. New algorithms are needed that use additional knowledge as constraints
to improve protein docking and three-dimensional prediction of complexes, and combine these with molec-
ular dynamics.
Post-transcriptional regulation
Post-transcriptional regulation is of upcoming importance. Non-coding DNA, formerly named junk DNA,
can give rise to non-coding RNAs that control gene expression by interfering with DNA, RNA, and proteins.
Recently, microRNA expression signatures were shown to accurately discriminate acute lymphoblastic
leukemia from acute myeloid leukemia (Mi et al., 2007). Regulation at the messenger RNA level consti-
tutes an additional layer of complexity added during evolution in higher organisms. Still, it is only poorly
understood. It will be a challenge to thoroughly investigate these important regulations and to devise
computational means to predict and model them.
Gene-based signatures
Future work needs to be done to assess the general usefulness of approaches based on gene regulatory
networks in improving prediction from gene expression data. In particular, the GeneRank algorithm that
was shown to work well for pancreatic cancer needs to be tested for other cancers as well. It will be
interesting to see to which extent genomic information will ultimately be used in future clinical practice.
A new era of genomic medicine?
Recent advances in DNA sequencing technology have made possible the complete sequencing of individ-
ual human genomes (Levy et al., 2007; Wheeler et al., 2008; Wang et al., 2008b). Further improvement
such as single molecule sequencing can increase the speed of sequencing and decrease the cost. The
goal of the $1,000 human individual genome might soon be reached. The Personal Genome Project,
initiated by George Church, aims at publishing the complete genomes and medical records of several vol-
unteers in order to enable research into personalised medicine. With ten volunteers to date, it is planned
to incrementally expand enrolment to 100,000 participants.
Last year, the sequencing of an acute myeloid leukaemia genome marked the first complete se-
quenced cancer genome (Ley et al., 2008). More sequencing studies are expected to follow, possibly
complemented by transcription profiling. It will be important to find out what can and what cannot be
inferred from this wealth of genomic information. As understanding genotype-phenotype relationships is
a central goal both in biology and medicine, it will be a great challenge to correlate genotypic data to
clinically relevant phenotypic data of the patient.

Appendix A
Appendix
A.1 GeneRank algorithm implementation in R
1 require(Matrix)
2
3 geneRank <- function(W, ex, d) {
4 cat("Starting GeneRank algorithm with d =", d, "\n")
5 ex = abs(ex)
6 norm.ex = ex/max(ex)
7
8 cat ("Calculating degrees\n")
9 degrees = colSums(W)
10 ind = which(degrees == 0)
11 degrees[ind] = 1
12
13 cat ("Initialise with 1/degrees\n")
14 D1 = as(diag(1/degrees), "sparseMatrix")
15
16 cat ("Create identity matrix\n")
17 eye = as(diag(1, nrow(W)), "sparseMatrix")
18
19 cat ("Adding degrees\n")
20 A = eye - d*(t(W) %*% D1)
21 b = (1-d) * norm.ex # initial node weights
22
23 cat ("Solving linear system\n")
24 r = solve(A, b)
25 return(r)
26 }
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